Immatics (NASDAQ: IMTX) shows promising PRAME and MAGEA4/8 trial results at ASCO 2026
Rhea-AI Filing Summary
Immatics N.V. reports extensive early‑stage clinical data across its PRAME‑ and MAGEA4/8‑targeted pipeline, highlighting activity in multiple hard‑to‑treat solid tumors. The 6‑K centers on updated Phase 1/1b results for IMA203CD8, IMA401 and anzu‑cel presented at the 2026 ASCO meeting.
For anzu‑cel in advanced melanoma, confirmed objective response rate was 56% (18/32) with overall response rate 64% (21/33) and disease control rate 91% (30/33). Median duration of response reached 14.6 months, median progression‑free survival 6.1 months and median overall survival 16.2 months, with some responses exceeding three years.
IMA203CD8 showed dose‑dependent anti‑tumor activity in heavily pretreated gynecologic cancers and synovial sarcoma, with manageable cytokine release syndrome and no treatment‑related Grade 5 events. IMA401, a MAGEA4/8 TCR bispecific, demonstrated a favorable tolerability profile and clinical activity at the 1–2 mg recommended Phase 2 dose, supporting a new IMA401/IMA402 combination cohort in squamous non‑small cell lung cancer. All datasets are preliminary and drawn from ongoing early‑phase trials.
Positive
- Robust early efficacy signals in melanoma and sarcoma: Anzu‑cel delivered a 56% confirmed objective response rate and 64% overall response rate in heavily pretreated advanced melanoma, with disease control in 91% of patients and median duration of response of 14.6 months, supporting a potentially differentiated profile.
Negative
- None.
Insights
Early data show strong responses in refractory tumors but remain preliminary.
Immatics discloses multi‑program Phase 1/1b data suggesting meaningful activity for PRAME‑directed cell therapies and its MAGEA4/8 bispecific. In advanced melanoma, anzu‑cel achieved a 56% confirmed objective response rate and 64% overall response rate, with median responses lasting 14.6 months.
Heavily pretreated gynecologic cancers and synovial sarcoma also showed notable tumor shrinkage with IMA203CD8 and anzu‑cel, alongside manageable cytokine release syndrome and limited neurotoxicity. The IMA401 bispecific’s tolerability at the 1–2 mg recommended Phase 2 dose and observed activity across several tumor types support further development and combination with IMA402 in squamous non‑small cell lung cancer.
From an investment‑thesis perspective, these datasets strengthen the biological case for PRAME and MAGEA4/8 targeting and broaden the potential addressable tumor spectrum. However, all trials are early‑phase, patient numbers are modest, and results are explicitly preliminary, so longer follow‑up and larger, registration‑enabling studies like the SUPRAME Phase 3 trial will be critical for confirming durability and safety.
Key Figures
Key Terms
PRAME medical
TCR T-cell therapy medical
cytokine release syndrome medical
objective response rate medical
bispecific T-cell engager medical
RECIST medical
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
June 1, 2026
Commission File Number: 001-39363
IMMATICS N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic of Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form 20-F |
☒ |
Form 40-F |
☐ | |
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
IMA203CD8 Data Release
On May 30, 2026, Immatics N.V. (the “Company” or “Immatics”) announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma.
Gynecologic Cancers
Patient Population. As of the March 30, 2026 data cutoff, 27 heavily pretreated patients with gynecologic cancers (24 patients with ovarian carcinoma and three with uterine cancer) received a one-time infusion of IMA203CD8. The median total infused dose across seven escalating dose levels was 3.3×109 TCR T cells (range 0.5×109 – 12.5×109) for ovarian carcinoma and 3.2×109 TCR T cells (range 1.3×109 – 10.1×109) for uterine cancer. All patients were heavily pretreated, including at least one prior line of platinum-based regimen. Patients with ovarian carcinoma had a median of four prior lines of systemic treatment (range 1 – 7), patients with uterine cancer had a median of two prior lines (range 1 – 3). The efficacy-evaluable patient population included 26 patients, 19 of whom were treated at clinically relevant doses (≥DL4c, median 5.4x109 TCR T cells, range 1.4×109 – 12.5×109): 17 with ovarian carcinoma and two with uterine cancer.
Safety Data. IMA203CD8 demonstrated predictable and manageable tolerability. The most frequent treatment-emergent adverse events (“TEAEs”) were anticipated cytopenias associated with lymphodepletion. Expected and manageable cytokine release syndrome (“CRS”) was observed, consistent with the mechanism of action (Grade 1: 44%, Grade 2: 44%, Grade 3: 7%). Some patients infrequently experienced immune effector cell-associated neurotoxicity syndrome (“ICANS”) and hemophagocytic lymphohistiocytosis (“HLH”) (any Grade: 7% each). No Grade 5 IMA203CD8-related adverse event was observed. Two dose-limiting toxicities (“DLT”) occurred and the maximum tolerated dose (“MTD”) was not reached. The following table shows TEAEs occurring in 25% or more of patients:
Based on the manageable tolerability profile, the Company expects to determine the recommended Phase 2 dose (“RP2D”) in 2026.
Anti-Tumor Activity. A one-time infusion of IMA203CD8 PRAME cell therapy showed anti-tumor activity in gynecologic cancers at clinically relevant doses (≥ DL4c):
| · | Objective response rate (“ORR”) was 63% (12/19) and confirmed ORR (“cORR”) was 50% (9/18) |
| o | There were two confirmed complete responses and two unconfirmed complete responses |
| o | 89% (8/9) of confirmed responses were ongoing as of the data cutoff with longest ongoing response at 12 months post infusion (metabolic complete response) |
| o | Responses were observed with and without low-dose IL-2 |
| · | Tumor reduction was 78% (14/18) |
| · | Disease Control Rate (“DCR”) at week 6 was 68% (13/19) |
| · | Median duration of response (“mDOR”), median progression free survival (“mPFS”) and median overall survival (“mOS”) were not reached, with median follow-up times (“mFU”) of 3.9, 5.3 and 5.3 months, respectively |
The graphic below sets forth the observed anti-tumor activity at clinically relevant doses (≥ DL4c).
* For those patients who achieved a (c)CR with <100% changes from baseline, target lesions were lymph nodes that resolved to <10 mm. + Patient had a PR prior to CR. BOR, best overall response; (c)CR, (confirmed) complete response; (c)ORR, (confirmed) objective response rate; PD, progressive disease; (c)PR, (confirmed) partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.
Synovial Sarcoma
Patient Population. As of the March 30, 2026 data cutoff, 12 heavily pretreated patients with synovial sarcoma were treated with a one-time infusion of IMA203CD8. The median total infused dose was 1.59×109 TCR T cells (range 0.89×109 – 10.00×109). Patients had a median of two prior lines of systemic therapy (range, 1 – 5).
Safety Data. IMA203CD8 demonstrated expected and manageable tolerability. The most frequent TEAEs were anticipated cytopenias associated with lymphodepletion. Expected and manageable CRS was observed, consistent with the mechanism of action (Grade 1: 42%, Grade 2: 42%, Grade 3: 17%). No patient experienced ICANS or HLH. No Grade 5 IMA203CD8-related adverse event was observed. One DLT occurred and the MTD was not reached. The following table shows TEAEs occurring in 25% or more of patients:
a Testicular/scrotal disorders includes grouped terms.
Anti-Tumor Activity. A one-time infusion of IMA203CD8 showed promising anti-tumor activity with deep and durable response in synovial sarcoma across all doses:
| · | ORR was 67% (8/12) and cORR was 64% (7/11) |
| o | 4 ongoing responses, including 1 confirmed complete response, with longest response ongoing at ~ 3 years |
| · | Tumor reduction was 92% (11/12) |
| · | DCR at week 6 was 100% (12/12) |
| · | mDOR was 14.8 months (3.7, 31.8+) at mFU of 31.0 months |
a ORR: according to RECIST 1.1 at any post-BL scan, PD or death at any prior timepoint; b cORR for patients with ≥2 post-BL scans per RECIST 1.1, PD or death at any prior timepoint, those with ongoing unconfirmed PR/CR at the data cutoff were excluded. BL, baseline; BOR: best overall response; (c)CR, (confirmed) complete response; (c)ORR, (confirmed) objective response rate; (c)PR, (confirmed) partial response; DCR, disease control rate; mDOR, median duration of response; mFU, median follow-up; NR, not reached; PD, progressive disease; SD, stable disease; TCR, T-cell receptor.
Next Development Steps
The clinical activity observed in ovarian cancer, a tumor type generally associated with lower levels of PRAME expression, together with the observed activity across tumor types with different and distinct tumor microenvironments, supports the broad applicability of IMA203CD8 across solid tumors with differing levels of PRAME and tumor biology, starting with ovarian and uterine cancer. Updated data from the ongoing study, including durability follow-up at the RP2D, are planned for presentation in the second half of 2026. The Company is expanding clinical evaluation of IMA203CD8 into additional PRAME-positive solid tumor indications to more fully assess its therapeutic potential.
IMA401 Data Release
On May 31, 2026, the Company announced extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific (TCER®) candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients with solid tumors, including head and neck cancer and lung cancer.
Patient Population. As of the March 2, 2026 data cutoff, 61 heavily pretreated patients with recurrent and/or refractory solid tumors across more than 15 different tumor types were treated with IMA401 with or without pembrolizumab, an immune checkpoint inhibitor (“ICI”). Patients had a median of three prior lines of systemic therapy (range: 1 – 8). 44 patients were treated at RP2D (1 – 2 mg), with 32 receiving monotherapy and 12 receiving the combination of IMA401 and pembrolizumab. Among these patients, head and neck cancer represented the largest subgroup treated at RP2D (n=14).
Safety Data. IMA401 demonstrated manageable tolerability. The tolerability profile of IMA401 with or without pembrolizumab was consistent across patient populations. The most frequent treatment-related adverse events (“TRAEs”) were expected and manageable CRS and transient lymphopenia, consistent with the mechanism of action, as well as neutropenia, mostly transient and manageable. No patient experienced ICANS. Five DLTs occurred (which were manageable in four cases) but no DLTs occurred at RP2D with dexamethasone premedication, and the MTD was not reached. Tolerability of IMA401 at RP2D in combination with pembrolizumab was consistent with IMA401 as a monotherapy at RP2D, with no overlapping and/or additive toxicity observed. At RP2D, tolerability was observed to be favorable, supporting broad combinability of IMA401. The following table shows TRAEs for IMA401 as monotherapy and IMA401 at RP2D with and without pembrolizumab:
a All TRAEs at least possibly related to IMA401 infusion and/or pembrolizumab infusion with grade 1-2 occurring in at least 10% of all patients, all events with ≥ Grade 3; b in patients with and without dexamethasone pre-medication; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase.
a All TRAEs at least possibly related to IMA401 infusion and/or pembrolizumab infusion with grade 1-2 occurring in at least 10% of all patients, all events with ≥ grade 3 and typical ICI-associated toxicities; b IMA401 dose in pembrolizumab expansion cohorts were 1 mg (n=8) or 1.5 mg (n=4).
Anti-Tumor Activity. Patients treated with IMA401 at RP2D as a monotherapy or in combination with pembrolizumab demonstrated clinical activity across multiple solid tumor indications, including melanoma, sqNSCLC, head and neck cancer and others:
| · | For head and neck cancer patients (largest patient subgroup treated at RP2D), cORR was 29% (4/14), DCR was 64% (9/14) and mDOR was 8.8 months. The 12-month overall survival (“OS”) rate was 63% and the six-month progression-free survival (“PFS”) rate was 43%. All responders achieved deep tumor reduction ranging from 60% – 100% and three of four responders were ongoing at data cutoff. |
| · | For melanoma patients: cORR was 33% (2/6) and DCR was 67% (4/6). Both confirmed responses lasted beyond six months post treatment, with one ongoing for >2.5 years. |
| · | A patient case highlighted a patient with ICI-resistant sqNSCLC who received IMA401 plus pembrolizumab in fifth-line (prior best overall response: stable disease) and achieved a partial response with shrinkage of all target lesions. |
a Two patients not shown in plot due to clinical progression before post-infusion scan. b One patient not shown in plot due to clinical progression before post-infusion scan. BL, Baseline; BOR, Best overall response; (c)PR, (confirmed) partial response; H&N, head and neck cancer; PD, progressive disease; RECIST, response evaluation criteria in solid tumors; SD, stable disease.
Preclinical Data. Target expression data from analyzed tumor samples showed that > 90% of patients with sqNSCLC are positive for PRAME and/or MAGEA4/8, and ~60% of patients with sqNSCLC are positive for both
targets, suggesting that a combination therapy against both targets could boost anti-tumor activity and counteract potential tumor escape mechanisms. IMA401/IMA402 combination demonstrated synergistic anti-tumor activity in MAGEA4/8 and PRAME double-positive tumor cell lines.
Anzu-cel Data Release
On June 1, 2026, the Company announced extended data from the ongoing Phase 1b clinical trial evaluating anzu-cel (anzutresgene autoleucel, IMA203) PRAME TCR T-cell therapy in heavily pretreated patients with advanced melanoma.
Patient Population. As of the September 24, 2025 data cutoff, 33 heavily pretreated patients with metastatic (stage IV) melanoma received a one-time infusion of anzu-cel at RP2D (1 – 10×109 TCR T cells). The treated patient population consisted of cutaneous melanoma (n=14), uveal melanoma (n=16), mucosal melanoma (n=2) and melanoma of unknown primary (n=1). All patients with cutaneous melanoma, mucosal melanoma and melanoma of unknown primary had metastatic stage IV disease including lesions in liver, brain and/or lung. All patients with uveal melanoma had metastatic stage IV disease with liver and/or extrahepatic metastases. Patients had a median of two prior lines of systemic treatment. The subgroup of patients with cutaneous melanoma (n=14) had a median of 2.5 lines of prior systemic treatments, thereof a median of two prior lines of immune checkpoint inhibitors. Of these, 64% (9/14) received a combination of ipilimumab and nivolumab and 29% (4/14) received a combination of nivolumab and relatlimab prior to anzu-cel infusion.
Safety Data. Anzu-cel has maintained a predictable and manageable tolerability profile, which was consistent across patients with different melanoma subtypes. The most frequent TEAEs were anticipated cytopenias associated with lymphodepletion. Expected and manageable CRS was observed, consistent with the mechanism of action (Grade 1 or 2: 82%, Grade ≥ 3: 18%). Some patients infrequently experienced ICANS (Grade 1 or 2: 6%, Grade ≥ 3: 6%) and HLH (Grade 1 or 2: 3%, Grade ≥ 3: 3%). The following table shows TEAEs occurring in 30% or more of patients:
a Includes rash and rash maculopapular.
Anti-Tumor Activity.
| All melanoma1 (n=33) | Cutaneous melanoma (n=14) | Uveal melanoma1 (n=16) | |
| cORR | 56% (18/32) | 50% (7/14) | 67% (10/15) |
| ORR | 64% (21/33) | 57% (8/14) | 69% (11/16) |
| DCR | 91% (30/33) | 93% (13/14) | 88% (14/16) |
| mDOR (range) / mFU [mo] | 14.6 (4.2, 38.2+) / 18.7 | 17.9 (4.2, 38.2+) / 18.7 | 11.0 (4.4, 31.6) / Not defined |
| mPFS (range) / mFU [mo] | 6.1 (1.4, 39.6+) / 20.0 | 6.0 (1.4, 39.6+) / 20.0 | 8.5 (1.4, 32.9) / 10.4 |
| mOS (range) / mFU [mo] | 16.2 (2.4, 39.6+) / 17.3 | 13.9 (2.4, 39.6+) / 20.0 | Not reached (4.5, 34.2) / 14.3 |
1 cORR excludes one patient with uveal melanoma who left study (withdrew consent) with ongoing unconfirmed PR.
The PFS rate was 55% at six months and 37% at 12 months. The overall survival rate was 70% at 12 months and 46% at 24 months. 42% (14/33) of patients experienced a deep response (≥50% tumor reduction). In these patients, mPFS was 15.9 months at 39.6 months mFU.
* Maximum change of target lesions and RECIST1.1 response at different timepoints. BL, baseline; BOR, best overall response; (c)CR, (confirmed) complete response; (c)PR, (confirmed) partial response; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.
Anzu-cel induced systemic anti-tumor activity across multiple metastatic sites, including difficult-to-treat metastases, such as liver, lung, lymph node, abdomen/peritoneum, skin and others. Even patients who had a best overall response of Progressive Disease (PD) according to RECIST 1.1 (n=3) experienced shrinkage of individual lesions. Progressive disease was frequently the result of new lesions, progression of non-target lesions, or selective outgrowths of individual lesions, while many target lesions remained controlled, indicating continued control of baseline disease. Responses occurred rapidly (median time to BOR: 1.4 months) and were durable across multiple metastatic sites, including target and non-target lesions.
These findings support the continued development of anzu-cel in advanced melanoma. Immatics’ ongoing Phase 3 clinical trial, SUPRAME, is evaluating the efficacy, safety and tolerability of anzu-cel PRAME TCR T-cell therapy as a monotherapy vs. investigator's choice in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a PD-1 immune checkpoint inhibitor.
In parallel, a Phase 2 cohort in metastatic uveal melanoma is ongoing and intended to support a potential label expansion for anzu-cel following expected initial approval in cutaneous melanoma.
* * *
Certain statements in this report may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, observations from the Company’s clinical trials, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND, CTA or BLA filings, estimated market opportunities of product candidates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not
possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this report should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this report are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.
* * *
In connection with the foregoing, the Company issued press releases, copies of which are attached hereto as Exhibit 99.1, Exhibit 99.2 and Exhibit 99.3, respectively, made available presentations, copies of which are attached hereto as Exhibit 99.4, Exhibit 99.5, Exhibit 99.6 and Exhibit 99.7, and made available an updated corporate presentation, a copy of which is attached hereto as Exhibit 99.8.
INCORPORATION BY REFERENCE
This Report on Form 6-K (other than the exhibits hereto) shall be deemed to be incorporated by reference into the registration statements on Form F-3 (Registration Nos. 333-240260, 333-274218 and 333-286151) of Immatics N.V. and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit No. | Description |
| 99.1 | Press release dated May 30, 2026 |
| 99.2 | Press release dated May 31, 2026 |
| 99.3 | Press release dated June 1, 2026 |
| 99.4 | Phase 1 Trial Results for IMA203CD8, a PRAME-Targeted T-cell Receptor (TCR) T-cell Therapy, in Ovarian Cancer |
| 99.5 | Phase 1 Trial Results with PRAME-targeted T-cell Receptor (TCR) T-cell Therapies in Synovial Sarcoma |
| 99.6 | First-in-Human Results With IMA401, a MAGEA4/8-targeted T-cell Receptor-based Bispecific T-cell Engager (TCER), in Recurrent or Refractory Solid Tumors |
| 99.7 | Patient-level Clinical Response Dynamics in Advanced Melanoma With Anzu-cel, a PRAME-targeted TCR T-cell Therapy |
| 99.8 | Corporate presentation dated June 1, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IMMATICS N.V. | ||
| Date: June 1, 2026 | ||
| By: | /s/ Harpreet Singh | |
| Name: | Harpreet Singh | |
| Title: | Chief Executive Officer | |
Exhibit 99.1
PRESS RELEASE
Immatics Presents
Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
| • | One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer with a 63% objective response rate (ORR), 50% confirmed ORR (cORR), including four complete responses, and longest ongoing response at 12 months |
| • | Additional Phase 1 data for IMA203CD8 in heavily pretreated patients with synovial sarcoma showed deep and durable responses with a 67% ORR and 64% cORR, including one complete response, and ongoing responses up to ~3 years |
| • | IMA203CD8 demonstrated a manageable and consistent tolerability profile across patient populations |
| • | Clinical anti-tumor activity observed across tumor types (ovarian carcinoma, uterine cancer, melanoma, synovial sarcoma) with distinct biology and differing levels of PRAME expression, including lower PRAME levels in ovarian carcinoma |
| • | Clinical profile of IMA203CD8 supports continued development in gynecologic cancers and expansion into other PRAME-positive solid tumors |
| • | Determination of recommended phase 2 dose (RP2D) remains expected in 2026 |
Houston, Texas and Tuebingen, Germany, May 30, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. One-time infusion of IMA203CD8 demonstrated meaningful clinical activity across different tumor types as well as manageable tolerability. The broad expression of PRAME in more than 50 cancers further supports the continued development of IMA203CD8 in multiple PRAME-positive solid tumors.
The updated Phase 1 results in gynecologic cancers will be presented on May 30, 2026, during the Rapid Oral Abstract Session – Gynecologic Cancer from 8:00-9:30 am CDT by Antonia Busse, M.D., Charité Medical University Hospital, Berlin, Germany (Abstract ID 5509). Presentation slides are accessible in the ‘Events & Presentations’ section of the Investors & Media section of the Company’s website. Phase 1 data in synovial sarcoma will be presented on May 31, 2026, during the Rapid Oral Abstract Session – Sarcoma from 4:30-6:00 pm CDT by Dejka M. Araujo M.D., The University of Texas MD Anderson Cancer Center (Abstract ID 11516). Presentation slides will be accessible on May 31, 2026.
| Immatics Press Release May 30, 2026 | 1 | 5 |
“These clinical data in ovarian cancer, uterine cancer and synovial sarcoma, along with previously released data in melanoma, further reinforce our aim to develop IMA203CD8 in PRAME-positive cancers beyond melanoma. PRAME is expressed in more than 50 cancers, and the compelling anti-tumor activity observed in these historically hard-to-treat indications supports its promise as a broadly applicable target,” said Cedrik Britten, M.D., Ph.D., Chief Medical Officer at Immatics. “We are encouraged by the consistency of response signals observed with IMA203CD8 and remain focused on advancing IMA203CD8 in gynecologic cancers with the potential to broaden development to other indications in a tumor-agnostic approach to deliver meaningful outcomes to patients.”
Next development steps:
The clinical activity observed in ovarian cancer, a tumor type generally associated with lower levels of PRAME expression, together with the observed activity across tumor types with different and distinct tumor microenvironments, supports the broad applicability of IMA203CD8 across solid tumors with differing levels of PRAME and tumor biology, starting with ovarian and uterine cancer. Updated data from the ongoing study, including durability follow-up at the RP2D, are planned for presentation in the second half of 2026. Immatics is expanding clinical evaluation of IMA203CD8 into additional PRAME-positive solid tumor indications to more fully assess its therapeutic potential.
Highlights of Immatics’ clinical data on IMA203CD8 presented at ASCO 2026
Gynecologic cancers:
Patient population: Heavily pretreated patient population with limited treatment options
| · | As of March 30, 2026, 27 heavily pretreated patients with gynecologic cancers received a one-time infusion of IMA203CD8 in the ongoing Phase 1 dose escalation/dose expansion trial (NCT03686124). |
| · | The median total infused dose across seven escalating dose levels was 3.3x109 TCR T cells (range 0.5x109 - 12.5x109 TCR T cells) for ovarian carcinoma and 3.2x109 TCR T cells (range 1.3x109 - 10.1x109 TCR T cells) for uterine cancer. |
| · | All patients were heavily pretreated, including at least one prior line of platinum-based regimen. Patients with ovarian carcinoma had a median of four lines of systemic treatment (range 1-7), patients with uterine cancer had a median of two lines (range 1-3). |
| · | The efficacy-evaluable1 patient population included 26 patients, 19 of whom were treated at clinically relevant doses (≥DL4c, median 5.4 x109 TCR T cells, range 1.4 – 12.5): 17 with ovarian carcinoma and two with uterine cancer |
Safety: Treatment with IMA203CD8 showed predictable and manageable tolerability
| · | IMA203CD8 demonstrated manageable tolerability in the 27 enrolled patients. |
| · | The most frequent treatment-emergent adverse events (TEAE) were anticipated cytopenias associated with lymphodepletion. |
| · | Expected and manageable cytokine release syndrome (CRS) was mostly low-grade and was consistent with the mechanism of action (Grade 1: 44%, Grade 2: 44%, Grade 3: 7%). |
| · | Immune effector cell-associated neurotoxicity syndrome (ICANS) and hemophagocytic lymphohistiocytosis (HLH) were infrequently observed (any Grade: 7%, each). |
| · | No IMA203CD8-related Grade 5 events occurred. |
1 All patients who received IMA203CD8 infusion and had at least one post-baseline scan, progressive disease or death.
| Immatics Press Release May 30, 2026 | 2 | 5 |
| · | Based on the manageable tolerability profile, the Company expects to determine the recommended Phase 2 dose (RP2D) in 2026. |
Anti-tumor activity: A one-time infusion of IMA203CD8 PRAME cell therapy showed anti- tumor activity in gynecologic cancers at clinically relevant doses (≥DL4c)
| · | Objective response rate (ORR): 63% (12/19), confirmed ORR (cORR)2: 50% (9/18) |
| o | Including two confirmed and two unconfirmed complete responses |
| o | 89% (8/9) of confirmed responses were ongoing as of the data cutoff with longest ongoing response at 12 months post infusion (metabolic complete response) |
| o | Responses were observed with and without low-dose IL-2 |
| · | Tumor reduction: 78% (14/18) |
| · | Disease Control Rate (DCR) at week 6: 68% (13/19) |
| · | Median duration of response (mDOR), median progression free survival (mPFS) and median overall survival (mOS) were not reached, with median follow-up times (mFU) of 3.9, 5.3 and 5.3 months, respectively |
* For those patients who achieved a (c)CR with <100% changes from baseline, target lesions were lymph nodes that resolved to <10 mm. + Patient had a PR prior to CR. BOR, best overall response; (c)CR: (confirmed) complete response; (c)ORR, (confirmed) objective response rate; PD, progressive disease; (c)PR, (confirmed) partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.
Synovial sarcoma:
| · | As of the March 30, 2026 data cutoff, 12 heavily pretreated patients with synovial sarcoma, who had received a median of two prior lines of systemic therapy (range, 1-5), were treated with a one-time infusion of IMA203CD8. |
2 cORR excludes one patient with ongoing unconfirmed response at data cutoff.
| Immatics Press Release May 30, 2026 | 3 | 5 |
| · | The safety profile was manageable and consistent with the mechanism of action. |
| · | The most frequent TEAEs were anticipated cytopenias associated with lymphodepletion. CRS events were expected, manageable and predominantly Grade 1/2. |
| · | No IMA203CD8-related Grade 5 events were observed. |
A one-time infusion of IMA203CD8 showed promising anti-tumor activity with deep and durable response in synovial sarcoma across all doses (median 1.59 × 10⁹ TCR T cells; range: 0.89–10.00 × 10⁹):
| · | ORR: 67% (8/12), cORR: 64% (7/11) |
| o | 4 ongoing responses, including 1 confirmed complete response, with longest response ongoing at ~ 3 years |
| · | Tumor reduction: 92% (11/12) |
| · | DCR at week 6: 100% (12/12) |
| · | mDOR: 14.8 months (3.7, 31.8+) at mFU of 31.0 months |
About IMA203CD8 PRAME Cell Therapy
IMA203CD8 is Immatics’ PRAME-directed TCR T-cell therapy engineered to recognize an intracellular PRAME-derived peptide presented by HLA-A*02:01 on the cell surface and initiate a potent and specific anti-tumor response. The co-transduction of CD8αβ alongside the PRAME TCR adds functional CD4+ T cells designed to boost anti-tumor activity. IMA203CD8 is currently being evaluated in a Phase 1 clinical trial in solid tumors expressing PRAME.
About PRAME
PRAME is a target expressed in more than 50 cancers. Immatics is the global leader in precision targeting of PRAME and has the broadest PRAME franchise with the most PRAME indications and modalities. The Immatics PRAME franchise currently includes three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy.
About Immatics
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.
Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedIn and Instagram.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, observations from the Company’s clinical trials, the timing,
| Immatics Press Release May 30, 2026 | 4 | 5 |
outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND, CTA or BLA filings, estimated market opportunities of product candidates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.
For more information, please contact:
Media
Trophic Communications
Phone: +49 151 74416179
immatics@trophic.eu
Immatics N.V.
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325
InvestorRelations@immatics.com
| Immatics Press Release May 30, 2026 | 5 | 5 |
Exhibit 99.2
PRESS RELEASE
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine
Supporting Development of IMA401/IMA402 Combination in Lung Cancer
| · | IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer |
| · | In head and neck cancer, IMA401 treatment at recommended Phase 2 dose (RP2D) with or without pembrolizumab resulted in a 29% confirmed ORR (4/14), 64% DCR (9/14) and mDOR of 8.8 months; all responders achieved deep responses with 60-100% tumor reduction |
| · | IMA401 MAGEA4/8 TCR bispecific demonstrated favorable tolerability at RP2D with or without pembrolizumab, suggesting its potential for broad combinability |
| · | IMA401 data will be presented in an oral presentation at the 2026 ASCO Annual Meeting and published simultaneously in Nature Medicine |
| · | The data support Immatics’ strategy to combine IMA401 with IMA402 (PRAME bispecific) in lung cancer and potentially other indications, where the combined target prevalence supports broad patient coverage and potential synergistic activity; the IMA401/IMA402 combination cohort is now enrolling at multiple clinical trial sites, with first data expected in 2027 |
Houston, Texas and Tuebingen, Germany, May 31, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced the presentation of extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific (TCER®) candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients with solid tumors, including head and neck cancer and lung cancer, in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. The data show a consistent and favorable tolerability profile across multiple tumor types and encouraging anti-tumor activity at the recommended Phase 2 dose (RP2D) with or without the immune checkpoint inhibitor (ICI) pembrolizumab. Results from the Phase 1 study are being published simultaneously in Nature Medicine.
Data from the ongoing Phase 1 study of IMA401 will be presented on May 31, 2026, during the Developmental Therapeutics Session – Immunotherapy from 8:00-11:00 am CDT by Martin Wermke, M.D., TU Dresden University of Technology, NCT/UCC Early Clinical Trial Unit, Dresden, Germany (Abstract ID: 2507). The slides are available in the ‘Events & Presentations’ section of the Investor & Media page on the Company’s website.
| Immatics Press Release May 31, 2026 | 1 | 6 |
Carsten Reinhardt, M.D., Ph.D., Chief Development Officer at Immatics, said, “The IMA401 clinical data represent an important step forward for our next-generation, off-the-shelf TCER® platform and reinforce the potential of this modality to address both advanced and earlier-stage solid tumors. Building on the encouraging clinical activity and supportive preclinical findings, we believe IMA401 may have even greater potential in combination with IMA402, our PRAME-directed bispecific. The initiation of the IMA401/IMA402 combination cohort in squamous cell non-small cell lung cancer marks a milestone toward broadening patient reach and delivering meaningful clinical benefit for patients with significant unmet needs.”
Based on the clinical data for IMA401, including the initial clinical signal in squamous cell non-small cell lung cancer (sqNSCLC), as well as preclinical proof-of-concept data and clinical data for IMA402, Immatics has initiated enrollment in a Phase 1 cohort at multiple clinical trial sites evaluating IMA401 targeting MAGEA4/8 in combination with IMA402 targeting PRAME in sqNSCLC. The dual targeting approach is designed to broaden patient coverage and potentially enhance anti-tumor activity by addressing two highly prevalent cancer targets, with sqNSCLC as the first indication, and further development potential for many others. Based on combined target prevalence, more than 90% of patients with sqNSCLC express PRAME and/or MAGEA4/8. The current addressable patient population for metastatic sqNSCLC in the United States and EU5 is estimated at approximately 40,000 patients per year. First data from the IMA401/IMA402 combination cohort are expected in 2027.
Highlights of Immatics’ clinical data on IMA401
Patient population: Heavily pretreated, highly heterogeneous patient population
| · | As of the data cutoff on March 2, 2026, 61 patients with recurrent and/or refractory solid tumors across >15 different tumor types were treated with IMA401 with or without an immune checkpoint inhibitor (ICI, pembrolizumab) in a Phase 1 dose-escalation basket trial (NCT05359445). |
| · | Patients were heavily pretreated with a median of three prior lines of systemic treatment (range: 1-8). |
| · | 44 patients were treated at RP2D (1-2 mg), with 32 receiving monotherapy and 12 receiving the combination of IMA401 and pembrolizumab. Among these patients, head and neck cancer represented the largest subgroup treated at RP2D (n=14). |
Safety: Favorable tolerability at RP2D supporting broad combinability of IMA401
| · | The tolerability profile of IMA401 with or without pembrolizumab was consistent across patient populations. |
| · | The most frequent clinically relevant treatment-related adverse events (TRAE) observed across dose levels were low-grade cytokine release syndrome (CRS) (38% G1-2, no ≥ Grade 3), expected and transient lymphopenia (33%), consistent with the mechanism of action, and neutropenia (31%). Within the RP2D range of 1-2 mg, neutropenia was mostly transient and manageable. |
| · | Notably, no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed. |
| Immatics Press Release May 31, 2026 | 2 | 6 |
| · | Tolerability of IMA401 at RP2D in combination with pembrolizumab was consistent with IMA401 as a monotherapy at RP2D, with no overlapping and/or additive toxicity observed. |
| · | Tolerability profile of IMA401, both as a monotherapy and with pembrolizumab, supports broad combination potential of IMA401. |
Anti-tumor activity and durability: Promising clinical activity with deep and durable responses
Patients treated with IMA401 at RP2D as a monotherapy or in combination with pembrolizumab demonstrated clinical activity across multiple solid tumor indications, including melanoma, sqNSCLC, head and neck cancer and others:
| · | Head and neck cancer (largest patient subgroup treated at RP2D): confirmed objective response rate (cORR) of 29% (4/14), disease control rate (DCR) of 64% (9/14), median duration of response (mDOR) of 8.8 months. The 12-month overall survival (OS) rate was 63% and the six-month progression-free survival (PFS) rate was 43%. All responders achieved deep tumor reduction ranging from 60-100% and three of four responders were ongoing at data cutoff. |
| · | Melanoma: cORR of 33% (2/6), DCR of 67% (4/6); both confirmed responses lasted beyond six months post treatment, with one ongoing for >2.5 years. |
| · | sqNSCLC: A presented patient case highlighted a patient with ICI-resistant sqNSCLC who received IMA401 plus pembrolizumab in fifth-line (prior best overall response: stable disease) and achieved a partial response with shrinkage of all target lesions. |
a Two patients not shown in plot due to clinical progression before post-infusion scan. b One patient not shown in plot due to clinical progression before post-infusion scan. BL: Baseline; BOR: Best overall response; (c)PR: (confirmed) partial response; H&N: head and neck cancer; PD: progressive disease; RECIST: response evaluation criteria in solid tumors; SD: stable disease.
Preclinical data: Supporting broad patient coverage and potential synergistic activity of IMA401/IMA402 combination
| Immatics Press Release May 31, 2026 | 3 | 6 |
| · | Target expression data from analyzed tumor samples showed that >90% of patients with sqNSCLC are positive for PRAME and/or MAGEA4/8, and ~60% of patients with sqNSCLC are positive for both targets, suggesting that a combination therapy against both targets could boost anti-tumor activity and counteract potential tumor escape mechanisms. |
| · | IMA401/IMA402 combination demonstrated synergistic anti-tumor activity in MAGEA4/8 and PRAME double-positive tumor cell lines. |
Data on the IMA401 Phase 1 trial are published simultaneously in Nature Medicine.
About Immatics TCR Bispecifics (TCER®)
Immatics’ next-generation half-life extended TCER® molecules are antibody-like “off-the-shelf” biologics that leverage the body’s immune system by redirecting and activating T cells towards cancer cells expressing a specific tumor target. The design of the TCER® molecules enables the activation of any T cell in the body to attack the tumor, regardless of the T cells’ intrinsic specificity. Immatics’ proprietary biologics are engineered with two binding regions: a TCR domain and a T cell recruiter domain. The TCER® format is designed to maximize efficacy while minimizing toxicities in patients. It contains a high-affinity TCR domain that is designed to bind specifically to the cancer target peptide on the cell surface presented by an HLA molecule. The antibody-derived, low-affinity T cell recruiter domain is directed against the TCR/CD3 complex and recruits a patient’s T cells to the tumor to attack cancer cells. With a low-affinity recruiter aiming for optimized biodistribution and enrichment of the molecule at the tumor site instead of the periphery, TCER® are engineered to reduce the occurrence of immune-related adverse events, such as cytokine release syndrome. In addition, the TCER® format comprises an Fc part that confers half-life extension, stability, and manufacturability. TCER® molecules are “off-the-shelf” biologics and thus immediately available for patient treatment. They can be distributed through standard pharmaceutical supply chains and can reach a large patient population without the need for specialized medical centers.
About IMA401 MAGEA4/8 Bispecific
IMA401 is a molecule from Immatics’ TCR bispecifics pipeline that targets an HLA-A*02:01-presented peptide derived from two different cancer-associated proteins, melanoma-associated antigen 4 and/or 8 (“MAGEA4/8”). The MAGEA4/8 peptide has been identified and validated by Immatics’ proprietary mass spectrometry-based target discovery platform XPRESIDENT® and is presented at a 5-fold higher target density (copy number per tumor cell) than the MAGEA4 peptide targeted in other clinical trials. IMA401 is currently being evaluated in a Phase 1 basket trial in patients with MAGEA4/8-positive solid tumors. The MAGEA4/8 peptide has a high prevalence in several solid tumor indications such as head and neck squamous cell carcinoma (HNSCC), squamous cell non-small cell lung cancer (sqNSCLC), as well as melanoma and other solid cancer types.
About IMA402 PRAME Bispecific
IMA402 is a molecule from Immatics’ TCR bispecifics (TCER®) pipeline directed against an HLA-A*02:01-presented peptide derived from PRAME. IMA402 is currently being evaluated in a Phase 1 trial in patients with solid tumors expressing PRAME. IMA402 is part of Immatics’ strategy to leverage the full clinical potential of targeting PRAME, one of the most promising targets for TCR-based therapies.
| Immatics Press Release May 31, 2026 | 4 | 6 |
About Immatics
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.
Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedIn and Instagram.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, observations from the Company’s clinical trials, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND, CTA or BLA filings, estimated market opportunities of product candidates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.
| Immatics Press Release May 31, 2026 | 5 | 6 |
For more information, please contact:
Media
Trophic Communications
Phone: +49 151 74416179
immatics@trophic.eu
Immatics N.V.
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325
InvestorRelations@immatics.com
| Immatics Press Release May 31, 2026 | 6 | 6 |
Exhibit 99.3
PRESS RELEASE
Immatics Presents Clinical Activity and Response
Dynamics
of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
| · | One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and metastatic uveal melanoma |
| · | Anzu-cel showed a 56% confirmed ORR, 14.6 months mDOR, 6.1 months mPFS and 16.2 months mOS at longer follow-up alongside a predictable and manageable tolerability profile in metastatic melanoma |
| · | Exploratory response analysis suggests continued control of baseline disease and anti-tumor activity across multiple metastatic disease sites with many lesions remaining controlled, some even after progression |
| · | Findings reinforce the continued effectiveness of anzu-cel to treat advanced melanoma; Phase 3 SUPRAME trial remains on track as it advances toward BLA submission in 1H 2027 |
Houston, Texas and Tuebingen, Germany, June 1, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced extended data from the ongoing Phase 1b clinical trial evaluating anzu-cel (anzutresgene autoleucel, IMA203) PRAME TCR T-cell therapy in heavily pretreated patients with advanced melanoma in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, USA. The dataset is focused on patients treated with anzu-cel at the recommended Phase 2 dose (RP2D), including longer follow-up and further characterization of the durability and systemic nature of the observed clinical responses.
The data will be presented on Monday, June 1, 2026, by Diwakar Davar, M.D., University of Pittsburgh Medical Center Hillman Cancer Center, Pennsylvania, USA during the Oral Abstract Session – Melanoma/Skin Cancers (Abstract ID 9508). The slides are available in the ‘Events & Presentations’ section of the Investor & Media section of the Company’s website.
“What excites us about anzu-cel is the strength of the clinical activity we are seeing in advanced melanoma that is further reinforced by the novel insights into the durability of responses and the systemic nature of anti-tumor activity observed across metastatic disease sites,” said Cedrik
| Immatics Press Release June 1, 2026 | 1 | 6 |
Britten, M.D., Ph.D., Chief Medical Officer at Immatics. “These findings continue to highlight the potential of anzu-cel to make a meaningful impact on the lives of patients with advanced melanoma. Through the ongoing SUPRAME Phase 3 trial, we are working to bring anzu-cel to more patients in urgent need of effective treatment options.”
Oral Presentation Summary – Anzu-cel Phase 1b Trial
Patient population: Heavily pretreated patient population with metastatic melanoma
| · | As of September 24, 2025, 33 heavily pretreated patients with metastatic (stage IV) melanoma received a one-time infusion of anzu-cel at the recommended Phase 2 dose (RP2D, 1 - 10x109 TCR T cells) in the Phase 1b dose expansion. |
| · | The treated patient population consisted of cutaneous melanoma (n=14), uveal melanoma (n=16), mucosal melanoma (n=2) and melanoma of unknown primary (n=1). |
| · | All patients with cutaneous melanoma, mucosal melanoma and melanoma of unknown primary had metastatic stage IV disease including lesions in liver, brain and/or lung. All patients with uveal melanoma had metastatic stage IV disease with liver and/or extrahepatic metastases. |
| · | Patients had a median of two prior lines of systemic treatment. The subgroup of patients with cutaneous melanoma (n=14) had a median of 2.5 lines of prior systemic treatments, including a median of two prior lines of immune checkpoint inhibitors. Of these, 64% (9/14) received a combination of ipilimumab and nivolumab and 29% (4/14) received a combination of nivolumab and relatlimab prior to anzu-cel infusion. |
Safety: Treatment with anzu-cel continued to show predictable and manageable tolerability
| · | Anzu-cel has maintained a manageable tolerability profile, which was consistent across patients with different melanoma subtypes. |
| · | The most frequent treatment-emergent adverse events were anticipated cytopenias associated with lymphodepletion. |
| · | Expected and manageable cytokine release syndrome (CRS) was mostly Grades 1 and 2, which is consistent with the mechanism of action. No patients experienced long-term CRS. |
| · | Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred infrequently, was manageable and mostly mild (Grades 1 and 2). |
Anti-tumor activity and durability: Rapid, deep and durable anti-tumor activity of anzu-cel PRAME cell therapy, including durable responses up to >3 years
| Immatics Press Release June 1, 2026 | 2 | 6 |
| All melanoma1 (n=33) |
Cutaneous melanoma (n=14) | Uveal melanoma1 (n=16) | |
| cORR | 56% (18/32) | 50% (7/14) | 67% (10/15) |
| ORR | 64% (21/33) | 57% (8/14) | 69% (11/16) |
| DCR | 91% (30/33) | 93% (13/14) | 88% (14/16) |
| mDOR (range) / mFU [mo] | 14.6 (4.2, 38.2+) / 18.7 | 17.9 (4.2, 38.2+) / 18.7 | 11.0 (4.4, 31.6) / Not defined |
| mPFS (range) / mFU [mo] | 6.1 (1.4, 39.6+) / 20.0 | 6.0 (1.4, 39.6+) / 20.0 | 8.5 (1.4, 32.9) / 10.4 |
|
mOS (range) / mFU [mo] |
16.2 (2.4, 39.6+) / 17.3 | 13.9 (2.4, 39.6+) / 20.0 | Not reached (4.5, 34.2) / 14.3 |
1 cORR excludes one patient with uveal melanoma who left study (withdrew consent) with ongoing unconfirmed PR.
The PFS rate was 55% at six months and 37% at 12 months. The overall survival rate was 70% at 12 months and 46% at 24 months.
42% (14/33) of patients experienced a deep response (≥50% tumor reduction). In these patients, mPFS was 15.9 months at 39.6 months mFU.
| Immatics Press Release June 1, 2026 | 3 | 6 |
* Maximum change of target lesions and RECIST 1.1 response at different timepoints. BL, baseline; BOR, best overall response; (c)CR, (confirmed) complete response; (c)PR, (confirmed) partial response; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.
Anzu-cel induced systemic anti-tumor activity across multiple metastatic sites, including difficult-to-treat metastases, such as liver, lung, lymph node, abdomen/peritoneum, skin and others. Even patients who had a best overall response of progressive disease (PD) according to RECIST 1.1 (n=3) experienced shrinkage of individual lesions. Progressive disease was frequently the result of new lesions, progression of non-target lesions, or selective outgrowths of individual lesions, while many target lesions remained controlled, indicating continued control of baseline disease. Responses occurred rapidly (median time to BOR: 1.4 months) and were durable across multiple metastatic sites, including target and non-target lesions.
These findings support the continued development of anzu-cel in advanced melanoma. Immatics’ ongoing Phase 3 clinical trial, SUPRAME, is evaluating the efficacy, safety and tolerability of anzu-cel PRAME TCR T-cell therapy as a monotherapy vs. investigator's choice in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a PD-1 immune checkpoint inhibitor.
In parallel, a Phase 2 cohort in metastatic uveal melanoma is ongoing and intended to support a potential label expansion for anzu-cel following expected initial approval in cutaneous melanoma.
| Immatics Press Release June 1, 2026 | 4 | 6 |
About PRAME
PRAME is a target expressed in more than 50 cancers. Immatics is the global leader in precision targeting of PRAME and has the broadest PRAME franchise with the most PRAME indications and modalities. The Immatics PRAME franchise currently includes three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy.
About Anzu-cel PRAME Cell Therapy
Anzu-cel (anzutresgene autoleucel; IMA203) is a PRAME-directed TCR T-cell therapy engineered to recognize an intracellular PRAME-derived peptide presented by HLA-A*02:01 on the cell surface and initiate a potent and specific anti-tumor response. Anzu-cel PRAME cell therapy is currently being evaluated in a registration-enabling randomized controlled Phase 3 trial, “SUPRAME,” in patients with unresectable or metastatic cutaneous melanoma who have disease progression on or after treatment with at least one checkpoint inhibitor. In parallel, the Phase 1/2 clinical trial is ongoing with a focus on uveal melanoma.
About Immatics
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics.
Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on LinkedIn and Instagram.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company’s future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, observations from the Company’s clinical trials, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND, CTA or BLA filings, estimated market opportunities of product candidates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these
| Immatics Press Release June 1, 2026 | 5 | 6 |
terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.
For more information, please contact:
Media
Trophic Communications
Phone: +49 151 7441 6179
immatics@trophic.eu
Immatics N.V.
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325
InvestorRelations@immatics.com
| Immatics Press Release June 1, 2026 | 6 | 6 |
Exhibit 99.4
PRESENTED BY: Phase 1 Trial R esults for IMA203CD8, a PRAME - Targeted T - cell Receptor (TCR) T - cell Therapy, in Ovarian C ancer Antonia Busse 1 , Winfried Alsdorf 2 , Oladapo O. Yeku 3 , Sarah E. Taylor 4 , Dejka M. Araujo 5 , Dirk Jaeger 6 , Katrin Wetzko 7 , Amir A. Jazaeri 8 , Samer Ali Srour 8 , Martin Wermke 9 , Alexander Mustea 10 , Friedrich Vollmer 11 , Norbert Hilf 11 , Nataliia Chorna 11 , Cedrik Michael Britten 11 , Tobias Albert Wilhelm Holderried 12 1 Charite Medical University Hospital, Berlin, Germany; 2 Department of Hematology and Oncology University Hospital Hamburg Eppendorf, Hamburg, Germany; 3 Massachusetts General Hospital, Harvard Medical School, Boston, MA; 4 Department of Obstetrics, Gynecology and Reproductive Services, University of Pittsburgh Medical Center, Pittsburgh, PA; 5 MD Anderson Cancer Center, Houston, TX; 6 Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany; 7 University Hospital Dresden, Dresden, Germany; 8 The University of Texas MD Anderson Cancer Center, Houston, TX; 9 TU Dresden University of Technology, NCT/UCC Early Clinical Trial Unit, Dresden, Germany; 10 Department of Gynecology and Gynecological Oncology, Bonn University Hospital, Bonn, Germany; 11 Immatics Biotechnologies GmbH, Tübingen, Germany; 12 University of Bonn, University Hospital Bonn, Medical Clinic and Polyclinic III Internal Medicine with a focus on Oncology, Hematology, and Rheumatology, Bonn, Germany Prof. Dr. med. Antonia Busse, A bstract #5509
PRESENTED BY: Key T akeaways • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies • IMA203CD8 is a one - time autologous TCR T - cell therapy targeting the cancer - associated antigen PRAME, which is broadly expressed in gynecologic cancers and represents a novel target for immunotherapies in this patient population • IMA203CD8 demonstrates a predictable and manageable tolerability profile and encouraging dose - dependent activity in patients with advanced gynecologic cancers • These findings support further development of IMA203CD8 to define its therapeutic potential in patients with gynecologic and other PRAME - positive cancers HLA: human leukocyte antigen; PRAME: preferentially expressed antigen in melanoma; TCR: T - cell receptor Prof. Dr. med. Antonia Busse, A bstract #5509 Data cutoff Mar 30, 2026
PRESENTED BY: IMA203CD8 is a Systemic TCR T - cell Therapy Designed to Target the Intracellular Tumor Antigen PRAME IMA203CD8 is an investigational therapy and its use has not been proven to be safe or effective. It has not been approved by the FDA or any other regulatory agency outside of the US. a Data on file: PRAME target prevalence is based on a proprietary mass spec - guided expression threshold applied to RNAseq data (approximate values; values between 95 - 100% shown as 95%). b Includes the following subtypes: clear cell carcinoma, endometrioid carcinoma, serous cystadenocarcinoma; HLA, human leukocyte antigen; NSCLC, non - small cell lung cancer; PRAME, preferentially expressed antigen in melanoma; TCR, T - cel l receptor. PRAME is expressed in >50 cancers % PRAME+ patients a Indication 95% Cutaneous Melanoma 95% Uterine Carcinoma 95% Uterine Carcinosarcoma 95% Synovial Sarcoma 90% Uveal Melanoma 90% Mucosal Melanoma 85% Ovarian Carcinoma Subtypes b 70% Squamous Cell NSCLC 65% Triple - negative Breast Carcinoma 45% Small Cell Lung Cancer 45% Esophageal Carcinoma Subtype 40% Kidney Carcinoma Subtype 35% Cholangiocarcinoma 30% HER2 - Enriched Breast Carcinoma 25% Adenocarcinoma NSCLC 25% Head & Neck Squamous Cell Carcinoma 20% Hepatocellular Carcinoma 20% Bladder Carcinoma Mechanism of action Prof. Dr. med. Antonia Busse, A bstract #5509
PRESENTED BY: Phase 1 Multicenter Trial of IMA203CD8 in PRAME+ Solid Tumors IMA203 - 101: NCT03686124; Based on initial safety data observed with anzu - cel (IMA203), IMA203CD8 dose escalation was initiated at DL3. Total TCR T cells calculated from defined number of TCR T cells /m 2 BSA per dose level x 1.8 m 2 BSA; a Dose level ≥ DL4c is evaluated “ IL - 2 , starting without IL - 2. If tolerable, add IL - 2 at the same dose or escalate to next dose without IL - 2; outpt IL - 2 admin . at investigator’s discretion. BID, twice daily; BSA, body surface area; DL, dose level; ECOG PS, Eastern Cooperative Oncology Group Performance Status; FU, follow - up; IL, interleukin; IU, international unit; PRAME, preferenti ally expressed antigen in melanoma; QD, daily; SOC, standard of care; SUBQ, subcutaneous; TCR, T - cell receptor. PRAME Testing Biopsy or archived tissue No longer required for indications with high PRAME prevalence, including ovarian and uterine cancer IMA203CD8 Manufacturing (~2 weeks) Lymphodepletion Fludarabine 30mg/m 2 Cyclophosphamide 500mg/m 2 Days - 6 to - 3 ц Low Dose IL - 2 a 1M IU SUBQ QD x 3d, then 1M IU SUBQ BID x 5d Leukapheresis HLA - A*02:01 Testing (blood) Patient Journey SCREENING / MANUFACTURING TREATMENT / OBSERVATION FU IMA203CD8 one - time infusion Enrichment at relevant DLs: ~1.4 – 10 billion total TCR T cells DL3 (n=1) ~0.36 - 0.86 x 10 9 total TCR T cells DL4a (n=6) ~0.87 - 1.44 x 10 9 total TCR T cells DL4c (n=2) ~1.45 - 2.16 x 10 9 total TCR T cells DL5 (n=5) ~2.17 - 3.6 x 10 9 total TCR T cells DL6 (n=8) ~3.6 - 7.2 x 10 9 total TCR T cells DL7 (n=5) ~7.2 - 10 x 10 9 total TCR T cells Dose Escalation Scheme Key Objectives Primary: • Tolerability • Determination of RP2D Secondary: • Efficacy • Pharmacokinetics Key Eligibility Criteria • Advanced or metastatic solid tumors • Age ≥ 18 years • ECOG PS 0 - 1 • HLA - A*02:01 positive • PRAME positive • No available SOC treatment options • Measurable disease (RECIST 1.1) • Adequate organ function Data cutoff Mar 30, 2026 Prof. Dr. med. Antonia Busse, A bstract #5509
PRESENTED BY: Patient Disposition a All patients who started lymphodepletion; b All patients who received IMA203CD8 infusion and had at least one post - baseline scan, progressive disease or death; DL, dose le vel; NSCLC, non - small cell lung cancer. Safety Population a N=90 Melanoma n=46 Synovial Sarcoma n=12 Gynecologic Indications n=27 Efficacy - evaluable Population b n=26 < DL4c n=7 Ovarian Carcinoma n=6 Uterine Cancer n=1 ≥ DL4c n=19 Ovarian Carcinoma n=17 Uterine Cancer n=2 Other n=5 Araujo et al, ASCO 2026 Busse et al, ESMO - IO 2025 Busse et al, ESMO - IO 2025 Cutaneous melanoma n=24 Uveal melanoma n=16 Mucosal melanoma n=3 Melanoma of unknown primary n=2 Acral melanoma n=1 Triple - negative breast cancer n=3 Lung adenocarcinoma n=1 NSCLC n=1 n=1 pending first post - baseline scan n=1 at DL3 n=6 at DL4a Data cutoff Mar 30, 2026 Prof. Dr. med. Antonia Busse, A bstract #5509
PRESENTED BY: Patients Were Heavily Pretreated with Limited Treatment Options n =27, includes all patients who started lymphodepletion; a Includes 1 patient with endometrial carcinoma; ADC, antibody - drug - conjugate; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase; na , not applicable; PARPi , PARP inhibitor; SLD, sum of longest diameter(s); TCR, T - cell receptor; ULN, upper limit of normal. Uterine Cancer a Ovarian Carcinoma n=3 n=24 52 (49, 55) 60 (35, 75) Age, median (range) 0 10 (42) ECOG PS 1 , n (%) 2 (67) 8 (33) LDH ≥1 x ULN, n (%) 8.1 (1.1, 12.4) 6.2 (1.5, 21.6) Tumor burden Target lesion SLD [cm], median (range) 4 (1, 4) 2 (1, 5) Number of target tumor lesions, median (range) 1 (33) 21 (88) Cancer subtype, high - grade serous , n (%) 2 (67) 10 (42) Liver metastasis, n (%) 3 (100) 17 (71) Peritoneal disease , n (%) na 19 (79) Platinum - resistant, n (%) Baseline Characteristics Uterine Cancer a Ovarian Carcinoma n=3 n=24 1 (33) 3 (100) 4 (17) 24 (100) Prior treatment, n (%) Radiation Systemic treatment 2 (1, 3) 1 (33) 4 (1, 7) 22 (92) Prior lines of systemic treatment Median, (range) ≥3, n (%) na 3 (100) 1 (1, 1) 3 (100) 1 (1, 1) - - 3 (100) 1 (0, 2) 24 (100) 3 (1, 5) 24 (100) 3 (1, 4) 18 (75) 17 (71) 2 (8) Lines post - platinum resistance, med (range) Chemotherapy, n (%) Lines of chemotherapy, median (range) Platinum - based regimen, n (%) Lines of platinum - based regimen, median (range) Targeted therapies, n (%) Bevacizumab PARPi Checkpoint inhibitors Treatment Experience n=3 n=24 Dose 3.2 (1.3, 10.1) 3.3 (0.5, 12.5) Total infused dose TCR T cells [x10 9 ], median (range) Data cutoff Mar 30, 2026 Prof. Dr. med. Antonia Busse, A bstract #5509
PRESENTED BY: Safety in Patients with Gynecologic Indications (n=27 a ) Tolerability across all indications: Busse et al ESMO - IO, 2025. a Includes all patients who started lymphodepletion; b One grade 5 event at DL4a (~1.4 billion total TCR T cells) was deemed to be unlikely related to IMA203CD8 by investigator. Pa ti ent died from sepsis in the setting of IEC - HS. This event led to further modifications of eligibility criteria to exclude patients at higher risk for infectious complications or severe immune - r elated toxicities, together with IL - 2 de - intensification; no further treatment - emergent fatal events were observed with escalati ng doses up to ~10 billion total TCR T cells. AE, adverse event; CRS, cytokine release syndrome; d, day; DL, dose level; DLT, do se - limiting toxicity; HLH, hemophagocytic lymphohistiocytosis; ICANS, immune effector cell - associated neurotoxicity syndrome; TCR, T - cell receptor; TEAE, treatment - emergent adverse event. Overall manageable tolerability profile • Most frequent TEAEs were anticipated cytopenias associated with lymphodepletion • Expected and manageable CRS, mostly grade 1 - 2, consistent with mechanism of action • 2 DLTs: – DL5: Grade 3 ICANS – DL7: G rade 4 skin infection • MTD not reached • No IMA203CD8 - related grade 5 events b Adverse events of special interest TEAEs in ≥25% of patients Any Time Grade ≥ 3 Any grade Preferred term, n (%) 0 22 (81) Nausea 20 (74) 20 (74) Neutropenia 17 (63) 18 (67) Anaemia 3 (11) 16 (59) Rash 11 (41) 16 (59) Thrombocytopenia 2 (7) 13 (48) Abdominal pain 0 12 (44) Vomiting 0 11 (41) Fatigue 1 (4) 10 (37) Hypokalaemia 0 9 (33) Constipation 9 (33) 9 (33) Lymphopenia 2 (7) 8 (30) Hypophosphataemia 0 8 (30) Pyrexia 1 (4) 7 (26) Hypomagnesaemia 0 7 (26) Hyponatraemia Any Time 26 (96) CRS, any grade, n (%) 12 (44) Grade 1 12 (44) Grade 2 2 (7) Grade 3 2 (7) HLH, any grade, n (%) 0 Grade 1 1 (4) Grade 2 0 Grade 3 1 (4) Grade 4 2 (7) ICANS, any grade, n (%) 1 (4) Grade 1 0 Grade 2 1 (4) Grade 3 Data cutoff Mar 30, 2026 Prof. Dr. med. Antonia Busse, A bstract #5509
PRESENTED BY: BOR in Patients with Gynecologic Indications at All DL (n=26 a ) Evaluable patients ≥DL4c 63% (12/19) ORR b 50% (9/18) cORR c 68% (13/19) DCR (at week 6) ,QGLFDWLRQ 7DUJHW/HVLRQVIURP%DVHOLQH 5(&,67 %HVW &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI %DVHOLQH :DWHUIDOO3ORW 6RUWHGE\'/*( &)/ 1ILUVW WKHQ< 3RSXODWLRQ $OOSDWLHQWV 'DWDFXW RII * * + ≥DL4c <DL4c Baseline PD Best overall response (RECIST 1.1) SD PR cPR CR cCR Ongoing a Two patients with ovarian cancer at DL4a and DL5 deceased prior to first post - BL scan non - evaluable for assessment of tumor redu ction, not depicted in plot but assessed for ORR calculation; b ORR: according to RECIST 1.1 at any post - BL scan, PD or death at any prior timepoint; c Confirmed ORR for patients with ≥2 post - BL scans per RECIST 1.1, PD or death at any prior timepoint, those with ongoing unconfi rmed PR/CR were excluded. * For those patients who achieved a (c)CR with <100% changes from baseline, target lesions were lymph nodes that resolved to <10 mm per RECIST 1.1; + Patient had a PR prior to CR. BL, baseline; BOR, best overall response; (c)CR, (confirmed) complete response; DCR, disease co nt rol rate; DL, dose level; (c)ORR, (confirmed) objective response rate; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable disease. Data cutoff Mar 30, 2026 Prof. Dr. med. Antonia Busse, A bstract #5509 Tumor reduction: 78% (14/18)
PRESENTED BY: PD Best overall response (RECIST 1.1) SD PR cPR CR cCR Ongoing Ovarian Cancer Indication Uterine Cancer # 'DWDFXW RII 3RSXODWLRQ *\Q2QF%XQGOH ,0$ &' LQ'/ FRUKLJKHU 6SLGHU3ORW 8WHULQH&DQFHU 2YDULDQ&DQFHU ,QGLFDWLRQ 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH 5(&,67 0RQWKVSRVW7FHOOLQIXVLRQ 7DUJHW/HVLRQVIURP%DVHOLQH >@ &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI 3' %DVHOLQH 35 2QJRLQJ Months Post T - cell Infusion # Changes in Tumor Size Over Time in Patients with Gynecologic Indications at ≥DL4c (n=19 a ) a One patient with ovarian cancer at DL5 deceased prior to first post - BL scan non - evaluable for assessment of tumor reduction, not de picted in plot but assessed for ORR calculation. For those patients who achieved a (c)CR with <100% changes from baseline, target lesions were lymph nodes that resolved to <10 mm per RECIST 1.1; # Ongoing confirmed PR (RECIST 1.1) as of l ast scan at month 7.5, suspected clinical progression by clinical site at month 6 in discrepancy to RECIST response due to tumor marker increase; patient off study at month 8 and receiving further anti - tumor treatment. BOR, best overall response; (c)C R, (confirmed) complete response; DCR, disease control rate; (c)ORR, (confirmed) objective response rate; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable disease. Data cutoff Mar 30, 2026 Prof. Dr. med. Antonia Busse, A bstract #5509 • 89% (8/9) of confirmed responses ongoing • longest ongoing response at 12 months post infusion (metabolic complete response)
PRESENTED BY: Conclusions • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies • IMA203CD8 is a one - time autologous TCR T - cell therapy targeting the cancer - associated antigen PRAME, which is broadly expressed in gynecologic cancers and represents a novel target for immunotherapies in this patient population • IMA203CD8 demonstrates a predictable and manageable tolerability profile and encouraging dose - dependent activity in patients with advanced gynecologic cancers • These findings support further development of IMA203CD8 to define its therapeutic potential in patients with gynecologic and other PRAME - positive cancers HLA, human leukocyte antigen; PRAME, preferentially expressed antigen in melanoma; TCR, T - cell receptor. Prof. Dr. med. Antonia Busse, A bstract #5509 Data cutoff Mar 30, 2026
PRESENTED BY: University Hospital Dresden University Hospital Bonn University Hospital Hamburg Charité Berlin University Hospital Heidelberg TUM University Hospital Munich IMA203 - 101 Phase 1 Trial (patients with gynecologic indications) Sponsor: Immatics Massachusetts General Hospital University of Pittsburgh Medical Center UT MD Anderson United States Thank You – Trial Participants & Caregivers Germany Prof. Dr. med. Antonia Busse, A bstract #5509
PRESENTED BY: Appendix Prof. Dr. med. Antonia Busse, A bstract #5509
PRESENTED BY: 0 10 20 30 1×10 1 1×10 2 1×10 3 1×10 4 1×10 5 1×10 6 1×10 7 40 60 80 1002004006008001000 Days post-infusion V e c t o r c o p i e s / µ g D N A Long - Term IMA203CD8 T - cell Persistence in Peripheral Blood Prof. Dr. med. Antonia Busse Sustained persistence of IMA203CD8 T cells beyond 1 - year post - infusion represent an important prerequisite for durable clinical benefit Data cutoff Mar 30, 2026
PRESENTED BY: Patients with Gynecologic Cancers Treated with IMA203CD8 at Doses ≥DL4c in Phase 1 (n=19) BOR, best overall response; DL, dose level; (c)CR, (confirmed) complete response; cPR , confirmed partial response; OC, ovarian cancer; PARPi , PARP inhibitor; PFS, progression free survival. Reason for Progression Comment BOR (Max % change of target lesions) BOR DL Total infused dose TCR - T cells 1 [x10 9 ] Prior treatments No of prior systemic treatment lines Indication Ongoing response at 5.3 months PFS, deepened from initial PR - 100 CR 5 3.15E+09 Pembrolizumab + Chemotherapy (carboplatin, paclitaxel) 1 Uterine Cancer Target lesion progression, new lesions Response until 2.8 months PFS - 100 CR 5 3.08E+09 Bevacizumab + chemotherapy (carboplatin, paclitaxel) PARPi Chemotherapy (caelyx, carboplatin) PARPi 4 OC, Fall tupe, perit. Suspected clinical progression by clinical site in discrepancy to RECIST response due to tumor marker increase Response until 7.4 months PFS - 74.4 cPR 5 2.30E+09 Chemotherapy (carboplatin, paclitaxel) Bevacizumab + chemotherapy (carboplatin, paclitaxel) PARPi + chemotherapy (caelyx, carboplatin) Chemotherapy (carboplatin, cisplatin, gemcitabine) Chemotherapy (paclitaxel) 5 OC, Fall tupe, perit. Ongoing response at 12.2 months PFS; metabolic complete response - 66.9 cPR 6 7.07E+09 Chemotherapy (carboplatin, paclitaxel) Bevacizumab + chemotherapy (carboplatin, paclitaxel) PARPi + chemotherapy (carboplatin, gemcitabine) Chemotherapy (carboplatin, doxorubicin) 4 OC, Fall tupe, perit. Ongoing response at 6.2 months PFS - 60.8 cCR 6 6.22E+09 Bevacizumab + chemotherapy (carboplatin, paclitaxel) Chemotherapy (carboplatin, doxorubicin) Chemotherapy (carboplatin, gemcitabine) Chemotherapy (paclitaxel) Chemotherapy (docetaxel) 5 OC, Fall tupe , perit . Ongoing response at 5.3 months PFS - 46.7 cCR 4c 1.43E+09 Chemotherapy (carboplatin, paclitaxel) 1 OC, Fall tupe, perit. Ongoing response at 4.6 months PFS - 43.6 cPR 6 6.59E+09 Chemotherapy (carboplatin, taxol ) PARPi Chemotherapy (carboplatin, caelyx ) PARPi PARPi Chemotherapy (carboplatin, gemcitabine) 6 OC, Fall tupe , perit . Ongoing response at 3.0 months PFS - 40.2 cPR 6 4.16E+09 Bevacizumab + PARPi + chemotherapy (paclitaxel, docetaxel, carboplatin) Chemotherapy (doxorubicin, carboplatin, gemcitabine) Chemotherapy (carboplatin, cyclophosphamide) 3 OC, Fall tupe, perit. Ongoing response at 5.3 months PFS - 38.2 cPR 7 12.5E+9 Chemotherapy (carboplatin, taxol) Chemotherapy (carboplatin, gemcitabine) Chemotherapy (mitomycin) Chemotherapy (cisplatin, paclitaxel) 4 OC, Fall tupe, perit. Prof. Dr. med. Antonia Busse Data cutoff Mar 30, 2026
PRESENTED BY: Patients with Gynecologic Cancers Treated with IMA203CD8 at Doses ≥DL4c in Phase 1 (n=19) BOR, best overall response; DL, dose level; (c)PR, (confirmed) partial response; SD, stable disease; PD, progressive disease; PARPi , PARP inhibitor; OC, ovarian cancer; PFS, progression free survival. Reason for Progression Comment BOR (Max % change of target lesions) BOR DL Total infused dose TCR - T cells 1 [x10 9 ] Prior treatments No of prior systemic treatment lines Indication Ongoing response at 2.5 months PFS - 60.9 cPR 7 7.48E+09 Chemotherapy (carboplatin, paclitaxel) 1 OC, Fall tupe, perit. Target and Non - target lesion progression Unconfirmed response until 3.0 months PFS - 40 PR 7 11.0E+9 Chemotherapy (carboplatin, paclitaxel) Chemotherapy (carboplatin, gemcitabine) PARPi + ICI + exp. Therapy Chemotherapy (paclitaxel) 4 OC, Fall tupe, perit. Ongoing unconfirmed response at 4.5 months PFS, deepened from initial SD - 34.7 PR 7 10.1E+9 Chemotherapy (carboplatin, paclitaxel) Exp. therapy (selinexor) TKI + ICI 3 Uterine Cancer New lesions Disease stabilization until 3.0 months PFS - 8.1 SD 4c 2.26E+09 Chemotherapy (carboplatin, taxol) Chemotherapy (carboplatin, paclitaxel) Bevacizumab Exp. therapy (AVB - 001) Bevacizumab + Chemotherapy (carboplatin, gemcitabine, gemzar) 5 OC, Fall tupe, perit. Target and non - target progression, new lesions Progressive disease at 1.5 months PFS - 40 PD 6 3.55E+09 PARPi + chemotherapy (carboplatin, paclitaxel) Bevacizumab PARPi + chemotherapy ( caelyx , carboplatin) Chemotherapy (topotecan) 4 OC, Fall tupe , perit . New lesions Progressive disease at 1.4 months PFS 2.4 PD 6 5.38E+09 Bevacizumab + PARPi + chemotherapy (carboplatin, paclitaxel) Chemotherapy (carboplatin, doxorubicin) Chemotherapy (paclitaxel) 3 OC, Fall tupe , perit . Non - target progression Progressive disease at 1.4 months PFS 2.6 PD 6 6.46E+09 Chemotherapy (carboplatin, paclitaxel) Bevacizumab + PARPi + chemotherapy (carboplatin, doxorubicin) Mirvetuximab Chemotherapy (topotecan) 4 OC, Fall tupe , perit . Target and non - target progression, new lesions Progressive disease at 1.4 months PFS 14.2 PD 5 3.02E+09 PARPi + chemotherapy (carboplatin, taxol) Bevacizumab + chemotherapy (carboplatin, doxorubicin) ADC (PRO1184) 3 OC, Fall tupe, perit. Target lesion progression, new lesions Progressive disease at 1.3 months PFS 21.7 PD 7 6.42E+09 Chemotherapy (carboplatin, paclitaxel) PARPi Chemotherapy (carboplatin, doxorubicin) 3 OC, Fall tupe, perit. Death Progressive disease at 1.1 months n/a PD 5 3.04E+09 Bevacizumab + chemotherapy (carboplatin, paclitaxel) Chemotherapy ( caelyx , carboplatin) Chemotherapy (carboplatin, gemcitabine) 3 OC, Fall tupe , perit . Prof. Dr. med. Antonia Busse Data cutoff Mar 30, 2026
Exhibit 99.5
PRESENTED BY: Phase 1 Trial Results with PRAME - targeted T - cell Receptor (TCR) T - cell Therapies in Synovial Sarcoma Dejka M. Araujo 1 , Manik Chatterjee 2 , Diwakar Davar 3 , Leonel Fernando Hernandez - Aya 4 , Ran Reshef 5 , Dmitry Pankov 6 , Delfi Krishna 7 , Friedrich Vollmer 7 , Ana Maia 7 , Regina Mendrzyk 7 , Cedrik Michael Britten 7 , Martin Wermke 8 1 The University of Texas MD Anderson Cancer Center, Houston, TX; 2 University Hospital Wuerzburg, Wuerzburg, Germany; 3 Department of Malignant Hematology and Medical Oncology, Pittsburgh, PA; 4 University of Miami, Miami, FL; 5 Columbia University Irving Medical Center, New York, NY; 6 Immatics, Houston, TX; 7 Immatics Biotechnologies GmbH, Tübingen, Germany; 8 TU Dresden University of Technology, NCT/UCC Early Clinical Trial Unit, Dresden, Germany Dejka M. Araujo, M.D., A bstract #11516
PRESENTED BY: Key Takeaways • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies • Anzutresgene autoleucel ( anzu - cel, IMA203) and IMA203CD8 are distinct investigational one - time autologous TCR T - cell therapies targeting the cancer - associated antigen PRAME, a novel target for synovial sarcoma • PRAME - targeted TCR T - cell therapies demonstrate an expected and manageable tolerability profile and durable antitumor activity in patients with metastatic synovial sarcoma • The potentially transformative clinical activity of PRAME - targeted TCR T - cell therapy in metastatic synovial sarcoma supports further development HLA, human leukocyte antigen; PRAME, preferentially expressed antigen in melanoma; TCR, T - cell receptor Dejka M. Araujo, M.D., A bstract #11516 Data cutoff Mar 30, 2026
PRESENTED BY: Two Distinct Systemic TCR T - cell Therapies Designed to Target the Intracellular Tumor Antigen PRAME Anzutresgene autoleucel and IMA203CD8 are distinct investigational therapies, and their use has not been proven to be safe or effective. These invest ig ational therapies have not been approved by the United States FDA or any other regulatory agency outside of the US. a Data on file: PRAME target prevalence is based on a proprietary mass spec - guided expression threshold applied to RNAseq data (ap proximate values; values between 95 - 100% shown as 95%). NSCLC, non - small cell lung cancer; PRAME, preferentially expressed antigen in melanoma; TCR, T - cell receptor. PRAME is expressed in >50 cancers % PRAME+ patients a Indication 95% Cutaneous Melanoma 95% Synovial Sarcoma 95% Uterine Carcinoma 95% Uterine Carcinosarcoma 90% Mucosal Melanoma 90% Uveal Melanoma 85% Ovarian Carcinoma Subtypes 70% Squamous Cell NSCLC 65% Triple - negative Breast Carcinoma 45% Esophageal Carcinoma Subtype 45% Small Cell Lung Cancer 40% Kidney Carcinoma Subtype 35% Cholangiocarcinoma 30% HER2 - Enriched Breast Carcinoma 25% Adenocarcinoma NSCLC 25% Head & Neck Squamous Cell Carcinoma 20% Bladder Carcinoma 20% Hepatocellular Carcinoma Anzutresgene autoleucel (anzu - cel, IMA203) IMA203CD8 CD4/CD8 T cells expressing CD8 αβ Engineered PRAME - specific TCR Engineered PRAME - specific TCR CD8 αβ Th1 cytokines and cytotoxic effector molecules Dejka M. Araujo, M.D., A bstract #11516
PRESENTED BY: Phase 1 Multicenter Trial of Anzu - cel or IMA203CD8 in PRAME+ Solid Tumors IMA203 - 101: NCT03686124; a PRAME testing no longer required for indications with high PRAME prevalence, including synovial sarcoma; b outpatient IL - 2 administration at investigator’s discretion. ECOG PS , Eastern Cooperative Oncology Group Performance Status; IL , interleukin; IU , international unit; HLA, human leukocyte antigen; PRAME, preferentially expressed in melanoma; RECIST, Response Evaluation Cr ite ria in Solid Tumors; SOC , Standard of Care; SUBQ , subcutaneous Key Objectives Patients enrolled to PRAME cell therapy: • Anzu - cel (IMA203): n=9 • IMA203CD8: n=12 PRAME Cell Therapy Manufacturing (~2 weeks) Leukapheresis HLA - A*02:01 Testing (blood) Patient Journey SCREENING / MANUFACTURING TREATMENT / OBSERVATION FOLLOW UP PRAME Testing Biopsy or archived tissue a PRAME Cell Therapy one - time infusion Data cutoff Mar 30, 2026 Lymphodepletion Fludarabine 30mg/m 2 Cyclophosphamide 500mg/m 2 Days - 6 to - 3 Low Dose IL - 2 b 1M IU SUBQ up to 10 days Key Objectives Primary: • Tolerability • Determination of RP2D Secondary: • Efficacy • Pharmacokinetics Key Eligibility Criteria • Advanced or metastatic solid tumors • Age ≥ 18 years • ECOG PS 0 - 1 • HLA - A*02:01 positive • PRAME positive • No available SOC treatment options • Measurable disease (RECIST 1.1) • Adequate organ function Data cutoff Mar 30, 2026 Dejka M. Araujo, M.D., A bstract #11516
PRESENTED BY: All Patients Had Metastatic Synovial Sarcoma Includes 1 patient treated with anzu - cel and post - PD with IMA203CD8; ECOG, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase; SLD, sum of longest diameter(s); TCR , T - cell receptor; ULN, upper limit of normal. IMA203CD8 Anzu - cel (IMA203) n=12 n=9 46 (20, 66) 49 (20, 63) Age, median (range) 4 (33) 3 (33) Female , n (%) 2 (17) 2 (22) ECOG PS 1 , n (%) 4 (33) 5 (56) LDH ≥1 x ULN, n (%) 8.1 (1.2, 41.1) 10.9 (3.8, 14.8) Tumor burden Target lesion SLD [cm], median (range) 2 (1, 5) 2 (2, 4) Target lesions, n, median (range) 11 (92) 5 (56) Lung metastasis, n (%) 2 (17) 1 (11) Bone metastasis, n (%) Baseline Characteristics IMA203CD8 Anzu - cel (IMA203) n=12 n=9 9 (75) 12 (100) 5 (42) 5 (42) 1 (8) 7 (78) 9 (100) 5 (56) 4 (44) 3 (33) Prior treatment, n (%) Radiation Chemotherapy, n (%) Targeted therapies, n (%) Pazopanib TCR T - cell therapy, n (%) 2 (1, 5) 5 (42) 3 (1, 6) 5 (56) Prior lines of systemic treatment Median, (range) ≥3, n (%) Treatment Experience n=12 n=9 Dose 1.59 (0.89, 10.00) 0.63 (0.35, 9.36) Total TCR T cells [x10 9 ], median (range) Data cutoff Mar 30, 2026 Dejka M. Araujo, M.D., A bstract #11516 PF1 SH2
PRESENTED BY: Anzu - cel (IMA203): Tolerability in Synovial Sarcoma a From start of LD - chemotherapy b From anzu - cel (IMA203) infusion. CRS, cytokine release syndrome; HLH, hemophagocytic lymphohistiocytosis; ICANS, immune effector cell - associated neurotoxicity sy ndrome; LD, lymphodepletion; TEAE, treatment - emergent adverse event. • Most frequent TEAEs were anticipated cytopenias associated with LD • No late onset or prolonged (Day ≥90 a ) grade ≥3 events observed, except for leukopenia and/or neutropenia in 2 patients • AESIs were low - grade (1 - 2), occurred by Day 30 b , and were transient • CRS was low - grade (1 - 2), expected and manageable, and resolved within 2 weeks • No HLH • 1 case of ICANS grade 1; onset Day 5, resolved in 2 days Adverse events of special interest (AESI) Grade ≥ 3 Any Grade Preferred term, n (%) 8 (89) 9 (100) Neutropenia 8 (89) 8 (89) Leukopenia 5 (56) 7 (78) Anemia 7 (78) 7 (78) Lymphopenia 4 (44) 7 (78) Thrombocytopenia 0 6 (67) Fatigue 0 6 (67) Nausea 0 5 (56) Vomiting 0 4 (44) Constipation 0 4 (44) Diarrhea 0 4 (44) Rash 0 3 (33) Alkaline phosphatase elevation 0 3 (33) Creatinine elevation 0 3 (33) Hypocalcemia 0 3 (33) Hypokalemia 0 3 (33) Hyponatremia 0 3 (33) Hypophosphatemia 0 3 (33) Insomnia 0 3 (33) Proteinuria 0 3 (33) Pyrexia 0 3 (33) Sinus tachycardia 0 3 (33) Transaminase elevation N=9 6 (67) CRS, any grade, n (%) 3 (33) Grade 1 3 (33) Grade 2 0 HLH, any grade, n (%) 1 (11) ICANS, any grade, n (%) 1 (11) Grade 1 TEAEs in ≥25% of patients (N=9) Data cutoff Mar 30, 2026 Dejka M. Araujo, M.D., A bstract #11516
PRESENTED BY: Anzu - cel (IMA203) : BOR in Patients with Synovial Sarcoma (n=9) 'DWDFXW RII 3RSXODWLRQ 6\QRYLDO6DUFRPD ,0$ 6SLGHU3ORW 6DUFRPD ,QGLFDWLRQ 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH 5(&,67 0RQWKVSRVW7FHOOLQIXVLRQ 7DUJHW/HVLRQVIURP%DVHOLQH >@ &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI 3' %DVHOLQH 35 Clinical activity including durable responses observed at all dose levels M e dian dose: 0.63 x10 9 total TCR T cells Best overall response (RECIST 1.1) SD PR cPR Change in Sum of Longest Diameter of Target Lesions from Baseline (%) ,QGLFDWLRQ 7DUJHW/HVLRQVIURP%DVHOLQH 5(&,67 %HVW &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI %DVHOLQH :DWHUIDOO3ORW 3RSXODWLRQ 6\QRYLDO6DUFRPD ,0$ 'DWDFXW RII 25 0 - 25 - 50 - 75 - 100 Baseline Change in Sum of Longest Diameter of Target Lesions from Baseline (%) a One patient with non - evaluable post - BL scan non included in assessment of tumor reduction and not depicted in plot but assessed for ORR calculation . ORR: according to RECIST 1.1 at any post - BL scan, PD or death at any prior timepoint; b Confirmed ORR for patients with ≥2 post - BL scans per RECIST 1.1, PD or death at any prior timepoint, those with ongoing unconfi rmed PR/CR were excluded. BL , baseline; (c)ORR, (confirmed) objective response rate; (c)PR , (confirmed) partial response; DCR, disease control rate; mDOR , median duration of response; mFU , median follow - up; NR, not reached; PD , progressive disease; SD , stable disease; TCR, T - cell receptor . Baseline PD PR Data cutoff Mar 30, 2026 Tumor reduction: 88% (7/8) 56% (5/9) ORR a 33% (3/9) cORR b 89% (8/9) DCR (at week 6) 10.5 (4.4, 23) NR mDOR (range), months mFU DL2 DL3 DL5 DL2 DL2 DL2 DL5 DL5 Dejka M. Araujo, M.D., A bstract #11516
PRESENTED BY: IMA203CD8: Tolerability in Synovial Sarcoma a Testicular/scrotal disorders includes grouped terms; b Grade 3 CRS with transient Grade 3 hepatotoxicity improved to Grade 2 within 10 days; CRS resolved completely without need fo r v asopressors/ventilator support; c Further modification of the inclusion/exclusion criteria and IL - 2 scheme allowed continuation of dose escalation from DL4c up to present DL7; CRS, cytokine release syndrome; HLH, hemophagocytic lymphohistiocytosis; ICANS, immune effector cell - associated neurotoxicity syndrome; LD, lymphodepletion; MTD, maximum tolerated dose; TEAE, treatment - emergent adverse event. • Most frequent TEAEs were anticipated cytopenias associated with lymphodepletion • Infrequent long - term (Day ≥ 90) grade ≥3 TEAEs included cytopenias (n=6) and/or hypertension (n=2) • AESIs were low - grade (1 - 2), occurred early, and were transient • CRS was mostly low - grade (1 - 2), expected and manageable • No HLH or ICANS • 1 DLT b at DL4b (MTD not reached c ) Adverse events of special interest (AESI) Grade ≥ 3 Any Grade Preferred term, n (%) 12 (100) 12 (100) Neutropenia 6 (50) 11 (92) Anemia 4 (33) 11 (92) Thrombocytopenia 1 (8) 11 (92) Transaminase elevation 9 (75) 9 (75) Lymphopenia 0 8 (67) Nausea 0 6 (50) Fatigue 0 5 (42) Rash 1 (8) 4 (33) Creatinine elevation 0 4 (33) Constipation 0 4 (33) Headache 0 4 (33) Hyponatremia 1 (8) 4 (33) Hypophosphatemia 0 4 (33) Pyrexia 0 4 (33) Testicular/scrotal disorders a 0 3 (25) Back pain 0 3 (25) Dyspnoea 2 (17) 3 (25) Hypertension 0 3 (25) Insomnia 0 3 (25) Edema peripheral N=12 12 (100) CRS, any grade, n (%) 5 (42) Grade 1 5 (42) Grade 2 2 (17) Grade 3 0 HLH, any grade, n (%) 0 ICANS, any grade, n (%) TEAEs in ≥25% of patients (N=12) Data cutoff Mar 30, 2026 Dejka M. Araujo, M.D., A bstract #11516
PRESENTED BY: 'DWDFXW RII 3RSXODWLRQ 6\QRYLDO6DUFRPD ,0$ &' 6SLGHU3ORW 6DUFRPD ,QGLFDWLRQ 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH 5(&,67 3' 3' %DVHOLQH %DVHOLQH 35 35 0RQWKVSRVW7FHOOLQIXVLRQ 7DUJHW/HVLRQVIURP%DVHOLQH >@ &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI 2QJRLQJ IMA203CD8: BOR in Patients with Synovial Sarcoma (n=12) a ORR: according to RECIST 1.1 at any post - BL scan, PD or death at any prior timepoint; cORR : according to RECIST 1.1 for patients with ≥2 post - BL scans, PD or death at any prior timepoint; b Confirmed ORR for patients with ≥2 post - BL scans per RECIST 1.1, PD or death at any prior timepoint, those with ongoing unconfirmed PR/CR were excluded. BL , baseline; BOR , best overall response; (c)CR , (confirmed) complete response; (c)ORR, (confirmed) objective response rate; (c)PR , (confirmed) partial response; DCR, disease control rate; mDOR , median duration of response; mFU , median follow - up; NR, not reached; PD , progressive disease; SD , stable disease; TCR, T - cell receptor. Clinical activity including durable responses observed at all dose levels Median dose: 1.59 x10 9 total TCR T cells Best overall response (RECIST 1.1) PD SD PR cPR CR cCR Ongoing ,QGLFDWLRQ %HVW &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI7DUJHW/HVLRQVIURP%DVHOLQH 5(&,67 %DVHOLQH 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH 5(&,67 2QJRLQJ :DWHUIDOO3ORW 3RSXODWLRQ 6\QRYLDO6DUFRPD ,0$ &' 'DWDFXW RII 25 0 - 25 - 50 - 75 - 100 Change in Sum of Longest Diameter of Target Lesions from Baseline (%) 15 - 1 - 18 - 26 - 41 - 42 - 50 - 61 - 66 - 73 - 77 - 100 BL Data cutoff Mar 30, 2026 Tumor reduction: 92% (11/12) DL4a DL3 DL4a DL4b DL7 DL3 DL4a DL4a DL4a DL4a DL4a DL4b Dejka M. Araujo, M.D., A bstract #11516 67% (8/12) ORR a 64% (7/11) cORR b 100% (12/12) DCR (at week 6) 14.8 (3.7, 31.8+) 31.0 mDOR (range), months mFU
PRESENTED BY: Patient Case: Long - Term Disease Control of >4 Years After Prior TCR T - cell Therapies a At time of IMA203CD8 infusion, right pleura metastasis not selected as a target lesion; subsequent PET - CT on April 2025 demonst rated no evidence of FDG - avid malignancy BL , baseline; BOR , best overall response; CR , complete response; cPR , confirmed partial response; DL , dose level; PD , progressive disease; PFS , progression - free survival; SD , stable disease; TKI , Tyrosine Kinase Inhibitor. Soft tissue sarcoma S ubtype : synovial sarcoma BOR: CR Chemotherapy 2011 - 2012: BOR: SD TKI (Pazopanib) 2018: BOR: SD MAGE - A4 - directed TCR T - cell therapy 2019: Initial Diagnosis Sep 2011 Prior Systemic Treatments Oct 2011 – Sep 2019 Anzu - cel (IMA203) Apr 2021 IMA203CD8 Oct 2023 Analysis of single lesions over time Status at the time of PD with anzu - cel (IMA203) Target lesion site PD Right pulmonary hilum metastasis New lesion Right infrahilar lymph node (lymphadenopathy) No evidence of disease Right pleura metastasis Suspected fibrosis - touch preps were acellular; not selected as target lesion for IMA203CD8 a Right pleura metastasis a 0 R Q W K V I U R P 7 & H O O , Q I X V L R Q , 0 $ , 0 $ & ' , Q I X V L R Q 5 L J K W 3 X O P R Q D U \ K L O X P P D V V 5 L J K W , Q I U D K L O D U O \ P S K Q R G H O \ P S K D G H Q R S D W K \ 1 H Z / H V L R Q , 0 $ & ' % D V H O L Q H 6 F D Q * ( 1 * ( 1 6 \ Q R Y L D O ௐ 6 D U F R P D $ Q D O \ V L V R I V L Q J O H O H V L R Q R Y H U W L P H ! \ H D U V 5 L J K W S O H X U D P H W D V W D V L V 5 L J K W S O H X U D P H W D V W D V L V / H V L R Q V W D W X V D W W K H W L P H R I 3 ' * ( 1 3 ' 1 H Z O H V L R Q 1 R H Y L G H Q F H R I G L V H D V H 6 X V S H F W H G I L E U R V L V W R X F K S U H S V Z H U H D F H O O X O D U 3 ' F 3 ' 3 5 % / Anzu - cel Apr 2021 IMA203CD8 Oct 2023 1.8 x 10 9 total TCR T cells Dose: 6.1 cm BL tumor burden: 2 No of lesions: ongoing cPR ( - 48%) BOR: ongoing at 29.4 months PFS: 0.4 x 10 9 total TCR T cells Dose: 8.4 cm BL tumor burden: 3 No of lesions: cPR ( - 46%) BOR: 24.4 months PFS: Data cutoff Mar 30, 2026 Male, 49 y/o at first trial enrollment Dejka M. Araujo, M.D., A bstract #11516 cPD IMA203CD8 BL scan Last anzu - cel scan
PRESENTED BY: Key Takeaways • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies • Anzutresgene autoleucel ( anzu - cel, IMA203) and IMA203CD8 are distinct investigational one - time autologous TCR T - cell therapies targeting the cancer - associated antigen PRAME, a novel target for synovial sarcoma • PRAME - targeted TCR T - cell therapies demonstrate an expected and manageable tolerability profile and durable antitumor activity in patients with metastatic synovial sarcoma • The potentially transformative clinical activity of PRAME - targeted TCR T - cell therapy in metastatic synovial sarcoma supports further development HLA, human leukocyte antigen; PRAME, preferentially expressed antigen in melanoma; TCR, T - cell receptor. Dejka M. Araujo, M.D., A bstract #11516 Data cutoff Mar 30, 2026
PRESENTED BY: Thank you — Trial Participants & Caregivers University Hospital Dresden University Hospital Würzburg University Hospital Hamburg IMA203 - 101 Phase 1 Trial ( patients with synovial sarcoma) Sponsor: Immatics University of Pittsburgh Medical Center UT MD Anderson United States University of Miami Health System Columbia University Medical Center Germany Data cutoff Mar 30, 2026 Dejka M. Araujo, M.D., A bstract #11516
PRESENTED BY: Appendix Dejka M. Araujo, M.D., A bstract #11516
PRESENTED BY: Anzu - cel Phase 1 Study Design Data cutoff Mar 30, 2026 Total TCR T cells calculated from defined number of TCR T cells/m2 body surface area (BSA) per dose level x 1.8 m2 BSA (BSA o f a verage patient). BSA, body surface area; DL, dose level; DLT, dose - limiting toxicity; TCR, T - cell receptor. Total n=9 patients with synovial sarcoma DL1 (n=0) ~0.07 - 0.11 x 10 9 total TCR T cells DL2 (n=4) ~0.22 – 0.32 x 10 9 total TCR T cells DL3 (n=2) ~0.36 – 0.86 x 10 9 total TCR T cells DL4 (n=0) ~0.36 - 2.16 x 10 9 total TCR T cells DL5 (n=3) ~2.16 – 8.46 x 10 9 total TCR T cells Phase 1b Dose Expansion at RP2D (1 - 10 billion total TCR T cells) Dejka M. Araujo, M.D. Data cutoff Mar 30, 2026
PRESENTED BY: Patients with Synovial Sarcoma Treated with Anzu - cel (IMA203) in Phase 1 a presented patient case; BOR , best overall response; DL , dose level; (c)PR , (confirmed) partial response; SD , stable disease; PD , progressive disease; PFS , progression free survival. Reason for Progression Comment BOR (Max % change of target lesions) BOR DL Total infused dose TCR - T cells 1 [x10 9 ] Prior treatments No of prior systemic treatment lines Indication Target and non - target progression Unconfirmed response until 2.8 months PFS - 75 PR DL5 3.94 Chemotherapy 1 Synovial Sarcoma Target progression and new lesions Response until 11.9 months PFS - 69 cPR DL5 6.01 TNF α + chemotherapy (melphalan) Chemotherapy 2 Synovial Sarcoma Target progression Response until 5.8 months PFS - 61 cPR DL2 0.39 Chemotherapy Chemotherapy 2 Synovial Sarcoma Target progression Response until 24.4 months PFS - 46 cPR DL2 0.41 Chemotherapy Pazopanib MAGEA4 TCR T - cell therapy 3 Synovial Sarcoma Target and non - target progression Unconfirmed response until 2.5 months PFS - 40 PR DL2 0.35 Chemotherapy Chemotherapy 2 Synovial Sarcoma Clinical PD Disease stabilization until 1.4 months PFS - 26 SD DL5 9.36 Chemotherapy Pazopanib Exp. therapy (NY - ESO - 1 TCR T cells) Pazopanib Exp. therapy (CFT8634) 5 Synovial Sarcoma Clinical PD Disease stabilization until 2.8 months PFS - 2 SD DL3 0.81 Chemotherapy Chemotherapy Chemotherapy Chemotherapy P azopanib MAGEA4 TCR T - cell therapy 6 Synovial Sarcoma a Target progression Disease stabilization until 2.5 months PFS 5 SD DL2 0.37 Chemotherapy Pazopanib Chemotherapy 3 Synovial Sarcoma Non - target progression Progressive disease at 1.4 months PFS n/a PD DL3 0.63 Chemotherapy Chemotherapy Chemotherapy Chemotherapy Pazopanib + chemotherapy 5 Synovial Sarcoma Dejka M. Araujo, M.D. Data cutoff Mar 30, 2026
PRESENTED BY: Phase 1a Dose Escalation Study Design 1 Based on initial safety data observed with anzu - cel (IMA 203 ), dose escalation for IMA 203 CD 8 was initiated at DL 3 ; 2 DL 4 a cleared in Dec 2023 ; 3 DLTs at DL 4 b triggered modifications of the eligibility criteria, adapted patient population is treated with DL 4 c . Each dose level ≥ DL 4 c is evaluated “ IL - 2 : start without IL - 2 ; if considered tolerable, either add IL - 2 at the same dose, or escalate to the next dose without IL - 2 ; total TCR T cells calculated from defined number of TCR T cells/m 2 BSA per dose level x 1 . 8 m 2 BSA (BSA of average patient) . BSA, body surface area ; DL, dose level ; DLT, dose - limiting toxicity ; IL, interleukin ; TCR, T - cell receptor . DL3 1 (n=2) ~0.36 - 0.86 x 10 9 total TCR T cells DL4a 2 (n=7) ~0.87 - 1.44 x 10 9 total TCR T cells DL4b 3 (n=2) ~1.45 - 2.16 x 10 9 total TCR T cells DL4c (n=0) ~1.45 - 2.16 x 10 9 total TCR T cells DL5 (n=0) ~2.17 - 3.6 x 10 9 total TCR T cells DL6 (n= 0 ) ~3.6 - 7.2 x 10 9 total TCR T cells DL7 (n=1) ~ 7.2 - 10 x 10 9 total TCR T cells Median dose of 1.59 billion total IMA203CD8 TCR T cells Total n=12 patients with synovial sarcoma ц Low Dose IL - 2 Dejka M. Araujo, M.D. Data cutoff Mar 30, 2026 PF1
PRESENTED BY: Patients with Synovial Sarcoma Treated with IMA203CD8 in Phase 1 BOR , best overall response; DL , dose level; cCR , confirmed complete response; (c)PR , (confirmed) partial response; SD , stable disease. PFS , progression free survival. Reason for Progression Comment BOR (Max % change of target lesions) BOR DL Total infused dose TCR - T cells 1 [x10 9 ] Prior treatments No of prior systemic treatment lines Indication Ongoing response at 32.4 months PFS - 100 cCR 4b 2.05 Chemotherapy 1 Synovial Sarcoma Target progression Response until 16.1 months PFS - 77 cPR 4a 1.15 Chemotherapy 1 Synovial Sarcoma Ongoing response at 34.7 months PFS - 73 cPR 4a 1.56 Chemotherapy Chemotherapy 2 Synovial Sarcoma Target and non - target progression and news lesions Response until 6.1 months PFS - 66 cPR 4a 1.61 Chemotherapy Pazopanib Chemotherapy 3 Synovial Sarcoma Ongoing response at 29.4 months PFS - 61 cPR 4a 1.81 Chemotherapy Pazopanib MAGEA4 TCR T - cell therapy 3 Synovial Sarcoma Target and non - target progression Response until 5.7 months PFS - 50 cPR 4a 1.53 Chemotherapy 1 Synovial Sarcoma Target and non - target progression and new lesions Response until 4.9 months PFS - 42 cPR 3 1.00 Pazopanib + chemotherapy Pazopanib 2 Synovial Sarcoma Ongoing response at 6.7 months PFS (confirmatory scan results pending) - 41 PR 7 10.00 Chemotherapy 1 Synovial Sarcoma Target progression and new lesions Disease stabilization until 5.5. months PFS - 26 SD 4b 1.49 Chemotherapy Pazopanib Pazopanib 3 Synovial Sarcoma Target progression Disease stabilization until 2.8 months PFS - 18 SD 4a 1.75 Chemotherapy 1 Synovial Sarcoma Non - target progression and new lesions Disease stabilization until 2.8 months PFS - 1 SD 3 0.89 Chemotherapy Chemotherapy Chemotherapy Chemotherapy Chemotherapy 5 Synovial Sarcoma Clinical PD Disease stabilization until 2.9 months PFS 15 SD 4a 1.68 Chemotherapy Chemotherapy Chemotherapy Pazopanib Chemotherapy 5 Synovial Sarcoma Dejka M. Araujo, M.D. Data cutoff Mar 30, 2026
Exhibit 99.6
PRESENTED BY: First - in - Human Results With IMA401 , a MAGEA4 /8 - targeted T - cell Receptor - based Bispecific T - cell Engager ( TCER ), in Recurrent or Refractory Solid Tumors Martin Wermke¹ , Dirk Jaeger² , Annalen Bleckmann³ , Manik Chatterjee⁴, Stefanie Groepper ⁵, Daniel Heudobler ⁶, Judith S Hecker⁷, Silvia Spoerl ⁸, Martin Sebastian⁹, Moritz Kleemiss¹ ⁰, Heiko Becker¹¹ , Stefan Knop¹² , Farastuk Bozorgmehr¹³ , Mathias Haenel¹ ⁴, Sarah Missel¹ ⁵, Carsten Reinhardt¹ ⁵, Olga Veremchuk¹ ⁵, Manuel Ruh¹ ⁵, Cedrik Michael Britten¹ ⁵, Sebastian Ochsenreither¹ ⁶ ¹ TU Dresden University of Technology, NCT/UCC Early Clinical Trial Unit, Dresden, Germany; ² National Centre for Tumor Diseases , Heidelberg, Germany; ³ Universitätsklinikum Münster, Münster, Germany; ⁴ University of Wuerzburg , Medizinische Klinik 2, Würzburg, Germany; ⁵ Marien Hospital Dusseldorf , Düsseldorf, Germany; ⁶ University Hospital Regensburg, Regensburg, Germany; ⁷ Department of Medicine III, Technical University of Munich, Munich, Germany; ⁸ University Hospital Erlangen, Erlangen, Germany; ⁹ University Hospital Frankfurt, Frankfurt, Germany; ¹⁰ University Hospital Bonn, Bonn, Germany; ¹¹ Depart men t of Hematology , Oncology , and Stem Cell Transplantation, Medical Center – University of Freiburg, Freiburg, Germany; ¹² Nuremberg General Hospital, Nuremberg , Germany; ¹³ Thoraxklinik Heidelberg gGmbH, University Hospital Heidelberg, Heidelberg, Germany; ¹⁴ Klinikum Chemnitz gGmbH, Chemnitz, Germany ¹⁵ Immatics Biotech nol ogies GmbH, Tübingen, Germany; ¹⁶ Charite Universitätsmedizin Berlin, Berlin, Germany Prof. Dr. med. Martin Wermke, Abstract #2507
PRESENTED BY: Key Takeaways • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies • IMA401 is a novel TCR - based bispecific T - cell engager targeting MAGEA4/8, expressed in multiple cancers incl. head & neck cancer and sqNSCLC • IMA401 demonstrates a manageable tolerability profile and encouraging efficacy as monotherapy or in combination with ICI • Next steps include a combination with a PRAME - directed TCR - based T - cell engager (IMA402) for >90% prevalence in sqNSCLC Prof. Dr. med. Martin Wermke, Abstract #2507 HLA, human leukocyte antigen; head and neck (H&N) cancer (squamous cell and adenocarcinoma); ICI, immune checkpoint inhibitor ; M AGE, melanoma - assicated antigen; PRAME, preferentially expressed in melanoma; sqNSCLC , squamous cell non - small cell lung cancer; TCR: T - cell receptor; Dose escalation data presented by Wermke et al., ESMO 2024. Data cutoff Mar 02, 2026
PRESENTED BY: Target Biology of IMA401 - Targeted MAGEA4/8 Peptide Prof. Dr. med. Martin Wermke, Abstract #2507 45% 40% 40% 30% 20% 65% Cutaneous melanoma n = 195 HNSCC n = 338 Ovarian carcinoma n = 351 sqNSCLC n = 91 Esophageal carcinoma n = 57 Bladder carcinoma n = 278 IMA401 target peptide shows high HLA - presentation levels MAGEA4/8 is expressed in multiple cancers Further increase in target presentation by IFN - γ MAGEA4 conventionally used peptide IMA401 target peptide MAGEA4 conventionally used peptide IMA401 target peptide MAGEA4/8 mRNA expression (TPM, log - scaled ) No clinical activity expected Clinical activity shown Potential for clinical activity Data on file: 1 MAGEA4/8 target prevalence by mRNA expression in late - stage solid tumors based on an optimized proprietary targe t expression threshold applied to TCGA data (TCGA stage III/IV); 2 Target peptide density in primary and metastatic solid tumors; median shown (solid line). Target peptide copy numbers per cell ( CpC ) measured by quantitative mass spec in paired samples (MAGEA4 vs. MAGEA4/8 in the same tumor); p - value by paired t - test, 3 CpC fold change in A375 cells presenting MAGEA4 and MAGEA4/8 peptides “ IFN - γ (100 U/mL, 48 h; n=3); p - value by paired t - test; HNSCC, head and neck squamous cell carcinoma; IFN - γ , interferon gamma, sqNSCLC , squamous cell non - small cell lung cancer; TPM, t ranscripts per million . Data cutoff Mar 02, 2026
PRESENTED BY: CD3/TCR Activated T cell Tumor Cell MAGEA4/8 pHLA IMA401 x Anti - tumor Activity High - affinity MAGEA4/8 pHLA binding (K D = 1.7 nM ; BLI) x Antibody - like format with half - life extension (HLE) Long half - life of 2 - 3 weeks a x Optimized tolerability Low binding to TCR/CD3 - expressing T cells (EC 50 ≥ 200 nM ; flow cytometry) IMA401 Designed to Improve Efficacy and Reduce Risk of CRS Prof. Dr. med. Martin Wermke, Abstract #2507 IMA401 is an investigational therapy and its use has not been proven to be safe or effective. It has not been approved by the FDA or any other regulatory agency o ut side of the US. a Median half - life IMA401: ~18 days, see appendix; BLI, biolayer interferometry; CRS, cytokine release syndrome; MAGEA, melanoma - associated antigen gene; pHLA , peptide - human leukocyte antigen; TCR, T - cell receptor. Data cutoff Mar 02, 2026
PRESENTED BY: IMA401 Phase 1 Basket Trial in Solid Tumors : Objectives and Eligibility Prof. Dr. med. Martin Wermke, Abstract #2507 Objectives Primary: • Determine MTD and/or RP2D in monotherapy and in combination with pembrolizumab Secondary: • Assess safety and tolerability • Evaluate initial anti - tumor activity (RECIST 1.1 and iRECIST ) • Assess pharmacokinetics Key Eligibility Criteria • Recurrent and/or refractory solid tumors a • HLA - A*02:01 positive • MAGEA4/8 - positive • ECOG performance status 0 - 1 • Received or not eligible for all available indicated standard of care treatments EudraCT No 2021 - 004326 - 30; NCT05359445; a Basket trial with >15 different tumor indications ; ECOG, Eastern Cooperative Oncology Group ; (i)RECIST, ( immune ) response evaluation criteria in solid tumors ; MTD, maximum tolerated dose; RP2D, recommended phase 2 dose. Data cutoff Mar 02, 2026
PRESENTED BY: Phase 1 Basket Trial of IMA401 in MAGEA4/8+ Solid Tumors Prof. Dr. med. Martin Wermke, Abstract #2507 0.18 mg 0.54 mg 1.8 mg 0.06 mg 1.2 mg 0.02 mg 0.0066 mg 2.0 mg 1.0 mg 1.5 mg 2.5 mg Phase 1a dose escalation completed 1.8 mg 1.2 mg 2.0 mg 1.0 mg 1.5 mg Dose selection : MTD not reached per adaptive BLRM model c , RP2D defined at 1 - 2 mg based on optimal risk - benefit - profile 1.0 mg 1.5 mg + Pembrolizumab + Pembrolizumab ICI combination : Pembrolizumab started 1 week before IMA401 (400 mg IV q6w) • MABEL - based starting dose • Dose escalation based on cohorts of 1 - 6 patients using adaptive design (BLRM model) • Initial q1w step dosing a (2 - 4 doses) up to target dose, q2w after reaching target dose b Phase 1a Dose Escalation 0.0066 mg - 2.5 mg IMA401 ( n=61 ) RP2D Selection 1.0 - 2.0 mg IMA401 ( n=32 ) ICI Combination at RP2D 1.0 or 1.5 mg IMA401 with Pembrolizumab ( n=12 ) RP2D selection completed IMA401 + ICI completed EudraCT No 2021 - 004326 - 30; NCT05359445; a Step dosing introduced at dose levels ≥1 mg, low - dose dexamethasone partially used as preventive measure for initial doses as ap plied for other bispecific T - cell engagers; ability to increase dose to previously cleared dose levels; b q2w: once every two weeks, weekly (q1w) IMA401 dosing was applied up to 0.54 mg; c MTD was not reached at 2.5 mg as defined by the adaptive BLRM model specifying probabilities of DLTs at tested doses. BLRM, Bayesian logistic regression model; ICI, immune checkpoint inhibitor; IV, intravenous; MABEL, minimum anticipated biological effect level; MTD, maximum tolerated dose, RP2D, recommended phase 2 dose; q6w, every 6 we eks. Data cutoff Mar 02, 2026
PRESENTED BY: RP2D (1 - 2 mg) All Dose Levels Baseline Characteristics IMA401 + Pembrolizumab b n=12 IMA401 (Monotherapy) n=32 IMA401 ± Pembrolizumab n=61 63 (33, 77) 62 (19, 82) 62 (19, 82) Age (years) , median (min, max) 12 (100)/ 0 (0) 19 (59)/ 13 (41) 39 (64)/ 22 (36) Sex , m ale/female n (%) 6 (42) 6 (50) 0 11 (34) 20 (63) 1 (3) 21 (34) 38 (62) 2 (3) ECOG performance status 0, n (%) 1, n (%) 2, n (%) 8 (67) 4 (33) 0 17 (53) 14 (44) 1 (3) 36 (59) 21 (34) 4 (7) LDH at baseline < 1xULN, n (%) 1 - 2xULN, n (%) > 2xULN, n (%) 63.1 (15.5, 121.0) 60 (11.3, 202.8) 67 (11.3, 202.8) Baseline tumor burden Target lesion SLD [cm], median (range) 4.5 (2, 10) 4 (33) 0 4 (1, 10) 10 (31) 2 (6) 4 (1, 10) 18 (30) 4 (7) Tumor lesions Number of lesions, median (min, max) Liver metastases, n (%) Brain metastases, n (%) Treatment Experience 3 (1, 4) 4 (1, 8) 3 (1, 8) No. of prior lines of systemic treatment median (min, max) 11 (92) 11 (92) 9 (75) 0 0 25 (78) 18 (56) 22 (69) 2 (6) 4 (13) 52 (85) 40 (66) 41 (67) 4 (7) 7 (11) Prior treatments, n (%) Chemotherapy ICI Targeted Therapy a Hormone Therapy Others Highly heterogenous patient population with >15 different indications Baseline Characteristics Prof. Dr. med. Martin Wermke, Abstract #2507 # of Patients Different Indications (all dose levels) 16 H&N (squamous, adenocarcinoma, others) 8 Melanoma (Cutaneous & Mucosal) 8 Synovial Sarcoma 4 sqNSCLC 4 TNBC 3 adNSCLC 3 Ovarian Carcinoma 2 Gastric Cancer 2 SCLC 2 Urothelial Carcinoma 1 Bladder Carcinoma 1 Esophageal Carcinoma 1 Gallbladder Adenocarcinoma 1 LCNEC Esophageal 1 LCNEC Lung 1 NET CUP 1 Non - melanoma Skin Cancer (Squamous) 1 Penile Cancer 1 Testicular GCT a Includes small molecule drugs and antibodies . b IMA401 dose in pembrolizumab expansion cohorts were 1 mg (n=8) or 1.5 mg (n=4); adNSCLC , adenocarcinoma non - small cell lung cancer ; ECOG, Eastern Cooperative Oncology Group; GCT, germ cell tumor; H&N, head and neck ; HNSCC, head and neck squamous cell carcinoma; ICI, immune checkpoint inhibitor ; LCNEC, large cell neuroendocrine carcinoma; LDH, lactate dehydrogenase ; NET CUP, neuroendocrine tumor of cancer of unknown primary ; RP2D, recommended phase 2 dose; SCLC, small cell lung cancer ; SLD, sum of longest diameter(s); sqNSCLC , squamous cell non - small cell lung cancer ; TNBC, triple - negative breast cancer ; ULN, upper limit of normal. Data cutoff Mar 02, 2026
PRESENTED BY: Tolerability of IMA401 Monotherapy Prof. Dr. med. Martin Wermke, Abstract #2507 IMA401 (Monotherapy) A ll treated patients > 2 mg n=7 1 - 2 mg (RP2D) n=32 All Dose Levels N=61 Treatment - related Adverse Events (safety analysis set) ≥ Grade 3 All Grades ≥ Grade 3 All Grades ≥ Grade 3 All Grades TRAEs a , n (%) 7 (100) 7 (100) 16 (50) 28 (88) 31 (51) 54 (89) Any TRAE 0 3 (43) 0 12 (38) 0 23 (38) Cytokine release syndrome 5 (71) 5 (71) 7 (22) 9 (28) 16 (26) 20 (33) Lymphopenia 5 (71) 5 (71) 5 (16) 11 (34) 11 (18) 19 (31) Neutropenia 2 (29) 3 (43) 0 5 (16) 2 (3) 10 (16) Thrombocytopenia 1 (14) 1 (14) 4 (13) 7 (22) 5 (8) 9 (15) Leukopenia 1 (14) 2 (29) 1 (3) 7 (22) 2 (3) 9 (15) Headache 3 (43) 4 (57) 2 (6) 2 (6) 7 (11) 8 (13) Anaemia 1 (14) 4 (57) 0 0 2 (3) 7 (11) Facial pain 0 1 (14) 1 (3) 3 (9) 1 (2) 7 (11) ALT increased 0 1 (14) 0 2 (6) 0 7 (11) Pyrexia 0 0 2 (6) 3 (9) 3 (5) 5 (8) AST increased 0 0 2 (6) 3 (9) 2 (3) 4 (7) Hypertension 0 0 0 0 1 (2) 2 (3) GGT increased 0 0 0 0 1 (2) 2 (3) Hypoxia 0 0 1 (3) 1 (3) 1 (2) 1 (2) C - reactive protein increased 0 0 0 0 1 (2) 1 (2) Chest pain 1 (14) 1 (14) 0 0 1 (2) 1 (2) Febrile neutropenia 1 (14) 1 (14) 0 0 1 (2) 1 (2) Pneumonia 0 0 1 (3) 1 (3) 1 (2) 1 (2) Sinus tachycardia • Most common AEs: • Low - grade CRS (38% G1 - G2, no ≥G3 ), mainly at first step dose, resolving within 1 - 3 days • Transient, mechanism - related lymphopenia • Mostly transient neutropenia, manageable with dexamethasone and G - CSF; not recurring after resolution with continued IMA401 treatment • No ICANS observed • MTD not reached • Neutropenia - related DLTs in 5 patients (incl. 3 at >RP2D b ) • No DLTs at RP2D with dexamethasone premedication Manageable tolerability profile with mostly transient AEs, consistent with MoA a All TRAEs at least possibly related to IMA401 infusion and / or pembrolizumab infusion with grade 1 - 2 occurring in at least 10% of all patients , all events with ≥ grade 3; b in patients with and without dexamethasone pre - medication , one possibly related death (pneumonia in the context of lung tumor progression and concurrent neutropenia) as previously reported , patient did not receive dexamethasone pre - medication ; ALT, a lanine aminotransferase; AST, aspartate aminotransferase; CSF, colony - stimulating factor , CRS, cytokine release syndrome , DLT, dose - limiting toxicity ; ICANS, immune effector cell - associated neurotoxicity syndrome ; GGT, g amma - glutamyltransferase ; MoA , mechanism of action ; RP2D, recommended phase 2 dose; TRAE, treatment - related adverse event . Data cutoff Mar 02, 2026
PRESENTED BY: IMA401 + Pembrolizumab IMA401 (Monotherapy) 1 - 2 mg (RP2D) b n=12 1 - 2 mg (RP2D) n=32 Treatment - related Adverse Events (safety analysis set) ≥ Grade 3 All Grades ≥ Grade 3 All Grades TRAEs a , n (%) 3 (25) 11 (92) 16 (50) 28 (88) Any TRAE 0 5 (42) 0 12 (38) Cytokine release syndrome 2 (17) 4 (33) 7 (22) 9 (28) Lymphopenia 0 1 (8) 5 (16) 11 (34) Neutropenia 0 1 (8) 0 5 (16) Thrombocytopenia 0 1 (8) 4 (13) 7 (22) Leukopenia 0 0 1 (3) 7 (22) Headache 0 0 2 (6) 2 (6) Anaemia 0 0 0 0 Facial pain 0 2 (17) 1 (3) 3 (9) Alanine aminotransferase increased 0 3 (25) 0 2 (6) Pyrexia 0 1 (8) 2 (6) 3 (9) Aspartate aminotransferase increased 0 0 2 (6) 3 (9) Hypertension 1 (8) 1 (8) 0 0 Gamma - glutamyltransferase increased 0 0 0 0 Hypoxia 0 0 1 (3) 1 (3) C - reactive protein increased 0 0 0 0 Chest pain 0 0 0 0 Febrile neutropenia 0 0 0 0 Pneumonia 0 0 1 (3) 1 (3) Sinus tachycardia Any group analyzed ICI - associated toxicities 0 Immune - mediated colitis 0 Immune - mediated pneumonitis 0 Immune - mediated hepatitis 0 Nephritis 0 Adrenal insufficiency 0 Immune - mediated hypophysitis No overlapping and/or additive toxicity observed in the combination cohort, supporting IMA401 combinability with ICIs. Tolerability of IMA401 at RP2D “ Pembrolizumab Prof. Dr. med. Martin Wermke, Abstract #2507 a All TRAEs at least possibly related to IMA401 infusion and / or pembrolizumab infusion with grade 1 - 2 occurring in at least 10% of all patients , all events with ≥ grade 3 and typical ICI - associated toxicities ; b IMA401 dose in pembrolizumab expansion cohorts were 1 mg (n=8) or 1.5 mg (n=4); ICI, immune checkpoint inhibitor ; RP2D, recommended phase 2 dose; TRAE, treatment - related adverse event . Data cutoff Mar 02, 2026
PRESENTED BY: Efficacy of IMA401 at RP2D “ Pembrolizumab Prof. Dr. med. Martin Wermke, Abstract #2507 H&N b ( n= 14) BOR (RECIST 1.1) PD SD PR cPR Ongoing response /disease control Other a (n=27, 14 different indications) IMA401 monotherapy IMA401 + Pembrolizumab 29 % ( 4/14 ) cORR 64% (9/14) DCR H&N (n=14) sqNSCLC Cut. Melanoma Cut. Melanoma Muc . Melanoma NET CUP Penile Cancer All H&N responders achieved deep responses with 60% - 100% tumor reduction Efficacy population: all patients in the safety set who received 4 IMA401 infusions in monotherapy and in addition at least 1 pe mbrolizumab infusion in combination therapy and had a post - baseline efficacy assessment, including patients with clinical progression; a Two patients not shown in plot due to clinical progression before post - infusion scan. b One patient not shown in plot due to clinical progression before post - infusion scan. BOR, best overall response; (c)ORR, (confir med) objective response rate; (c)PR, (confirmed) partial response; DCR, disease control rate; H&N, head and neck cancer; PD, progressive dis eas e; PFS, progression - free survival; RECIST, response evaluation criteria in solid tumors; RP2D, recommended phase 2 dose; SD, stable disease; OS, overall survival; mDOR , median duration of response. Data cutoff Mar 02, 2026
PRESENTED BY: 0 6 12 18 24 -100 -50 0 50 100 Months post First IMA401 Infusion C h a n g e i n S u m o f L o n g e s t D i a m e t e r o f T a r g e t L e s i o n s f r o m B a s e l i n e [ % ] BL PR ⯈ Palliative Radiotherapy + ⯈ ⯈ ⯈ ⯈ Durable Responses to IMA401 “ Pembrolizumab in Patients with H&N Cancer Prof. Dr. med. Martin Wermke, Abstract #2507 Efficacy population: all patients in the safety set who received 4 IMA401 infusions in monotherapy and in addition at least 1 pe mbrolizumab infusion in combination therapy and had a post - baseline efficacy assessment, including patients with clinical progression; a One patient not shown in plot due to clinical progression before post - infusion scan. BOR, best overall response; cPR , confirmed partial response; DOR, duration of response; H&N, head and neck cancer; PD, progressive disease; PR, partial response; RECIST, response evaluation criteria in solid tumors; RP2D, recommended phase 2 dose; SD, stable disease. n=14 a IMA401 + Pembrolizumab 8.8 mo mDOR 63% 43% 12m OS rate 6m PFS rate 3 of 4 responses ongoing at data cut - off Data cutoff Mar 02, 2026
PRESENTED BY: Patient Case: Partial Response after IMA401 + Pembrolizumab since 5+ months in H&N Cancer Prof. Dr. med. Martin Wermke, Abstract #2507 Scans courtesy of treating physician Dr. Moritz Kleemiß , UK Bonn; BOR, best overall response; H&N, head and neck; HNSCC, squamous cell carcinoma of the head and neck PR, partial re spo nse; q6w, every 6 weeks; SD, stable disease. 12 Patient Characteristics & Outcome 69 - year - old male with HNSCC, initial diagnosis in September 2023 Patient & Diagnosis Multiple metastases in lung and in one lymph node Disease at Baseline 2 prior lines of systemic therapy with BOR SD • Pembrolizumab, BOR: SD (adjuvant) • Pembrolizumab, carboplatin, 5 - fluorouracil, BOR: SD (metastatic) • Progressed prior to IMA401 treatment Prior systemic therapy 1.5 mg IMA401 + 400 mg pembrolizumab q6w Study Treatment Ongoing PR at 5+ months, BOR - 70% Response Assessment Lung, right lower lobe 2 months 3.5 months 5 months Baseline Lung, right upper lobe 0 5 10 15 20 Lung, right upper lobe Lung, right lower lobe S ize (mm) 18.9 mm 5.3 mm 5.4 mm 4.5 mm 19.8 mm 12.8 mm 7.8 mm 7.0 mm Data cutoff Mar 02, 2026
PRESENTED BY: Patient Case: Partial Response after IMA401 + Pembrolizumab in sqNSCLC Prof. Dr. med. Martin Wermke, Abstract #2507 a Treatment start 5 weeks after last prior systemic therapy; scans courtesy of treating physician Prof. Dr. Martin Wermke , TU Dresden; BOR, best overall response; ICI, immune checkpoint inhibitor; PR, partial response; Pt, patient; Q6W, once ever y 6 weeks; SD, stable disease; sqNSCLC , squamous cell non - small cell lung cancer. Lung Baseline 7 weeks Jaw Head Head PR with IMA401 in 5 th line ICI - resistant sqNSCLC patient with shrinkage of all target lesions Patient Characteristics & Outcome 63 - year - old male with ICI - resistant sqNSCLC ; initial diagnosis in July 2018 Patient & Diagnosis Multiple metastases i n lymph nodes, skin, lung and bone Disease at Baseline 4 prior lines of systemic therapy with BOR SD • Adjuvant: cisplatin, vinorelbine • Carboplatin, ipilimumab, nivolumab, paclitaxel, BOR: SD • Docetaxel, ramucirumab, BOR: SD • Progressed after all prior treatments • Carboplatin, gemcitabine, BOR: SD, discontinued early due to toxicity Prior systemic therapy 1 mg IMA401 + 400 mg pembrolizumab Q6W; Pt died during a biopsy due to pulmonary haemorrhage Study Treatment a PR at first scan post IMA401 treatment start with - 39% tumor reduction Response Assessment Data cutoff Mar 02, 2026
PRESENTED BY: MAGEA4/8 + PRAME + IMA401 MAGEA4/8 + IMA402 PRAME Bispecific Dual Targeting in sqNSCLC Prof. Dr. med. Martin Wermke, Abstract #2507 MAGEA4/8 + PRAME + >90% MAGEA4/8 OR PRAME of sqNSCLC Double Positive ~60% of sqNSCLC Representative duplex IF image of a double positive human sqNSCLC tumor PRAME (red) MAGEA4 (green) In vitro model of PRAME and MAGEA4/8 double positive tumor Double Positive Tumors: Potentially Synergistic Anti - Tumor Activity IMA402 PRAME Bispecific a • PRAME is a cancer testis antigen expressed in more than 50 cancers • IMA402 PRAME Bispecific Phase 1a dose escalation completed ( NCT05958121 ) • Heavily pre - treated last - line patients • Favorable tolerability in RP2D range with no high - grade CRS, no ICANS • 30% (6/20) cORR across all indications Data on file - dot plot: PRAME and MAGEA4/8 mRNA expression in stage III/IV sqNSCLC TCGA samples (TPM, log - scale), PRAME and MAGEA4/8 target prevalences are based on an optimized proprietary target expression th reshold applied to TCGA data; Bar graph: In vitro LDH - killing assay, A375 tumor cell line with low target density of PRAME (~50 copies per cell) and medium target density of MAGEA4/8 (~250 copies per cell) , Bispecific concentration: 1nM IMA401 and 10 nM IMA402; a Immatics Corporate Data Release, Nov 2025, data cut - off Sep 26, 2025; cORR , confirmed objective response rate; CRS, cytokine release syndrome; ICANS, immune effector cell - associated neurotoxicity syndrome; IF, immu nofluorescence; RP2D, recommended phase 2 dose; sqNSCLC , squamous cell non - small cell lung cancer. Data cutoff Mar 02, 2026
PRESENTED BY: Key Takeaways • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies • IMA401 is a novel TCR - based bispecific T - cell engager targeting MAGEA4/8, expressed in multiple cancers incl. head & neck cancer and sqNSCLC • IMA401 demonstrates a manageable tolerability profile and encouraging efficacy as monotherapy or in combination with ICI • Next steps include a combination with a PRAME - directed TCR - based T - cell engager (IMA402) for >90% prevalence in sqNSCLC Prof. Dr. med. Martin Wermke, Abstract #2507 HLA, human leukocyte antigen; head and neck (H&N) cancer (squamous cell and adenocarcinoma); ICI, immune checkpoint inhibitor ; M AGE, melanoma - assicated antigen; PRAME, preferentially expressed in melanoma; sqNSCLC , squamous cell non - small cell lung cancer; TCR: T - cell receptor; Dose escalation data presented by Wermke et al., ESMO 2024. Data cutoff Mar 02, 2026
PRESENTED BY: 16 IMA401 Phase 1 Trial Sponsor: Immatics Thank You – Trial Participants & Caregivers Prof. Dr. med. Martin Wermke, Abstract #2507 University Hospital, Dresden University Hospital Bonn Charité – University Medicine Berlin University Hospital Heidelberg TUM University Hospital Munich Germany University Hospital Würzburg Marien Hospital Düsseldorf University Hospital Münster University Hospital Frankfurt University Medical Center Freiburg University Hospital Regensburg Nuremberg General Hospital University Hospital Erlangen Chemnitz Clinical Centre National Centre for Tumor Diseases, Heidelberg
PRESENTED BY: Appendix Prof. Dr. med. Martin Wermke, Abstract #2507
PRESENTED BY: IMA401 Bispecific Pharmacokinetics in Patients Prof. Dr. med. Martin Wermke, Abstract #2507 Shown are the median and interquartile ranges (25 - 75%) for all patients with evaluable PK samples that received biweekly target doses at or above 1 mg. Median half - life: 17.5 days (n=22) Data cutoff Mar 02, 2026
PRESENTED BY: Patient Disposition Prof. Dr. med. Martin Wermke, Abstract #2507 Dose groups are shown according to highest actual IMA401 dose received at any time point, as initial target dose or via intrapatient dose escalation and as monotherapy or combination with pembrolizumab. Efficacy population: all patients in the safety set who received 4 IMA401 infusions in monotherapy and in addition at least 1 pembrolizumab infusion in combination therapy a nd had a post - baseline efficacy assessment, including patients with clinical progression; H&N, head and neck cancer; RP2D, recommended phase 2 dose. Infused Patients (n=61 enrolled patients) 1 - 2 mg RP2D IMA401 Monotherapy (n=32) <1mg (n=8) Patients not evaluable for efficacy: Received < 4 IMA401 infusions: n=2 >2mg (n=7) IMA401 Monotherapy >2mg (n=7) <1mg (n=10) IMA401 Monotherapy 1 - 2 mg RP2D IMA401 + Pembrolizumab (n=12) 1 - 2 mg RP2D IMA401 + Pembrolizumab (n=11) 1 - 2 mg RP2D IMA401 Monotherapy (n=30) H&N n=8 Other n=22 Patients not evaluable for efficacy: Received < 4 IMA401 infusions: n=2 Patients not evaluable for efficacy: Received < 4 IMA401 infusions: n=1 Other n=5 H&N n=6 Safety Population Efficacy Population Data cutoff Mar 02, 2026
PRESENTED BY: Baseline Characteristics for IMA401 at RP2D ± Pembrolizumab in Patients with H&N Cancer Prof. Dr. med. Martin Wermke, Abstract #2507 This Phase 1 basket trial was not specifically designed for H&N cancer ; therefore , some H&N subclassification data may be limited or not fully conclusive . ECOG, Eastern Cooperative Oncology Group ; H&N, head and neck ; ICI, immune checkpoint inhibitor ; LDH, lactate dehydrogenase ; RP2D, recommended phase 2 dose; ULN, upper limit of normal. H&N Baseline Characteristics (safety analysis set) RP2D (1 - 2mg) n = 14 62.5 (35, 70) Age (years) , median (min, max) 12 (86)/ 2 (14) Sex , m ale/female n (%) 6 (43) 8 (57) 0 (0) ECOG performance status 0, n (%) 1, n (%) 2, n (%) 9 (64) 5 (36) 0 (0) LDH at baseline < 1xULN, n (%) 1 - 2xULN, n (%) > 2xULN, n (%) 54.1 (15.5, 129.0) Baseline tumor burden Median target lesion sum of diameter (mm) (min, max) 3 (2, 10) 3 (21) 0 (0) Tumor lesions Number of lesions, median (min, max) Liver metastases, n (%) Brain metastases, n (%) Treatment Experience 2.5 (1, 8) No. of prior lines of systemic treatment median (min, max) 12 (86) 11 (79) 10 (71) 1 (7) 0 (0) Prior treatments, n (%) Chemotherapy ICI Targeted Therapy a Hormone Therapy Others H&N Baseline Characteristics (safety analysis set) RP2D (1 - 2mg) n = 14 8 (57) 2 (14) 1 (7) 3 (21) Main tumor location, n (%) Oral cavity Larynx Hypopharynx Other 3 (21) 2 (14) 9 (64) p16, n (%): p16 - positive p16 - negative p16 unknown All H&N patients treated in the IMA401 + pembrolizumab combination cohort received prior ICI Data cutoff Mar 02, 2026
PRESENTED BY: Summary of AEs in Patients treated with IMA401 “ Pembrolizumab Prof. Dr. med. Martin Wermke , Abstract #2507 a IMA401 dose in pembrolizumab expansion cohorts were 1 mg (n=8) or 1.5 mg (n=4); b Two of the three deaths were unrelated to IMA401 and / or pembrolizumab . One treatment - unrelated death was due to pulmonary hemorrhage ( biopsy - related ) and the other was due to respiratory failure ( unrelated ). AE, adverse event ; CRS, cytokine release syndrome ; ICANS, immune effector cell - associated neurotoxicity syndrome ; RP2D, recommended phase 2 dose; SAE, serious adverse events . IMA401 + Pembrolizumab IMA401 (Monotherapy) All treated patients Safety Summary (safety analysis set) 1 - 2mg (RP2D) a n=12 >2 mg n=7 1 - 2 mg (RP2D) n=32 All DL N=61 4 (33) 6 (86) 8 (25) 24 (39) Any SAE 1 (8) 3 (43) 5 (16) 11 (18) Treatment - related SAEs 0 1 (14) 3 (9) 4 (7) Dose reduction due to AE 1 (8) 0 3 (9) 4 (7) Dose interruption due to AE 1 (8) 4 (57) 6 (19) 13 (21) Dose delayed due to AE 1 (8) 1 (14) 1 (3) 4 (7) Dose discontinuation due to AE Deaths due to AE b 0 1 (14) 0 1 (2) due to related AEs 2 (17) 0 0 2 (3) due to unrelated AEs AEs of special interest 5 (42) 3 (43) 12 (38) 23 (38) CRS 0 0 0 0 ICANS Data cutoff Mar 02, 2026
PRESENTED BY: Tolerability of IMA401 at RP2D “ Pembrolizumab in all Indications and in Patients with H&N Cancer IMA401 RP2D (1 - 2 mg) ± Pembrolizumab IMA401 RP2D (1 - 2 mg) ± Pembrolizumab H&N n=14 all indications n=44 Treatment - related Adverse Events (safety analysis set) ≥ Grade 3 All Grades ≥ Grade 3 All Grades TRAEs a , n (%) 5 (36) 14 (100) 19 (43) 39 (89) Any TRAE 0 6 (43) 0 17 (39) Cytokine release syndrome 2 (14) 4 (29) 9 (20) 13 (30) Lymphopenia 1 (7) 4 (29) 5 (11) 12 (27) Neutropenia 0 2 (14) 0 6 (14) Thrombocytopenia 0 1 (7) 4 (9) 8 (18) Leukopenia 0 2 (14) 1 (2) 7 (16) Headache 0 0 2 (5) 2 (5) Anaemia 0 0 0 0 Facial pain 0 1 (7) 1 (2) 5 (11) Alanine aminotransferase increased 0 2 (14) 0 5 (11) Pyrexia 0 0 2 (5) 4 (9) Aspartate aminotransferase increased 1 (7) 1 (7) 2 (5) 3 (7) Hypertension 1 (7) 1 (7) 1 (2) 1 (2) Gamma - glutamyltransferase increased 0 0 0 0 Hypoxia 0 0 1 (2) 1 (2) C - reactive protein increased 0 0 0 0 Chest pain 0 0 0 0 Febrile neutropenia 0 0 0 0 Pneumonia 0 0 1 (2) 1 (2) Sinus tachycardia Data cutoff Mar 02, 2026 . a All TRAEs at least possibly related to IMA401 infusion and/or pembrolizumab infusion with grade 1 - 2 occurring in at least 10% of all SAS patients, all events with ≥ grade 3 ; CSF, colony - stimulating factor, CRS, cytokine release syndrome, H&N, head and neck; RP2D, recommended phase 2 dose; TRAE, treatment - related adverse event. Data cutoff Mar 02, 2026 Prof. Dr. med. Martin Wermke , Abstract #2507
PRESENTED BY: PR -100 -50 0 50 100 -11 -6 0 18 29 56 62 -100-100 -75 -73 -70 -66 -62 -50 -43 -39 -25 -22 -20 -19 -19 -15 -15 -14 -12 -7 -6 0 1 2 3 9 10 13 13 19 19 20 22 38 40 67 69 96 -36 -31 -4 6 9 14 29 98 B e s t % C h a n g e i n S u m o f L o n g e s t D i a m e t e r o f T a r g e t L e s i o n s f r o m B a s e l i n e a n d B O R ( R E C I S T 1 . 1 ) BL ⯈ BOR (RECIST 1.1) Ongoing response/ disease control PD PR cPR SD SD IMA401 + Pembrolizumab ⯈ ⯈ ⯈ < 1 mg 1 - 2 mg (RP2D Range) > 2 mg ⯈ SDPD ⯈ ⯈ ⯈ S y n o v i a l S a r c o m a S y n o v i a l S a r c o m a H N S C C S y n o v i a l S a r c o m a H N S C C T N B C C u t . M e l a n o m a E s o p h a g e a l C a r c i n o m a C u t . M e l a n o m a S C L C S C L C T N B C s q N S C L C G a l l b l a d d e r A d e n o c a r c i n o m a G a s t r i c A d e n o c a r c i n o m a L C N E C E s o p h a g e a l a d N S C L C G a s t r i c C a n c e r T N B C H N S C C S y n o v i a l S a r c o m a O v a r i a n C a r c i n o m a H & N - L a c r i m a l S a c H N S C C H N S C C C u t . M e l a n o m a H N S C C H & N - A d e n o i d C y s t i c C a r c i n o m a U r o t h e l i a l C a r c i n o m a s q N S C L C S y n o v i a l S a r c o m a L C N E C L u n g C u t . M e l a n o m a H N S C C S y n o v i a l S a r c o m a O v a r i a n C a n c e r C u t . M e l a n o m a H N S C C a d N S C L C s q N S C L C O v a r i a n C a r c i n o m a H N S C C B l a d d e r C a r c i n o m a s q N S C L C C u t . M e l a n o m a M u c . M e l a n o m a H N S C C N E T C U P H N S C C H & N - S a l i v a r y G l a n d A d e n o c a r c i n o m a C u t . M e l a n o m a H N S C C P e n i l e C a n c e r IMA401 monotherapy BOR of IMA401 at all DLs ± Pembrolizumab Prof. Dr. med. Martin Wermke, Abstract #2507 Three patients treated at RP2D not shown in plot due to clinical progression before post - infusion scan ; BOR, best overall response; cPR , confirmed partial response; H&N, head and neck cancer ; sq / adNSCLC , squamous cell /adenocarcinoma non - small - cell lung cancer ; LCNEC, large cell neuroendocrine carcinoma; NET CUP, neuroendocrine cancer of unknown primary ; PD, progressive disease ; PR, partial response; RP2D, recommended phase 2 dose; RECIST, Response Evaluation Criteria in Solid Tumors ; SCLC, small cell lung cancer ; SD, stable disease ; TNBC, triple - negative breast cancer . PR -100 -50 0 50 100 -11 -6 0 18 29 56 62 -100-100 -75 -73 -70 -66 -62 -50 -43 -39 -25 -22 -20 -19 -19 -15 -15 -14 -12 -7 -6 0 1 2 3 9 10 13 13 19 19 20 22 38 40 67 69 96 -36 -31 -4 6 9 14 29 98 B e s t % C h a n g e i n S u m o f L o n g e s t D i a m e t e r o f T a r g e t L e s i o n s f r o m B a s e l i n e a n d B O R ( R E C I S T 1 . 1 ) BL ⯈ BOR (RECIST 1.1) Ongoing response/ disease control PD PR cPR SD SD IMA401 + Pembrolizumab ⯈ ⯈ ⯈ < 1 mg 1 - 2 mg (RP2D Range) > 2 mg ⯈ SDPD ⯈ ⯈ ⯈ S y n o v i a l S a r c o m a S y n o v i a l S a r c o m a H N S C C S y n o v i a l S a r c o m a H N S C C T N B C C u t . M e l a n o m a E s o p h a g e a l C a r c i n o m a C u t . M e l a n o m a S C L C S C L C T N B C s q N S C L C G a l l b l a d d e r A d e n o c a r c i n o m a G a s t r i c A d e n o c a r c i n o m a L C N E C E s o p h a g e a l a d N S C L C G a s t r i c C a n c e r T N B C H N S C C S y n o v i a l S a r c o m a O v a r i a n C a r c i n o m a H & N - L a c r i m a l S a c H N S C C H N S C C C u t . M e l a n o m a H N S C C H & N - A d e n o i d C y s t i c C a r c i n o m a U r o t h e l i a l C a r c i n o m a s q N S C L C S y n o v i a l S a r c o m a L C N E C L u n g C u t . M e l a n o m a H N S C C S y n o v i a l S a r c o m a O v a r i a n C a n c e r C u t . M e l a n o m a H N S C C a d N S C L C s q N S C L C O v a r i a n C a r c i n o m a H N S C C B l a d d e r C a r c i n o m a s q N S C L C C u t . M e l a n o m a M u c . M e l a n o m a H N S C C N E T C U P H N S C C H & N - S a l i v a r y G l a n d A d e n o c a r c i n o m a C u t . M e l a n o m a H N S C C P e n i l e C a n c e r IMA401 monotherapy Data cutoff Mar 02, 2026
PRESENTED BY: Clinical Responses of IMA401 at RP2D ± Pembrolizumab in Patients with H&N Cancer a Target lesion sum of diameter ; b Max change not shown due to clinical progression before post - infusion scan ; BOR, best overall response; (c)PR, ( confirmed ) partial response; H&N, head and neck cancer ; PD, progressive disease ; RP2D, recommended phase 2 dose; SD, stable disease . Ongoing treatment PFS (months) BOR (Max % change of target lesions) BOR (RECIS T 1.1) Baseline Tumor Burden (mm) a Pembrolizumab (≥ one dose) Highest dose received (mg) List of prior treatment lines No of prior treatment lines Indication Yes 7.6 (ongoing) - 100 cPR 16 Yes 1.5 Carboplatin/ Cetuximab/ Pembrolizumab/ Nivolumab Nivolumab/ Cisplatin Cetuximab/ Fluorouracil/ Carboplatin 3 H&N – HNSCC Yes 14.9 (ongoing) - 73 cPR 32 No 2 Cisplatin 1 H&N – Salivary gland adenocarcinoma Yes 5.3 (ongoing) - 70 cPR 39 Yes 1.5 Pembrolizumab Pembrolizumab/ Carboplatin/ Fluorouracil 2 H&N – HNSCC Yes 10.2 - 6 2 cPR 39 No 2 Cisplatin/ Carboplatin Pembrolizumab/ Fluorouracil/ Carboplatin Cetuximab/ Docetaxel 3 H&N – HNSCC No 2.6 - 22 SD 67 No 1.5 Cisplatin/ Carboplatin Nivolumab Cisplatin/ Cetuximab/ Docetaxel 3 H&N – HNSCC Yes 2.8 (ongoing) - 1 5 SD 121 Yes 1 Cisplatin Cisplatin/ Fluorouracil sodium/ Pembrolizumab Cetuximab/ Paclitaxel 3 H&N – HNSCC No 2.4 - 7 SD 59 No 1 . 2 Cisplatin Carboplatin/ Paclitaxel/ Cetuximab 2 H&N – HNSCC Yes 3.7 (ongoing) 9 SD 55 No 1 Axitinib 1 H&N – Adenoid cystic carcinoma of submandibular gland No 2.2 19 SD 53 No 1.5 Cemiplimab 1 H&N – Squamous cell carcinoma right lacrimal sac Yes 1.4 10 PD 29 Yes 1 Cisplatin Carboplatin/ Fluorouracil/ Pembrolizumab 2 H&N – HNSCC No 1.1 13 PD 82 Yes 1 Pembrolizumab/ Cisplatin/ Fluorouracil Cetuximab 2 H&N – HNSCC No 1.4 19 PD 129 No 1.2 Pembrolizumab Docetaxel Cetuximab 3 H&N – HNSCC No 1.2 38 PD 37 No 1.8 Cisplatin Carboplatin/ Paclitaxel Tipifarnib Tipifarnib/ Bicalutamide/ Triptorelin VB - N - 10 - NEO/ Atezolizumab Trastuzumab deruxtecan/ Darolutamide Abiraterone/ Trastuzumab deruxtecan Sacituzumab govitecan 8 H&N - HNSCC No 1.4 N/A b N/A 110 Yes 1 Cisplatin Dostarlimab / Nelistotug Carboplatin/ Paclitaxel/ Cetuximab 3 H&N – HNSCC Data cutoff Mar 02, 2026
PRESENTED BY: Thank you Prof. Dr. med. Martin Wermke, Abstract #2507
Exhibit 99.7
PRESENTED BY: Patient - level Clinical Response Dynamics in Advanced Melanoma With Anzu - cel, a PRAME - targeted TCR T - cell Therapy Diwakar Davar 1 , Sapna Pradyuman Patel 2 , Leonel Fernando Hernandez - Aya 3 , Tobias Albert Wilhelm Holderried 4 , Antonia Busse 5 , Apostolia Maria Tsimberidou 6 , Dejka M. Araujo 6 , Manik Chatterjee 7,8 , Winfried Alsdorf 9 , Silvana Hengler 10 , M. Alper Kursunel 10 , Delfi Krishna 11 , Dmitry Pankov 11 , Cedrik Michael Britten 10 , Martin Wermke 12 ¹University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center, Pittsburgh,PA ; 2 UCHealth, University of Colorado Hospital, Aurora, CO; 3 University of Miami, Miami, FL; 4 University Hospital Bonn, Bonn, Germany; 5 Charite Medical University Hospital, Berlin, Germany; 6 The University of Texas MD Anderson Cancer Center, Houston, TX; 7 Translational Oncology /Early Clinical Trial Unit (ECTU), Comprehensive Cancer Center Mainfranken; 8 University Hospital Würzburg, Würzburg, Germany; 9 Department of Hematology and Oncology University Hospital Hamburg Eppendorf, Hamburg, Germany; 10 Immatics Biotechnologies GmbH, Tuebingen, Germany; 11 Immatics US, Inc., Houston, TX, USA; 12 University Hospital Carl Gustav Carus, Dresden, Germany Diwakar Davar M.D., Abstract #9508
PRESENTED BY: Key Takeaways • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies • Anzutresgene autoleucel ( anzu - cel, IMA203) is a one - time autologous TCR T - cell therapy targeting the cancer - associated antigen PRAME, which is expressed in >50 cancers and represents a novel immunotherapy target for melanoma • Anzu - cel demonstrates a predictable and manageable tolerability profile and rapid, deep, and durable systemic antitumor activity in settings of high unmet need: metastatic PD - 1 - relapsed melanoma and metastatic uveal melanoma • Exploratory response analysis supports the hypothesis that the broad systemic reach of anzu - cel can sustain disease control across multiple metastatic sites • Findings support continued development of anzu - cel in melanoma, including the randomized Phase 3 SUPRAME trial (NCT06743126) Diwakar Davar M.D., Abstract #9508 Anzu - cel, anzutresgene autoleucel ; HLA, human leukocyte antigen; PRAME, preferentially expressed antigen in melanoma; TCR, T - cell receptor.
PRESENTED BY: Anzu - cel is a Systemic TCR T - cell Therapy Designed to Target the Intracellular Tumor Antigen PRAME Diwakar Davar M.D., Abstract #9508 Anzutresgene autoleucel (anzu - cel, IMA203) is an investigational therapy and its use has not been proven to be safe or effective . It has not been approved by the United States Food and Drug Administration (FDA) or any other regulatory agency outside of the US. 1 Data on file: PRAME target prevalence is based on a proprietary mass spec - guided expression threshold applied to RNAseq and/or IHC data (approximate values; values between 95 - 100% shown as 95%); HL A, human leukocyte antigen; NSCLC, non - small cell lung cancer; PRAME, preferentially expressed antigen in melanoma ; TCR, T - cell receptor; TNBC, triple - negative breast cancer. PRAME is expressed in more than 50 cancers Mechanism of action anzu - cel (IMA203) PRAME - HLA - A*02:01 complex Proteasome Peptides HLA - A*02:01 Tumor cell Engineered PRAME - specific TCR PRAME prevalence in selected indications % PRAME positive tumors a Indication 95% 95% 95% 95% 90% 90% 85% 70% 65% Cutaneous Melanoma Uterine Carcinoma Uterine Carcinosarcoma Synovial Sarcoma Uveal Melanoma Mucosal melanoma Ovarian Carcinoma Squamous Cell NSCLC TNBC
PRESENTED BY: Phase 1 Multicenter Trial of Anzu - cel in Advanced PRAME+ Solid Tumors Diwakar Davar M.D., Abstract #9508 Anzu - cel, a nzutresgene autoleucel ; BID, twice daily; ECOG PS, Eastern Cooperative Oncology Group performance status; FU, follow - up; HLA, human leukocyte antigen; I L, interleukin; IU, international unit; mRNA, messenger ribounucleic acid; QC, quality control; RP2D, recommended phase 2 dose at 1 - 10 î 10 9 TCR T cells; SUBQ, subcutaneous; TCR, T - cell receptor . 1. Gragert L et al. Hum Immunol. 2013;74:1313 - 1320 and census numbers. Data cutoff Sep 24, 2025 Key Objectives Primary • Tolerability • Determination of RP2D Secondary • Anzu - cel T - cell engraftment, persistence • Efficacy Key Eligibility Criteria • Advanced (unresectable and/or metastatic) solid tumors • Age ≥ 18 years • ECOG PS 0 - 1 • HLA - A*02:01 positive • PRAME positive • No available SOC treatment options • Measurable disease (RECIST 1.1) • No active brain metastasis SCREENING / MANUFACTURING Leukapheresis Anzu - cel One - time infusion Lymphodepletion Fludarabine 30mg/m 2 Cyclophosphamide 500mg/m 2 Days - 6 to - 3 Low Dose IL - 2 1M IU SUBQ Days 1 - 5; 1M IU SUBQ BID Days 6 - 10 (Outpatient administration at investigator’s discretion) PRAME Testing Biopsy or archived tissue TREATMENT / OBSERVATION FU HLA - A*02:01 Testing blood Prevalence 1 : US: 41% EU: 48% Manufacturing of anzu - cel ~2 - week turnaround time Patient Journey
PRESENTED BY: Phase 1 Subset: Patients with Advanced Melanoma • Subset analysis focused on patients treated in phase 1b with anzu - cel at the RP2D (1 - 10 10 9 TCR T cells) Diwakar Davar M.D., Abstract #9508 a Melanoma efficacy population excludes 1 patient with uveal melanoma with ongoing unconfirmed PR from cORR ; b Mucosal melanoma n=2, melanoma of unknown primary n=1; RP2D: 1 - 10 î 10 9 TCR T cells; DL4: 0.2 - 1.2 î 10 9 TCR T cells/m 2 body surface area. Anzu - cel, a nzutresgene autoleucel ; cORR , confirmed overall response rate; DL, dose level; PR, partial response; RP2D, recommended phase 2 dose; TCR, T - cell receptor . Data cutoff Sep 24, 2025 Total Safety Population (N=74) Melanoma Efficacy Population a (n=33) n=13 non - melanoma n=3 o ther melanoma b n=14 cutaneous melanoma n=16 u veal melanoma n=27 Phase 1a Dose Escalation (DL1 - 4) n=1 in Phase 1a started lymphodepletion but did not receive IMA203 n=46 Phase 1b Dose Expansion (RP2D) RP2D defined at 1 - 10 ൈ 10 9 TCR T cells
PRESENTED BY: Patients Had Metastatic Melanoma in High Unmet Need Settings: PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma Diwakar Davar M.D., Abstract #9508 a Mucosal melanoma n=2; melanoma of unknown primary n=1. ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; LDH, lactate dehydrogenase; TCR, T - cell receptor; UL N, upper limit of normal. Data cutoff Sep 24, 2025 Other Melanoma a n=3 Uveal Melanoma n=16 Cutaneous Melanoma n=14 All Melanoma n=33 Baseline Characteristics 51 (40, 58) 62 (32, 74) 55 (31, 79) 57 (31, 79) Age, median (range) 100 63 21 48 Female, % 33 44 36 39 Baseline ECOG status 1, % 2 (1, 3) 2 (0, 6) 2.5 (1, 5) 2 (0, 6) Prior lines of systemic treatment, median ( range) 2 (1, 2) 1 (0, 4) 2 (1, 3) 1 (0, 4) Prior ICI treatment, median (range) 100 (3/3) 63 (10/16) 100 (14/14) 82 (27/33) ≥1 line of ICI treatment, % (n/N) — 63 (10/16) — — Prior tebentafusp , % (n/N) 8.7 (2.1, 17) 10.3 (3.1, 21) 12.1 (1.5, 31) 10.4 (1.5, 31) Tumor burden Target lesion SLD, cm, median (range) 17 (5, 20) 7 (3, 13) 6 (1, 10) 6 (1, 20) Target + non - target lesions, n, median (range) 67 94 64 79 Liver metastasis, % 33 0 0 3 Brain metastasis, % 100 50 71 64 Lung metastasis, % 13 (81) Uveal melanoma: Liver + extrahepatic, n (%) 2 (13) / 1 (6) Liver only / extrahepatic only, n (%) 33 0.9 (0.8, 1.6) 56 1.1 (0.7, 9.1) 64 1.1 (0.7, 9) 58 1 (0.7, 9.1) Elevated LDH at baseline, % LDH ULN, median, (range) Other Melanoma Uveal Melanoma Cutaneous Melanoma All Melanoma Treatment Experience 3.33 (1.73, 7.94) 3.94 (1.62, 8.43) 4.58 (1.30, 10.20) 4.04 (1.30, 10.20) Infused TCR T cell dose ( 10 9 ), median (range)
PRESENTED BY: Anzu - cel Demonstrated a Predictable and Manageable Tolerability Profile • Most frequent TEAEs were anticipated cytopenias associated with lymphodepletion ▪ Most grade ≥3 cytopenias (any lineage) resolved to grade 2 or better within 30 days of lymphodepletion • Immune - mediated AESIs occurred by Day 30 of TCR T - cell infusion ▪ Expected and manageable CRS, mostly grade 1/2, consistent with mechanism of action ▪ Infrequent, manageable, and mostly mild ICANS Diwakar Davar M.D., Abstract #9508 a Includes rash and rash maculopapular. Grades were determined according to NCI - CTCAE v5.0. Grades for CRS and ICANS were determin ed according to CARTOX criteria ( Neelapu et al, 2018, for patients enrolled under protocol v11.0 and higher according to Neelapu et al. 2019). All TEAEs regardless of relatedness to study treatment are presented. System Organ Class Blood and lymphatic sy st em disorders excluded from analysis; Adverse events are coded to Preferred Term (PT) according to the MedDRA v24.0. Patients are only counted once per preferred time by the highest severity grade reported in the EDC. AES I, adverse event of special interest; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRS, cytokine release syndrome; d, day; HLH, haemophagocytic lymphohistiocytosis; ICANS, immune effector cell - associated neurotoxicity syndrome; mo , month; TEAE, treatment - emergent adverse event. All Melanoma ( n =33) TEAEs in ≥30% Grade ≥3 Any grade Preferred term, n (%) 0 22 (67) Nausea 6 (18) 17 (52) ALT/AST increased 3 (9) 14 (42) Rash a 0 13 (39) Fatigue 0 12 (36) Constipation 3 (9) 10 (30) Hyponatremia 0 10 (30) Pyrexia All Melanoma (n=33) AESI Grade ≥3 Any grade Preferred term, n (%) 6 (18) 33 (100) CRS 2 (6) 4 (12) ICANS 1 (3) 2 (6) HLH All Melanoma (n=33) Key Lab Abnormalities Grade ≥3 Any grade Preferred term, n (%) 33 (100) 33 (100) Any cytopenia 33 (100) 33 (100) Neutropenia 17 (52) 33 (100) Anemia 13 (39) 31 (94) Thrombocytopenia 3 3 (100) 33 (100) Leukopenia 33 (100) 33 (100) Lymphopenia Data cutoff Sep 24, 2025
PRESENTED BY: Anzu - cel Induced Rapid and Deep Responses in Metastatic PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma Diwakar Davar M.D., Abstract #9508 a Includes melanoma (other) n=3: MM n=2, MUP n=1; b Exploratory analysis of confirmed ORR for patients with ≥2 post - BL scans per RECIST 1.1, PD or death at any prior timepoint, tho se with ongoing unconfirmed PR/CR were excluded. c Patient left study (withdrew consent) with ongoing unconfirmed PR.* Maximum change of target lesions and RECIST1.1 response at different t ime points. Anzu - cel, a nzutresgene autoleucel ; BOR, best overall response; cCR , confirmed complete response; cORR , confirmed objective response rate; cPR , confirmed partial response; DCR, disease control rate at week 6; PD, progressive disease; PR, partial response; RECIST, Res pon se Evaluation Criteria in Solid Tumors; SD, stable disease. n=33 n=3 n=16 n=14 6 4 % (21/33) 2/3 6 9 % (11/16) 57% (8/14) ORR 5 6 % (18/3 2 ) 1/3 6 7 % (10/15) 5 0 % (7/1 4 ) cORR b 91% (30/33) 3/3 8 8 % (14/16) 9 3 % (13/14) DCR Cutaneous Melanoma Uveal Melanoma Melanoma (other) a All Melanoma • Median time to BOR was 1.4 months (1.2 - 2.8) • Most responders exhibit shrinkage of ≥1 lesion by first scan • Responses observed in target and non - target lesions Data cutoff Sep 24, 2025 BOR (RECIST 1.1) PD SD PR cPR cCR Ongoing
PRESENTED BY: Anzu - cel Induced Durable Responses in Metastatic PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma Diwakar Davar M.D., Abstract #9508 a Includes melanoma (other) n=3: mucosal melanoma n=2, melanoma of unknown primary n=1. Anzu - cel, a nzutresgene autoleucel ; BL, baseline; cCR , confirmed complete response; cPR , confirmed partial response; mDOR , median duration of response; mFU , median follow - up; mo , month; ND, not defined; PD, progressive disease; PR partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease. Data cutoff Sep 24, 2025 Change in Sum of Longest Diameter of Target Lesions from Baseline [%] Months Post T - cell Infusion Ongoing response at 39.6 mo Response until 32.9 mo BL PR All Melanoma a n=33 Uveal Melanoma n=16 Cutaneous Melanoma n=14 14.6 (4.2, 38.2+) 11 (4.4, 31.6) 17.9 (4.2, 38.2+) mDOR [ mo ] (range) 18.7 ND 18.7 mFU [ mo ] cCR cPR PR SD PD Ongoing
PRESENTED BY: Anzu - cel Induced Durable Responses in Metastatic PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma Diwakar Davar MD, Abstract #9508 a Includes melanoma (other) n=3: mucosal melanoma n=2, melanoma of unknown primary n=1; PFS and OS of ongoing patients censored a t data - cut; PFS and OS rates were calculated using Kaplan - Meier method. Anzu - cel, a nzutresgene autoleucel ; mFU , median follow - up; mOS , median overall survival; mPFS , median progression - free survival; OS, overall survival; PFS, progression - free survival. Data cutoff Sep 24, 2025 Median Progression Free Survival Median Overall Survival All Melanoma a n=33 Uveal Melanoma n=16 Cutaneous Melanoma n=14 6.1 (1.4, 39.6+) 20.0 8.5 (1.4, 32.9) 10.4 6.0 (1.4 , 39.6+) 20.0 mPFS [ mo ] (range) mFU [ mo ] All Melanoma a n=33 Uveal Melanoma n=16 Cutaneous Melanoma n=14 16.2 (2.4, 39.6+) 17.3 NR (4.5, 34.2) 14.3 1 3 .9 (2.4, 39.6+) 20.0 mOS [ mo ] (range) mFU [ mo ] 6 - month PFS rate: 55% 100 PFS [%] 0 75 50 25 0 6 12 18 24 30 36 42 Time from Infusion [months] 33 16 8 4 2 2 1 0 0 15 20 23 24 24 25 25 At Risk Events PFS for All Melanoma Indications (n=33) 12 - month PFS rate: 37% 24 - month OS: 46% 100 OS [%] 0 75 50 25 0 6 12 18 24 30 36 42 Time from Infusion [months] 33 29 17 7 3 3 1 0 0 2 9 14 14 14 14 14 At Risk Events OS for All Melanoma Indications (n=33) 12 - month OS: 70%
PRESENTED BY: Anzu - cel Induced Systemic Antitumor Activity Across Metastatic Compartments Diwakar Davar M.D., Abstract #9508 a Other includes bone, brain, kidney, pericardium right, pleura, right adrenal, upper abdomen peritoneal implants, retroperiton eum , soft tissue, gluteal, dorsal, and subcutaneous nuchal. Anzu - cel, a nzutresgene autoleucel . Best Change per Target L esion (n=33) Data cutoff Sep 24, 2025 100 75 50 25 0 - 25 - 50 - 75 - 100 Best % Change of Diameter from Baseline Abdomen/Peritoneum Liver Lung Lymph Node Skin Other a
PRESENTED BY: RECIST Progression After Anzu - cel Frequently Reflected New or Focal Lesion Escape Rather Than Broad Systemic Regrowth Diwakar Davar M.D., Abstract #9508 cCR (1) cPR (17) PR (3) SD (9) PD (3) No Progression (9) Non - target Lesion Only (5) New Lesion Only (10) Target/Non - target Lesions (1) Target/New Lesions (2) Non - target/New Lesions (2) Target/Non - target/New Lesions (2) Target Lesion Only (2) Best Overall Response Progression Data cutoff Sep 24, 2025 Lesion - Level Analysis at RECIST PD N=33 Overall population 9 (27) No progression , n (%) 24 (73) Progressive disease a , n (%) n=24 RECIST PD category a Best overall response 11 (46) BOR of SD or PD , n (%) 13 (54) BOR of PR or CR , n (%) Involved organ(s) at PD 12 (50) 1, n (%) 6 (25) 2, n (%) 6 (25) ≥3, n (%) Tumor Growth at PD 8 (33) Enlargement only , n (%) 10 (42) New lesion(s) only , n (%) 6 (25) Both , n (%) 20.0 mo mFU for PFS a Patients with radiologic PD (RECIST 1.1) (n=24). Involved organ count is exploratory and based on lesion - level RECIST records at data cut, including TL progression, new lesions, and documented NTL unequivocal PD; NTL response reconciliation was ongoing a ft er extraction. BOR, best overall response; (c)CR, (confirmed) complete response; (c)ORR, (confirmed) objective response rate; (c)PR, (confirmed) parti al response; mFU , median follow - up; PD, progressive disease; NTL, non - target lesion; PFS, progression - free survival RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; TL, target lesion
PRESENTED BY: Sustained Control of Target Lesions Across Metastatic Compartments at Progression Diwakar Davar M.D., Abstract #9508 Exploratory analysis limited to target lesions and does not capture concurrent non - target lesion progression or new lesions in t he same organ. Percent change reflects median change in target - lesion sum of longest diameters from nadir to PD. Other includes: bone, brain, kidney, pericardium, pleura, adrenal, upper abdomen, peritoneum, retroperitoneum, soft tissue, gluteal, dorsal, su bcutaneous nuchal. PD, progressive disease; TL, target lesion(s). PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors. • Many target lesions remain controlled at the time of RECIST PD • PD frequently driven by new lesions, progression of non - target lesions, or selective outgrowth of individual target lesions ▪ Brain was not a common site for relapse (n=1) • This pattern supports the hypothesis that the broad systemic reach of anzu - cel can sustain disease control across multiple metastatic sites Data cutoff Sep 24, 2025 18 (0, 114) 0 (0, 0) 0 (0, 100) 0 (0, 31) 0 (0, 225) 0 (0, 9) Median change from nadir at PD, % (range) 0 5 10 15 20 25 30 Abdomen/ Peritoneum Liver Lung Lymph Node Skin Other Number of Patients No RECIST 1.1 PD PD, target lesions in organ stable PD, target lesions in organ progressing Target Lesion Location, by RECIST Progression Status (n=33) n=7 n=6 n=13 n=5 n=1 n=8 n=2 n=5 n=7 n=4 n=2 n=2 n=5 n=5
PRESENTED BY: Rapid LDH Rebound Was not Associated with Progression LDH Analysis at RECIST PD n=33 Overall population 9 (27) No progression , n (%) 24 (73) Progressive disease a , n (%) n=33 LDH at baseline 9 (38) Normal , n (%) 15 (63) Elevated , n (%) 0 NA , n (%) n=24 LDH at PD 8 (33) Normal , n (%) 15 (63) Elevated , n (%) 1 (4) NA b , n (%) 20.0 mo mFU for PFS Diwakar Davar M.D., Abstract #9508 a Patients with radiologic PD (RECIST 1.1) (n=24). b No LDH measurement available for one patient within 6 weeks before/after RECIST PD. LDH, lactate dehydrogenase; PD, progressive disease; RECIST, Response Evaluation Criteria in Solid Tumors ; ULN, upper limit of normal . • Transient increase following anzu - cel infusion (likely indicates tumor cytolysis) • Subsequent decrease toward baseline over time • At RECIST PD, LDH kinetics do not indicate rapidly progressing disease B a s e l i n e P e a k w i t h i n 4 W e e k s a t P r o g r e s s i o n 0.5 1 2 4 8 16 32 64 L D H ( F o l d c h a n g e r e l a t i v e t o U L N ) p = 0.0001 p > 0.9999 p < 0.0001 LDH Level ( xULN ) LDH Over Time, n=23 a,b Data cutoff Sep 24, 2025
PRESENTED BY: Key Takeaways • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies • Anzutresgene autoleucel ( anzu - cel, IMA203) is a one - time autologous TCR T - cell therapy targeting the cancer - associated antigen PRAME, which is expressed in >50 cancers and represents a novel immunotherapy target for melanoma • Anzu - cel demonstrates a predictable and manageable tolerability profile and rapid, deep, and durable systemic antitumor activity in settings of high unmet need: metastatic PD - 1 - relapsed melanoma and metastatic uveal melanoma • Exploratory response analysis supports the hypothesis that the broad systemic reach of anzu - cel can sustain disease control across multiple metastatic sites • Findings support continued development of anzu - cel in melanoma, including the randomized Phase 3 SUPRAME trial (NCT06743126) Diwakar Davar M.D., Abstract #9508 Anzu - cel, anzutresgene autoleucel ; HLA, human leukocyte antigen; PRAME, preferentially expressed antigen in melanoma; TCR, T - cell receptor.
PRESENTED BY: 16 Anzu - cel (IMA203) Phase 1 Trial Sponsor: Immatics Thank You – Trial Participants & Caregivers 16 University of Pittsburgh Medical Center UT MD Anderson United States University of Miami University Hospital Dresden University Hospital Hamburg Charité Berlin Germany University Hospital Würzburg CCC Comprehensive Cancer Center Mainfranken University Hospital Bonn Diwakar Davar M.D., Abstract #9508
PRESENTED BY: Appendix Diwakar Davar M.D., Abstract #9508
PRESENTED BY: Melanoma Efficacy Population (n=33) 1 Transduced viable CD8 T cells ; BOR, Best overall response ; DL, Dose level ; PD, Progressive Disease; SD, Stable Disease; PR, Partial Response; cPR , Confirmed Partial Response; PFS, Progression - free survival ( censored at data - cut ) Reason for Progression Comment BOR (Max % change of target lesions) BOR Total infused dose TCR - T cells 1 [x10 9 ] Prior local liver - directed treatments Prior treatments No of prior systemic treatment lines Indication Patient ID Ongoing response at 20.0 months PFS - 73.3 cCR 10.20 Relatlimab + Nivolumab 1 Cut. Melanoma A - DL5 - 27 Target lesion and non - target lesion, new lesions Response until 32.9 months PFS - 84.3 cPR 4.16 Pexmetinib (previously ARRY - 614) + Nivolumab 1 Uveal Melanoma A - DL5 - 01 Ongoing response at 8.7 months PFS - 83.8 cPR 7.93 Liver ablation Brenetafusp 1 Uveal Melanoma A - DL5 - 36 Non - target lesion progression Response until 12.4 months PFS - 78.8 cPR 7.19 Valproic acid + Sunitinib Tebentafusp 2 Uveal Melanoma A - DL5 - 21 New lesion Response until 17.6 months PFS - 78.4 cPR 8.14 Melphalan Melphalan Tebentafusp 2 Uveal Melanoma A - DL5 - 26 Ongoing response at 39.6 months PFS - 78.3 cPR 1.30 Dabrafenib + Trametinib Pembrolizumab Dabrafenib + Trametinib + Vemurafenib + Cobimetinib Tebentafusp Encorafenib + Binimetinib 5 Cut. Melanoma A - DL4 - 03 Non - target lesion progression Response until 20.7 months PFS - 69.5 cPR 9.80 Nivolumab Pembrolizumab Ipilimumab + Nivolumab 3 Cut. Melanoma A - DL5 - 13 Patient died from progressive disease Response until 15.9 months PFS - 65.1 cPR 5.12 Interferon Pembrolizumab Ipilimumab + Nivolumab 3 Cut. Melanoma A - DL5 - 03 Ongoing response at 10.4 months PFS - 58.7 cPR 3.68 Tebentafusp 1 Uveal Melanoma A - DL5 - 34 New lesions Response until 5.7 months PFS - 65.9 cPR 1.55 Ipilimumab + Nivolumab Encorafenib + Binimetinib + Nivolumab + Relatlimab 2 Cut. Melanoma A - DL4 - 07 New lesions Response until 5.6 months PFS - 58.8 cPR 3.02 Pembrolizumab 1 Cut. Melanoma A - DL5 - 15 Target lesion and non - target lesion progression Response until 6.0 months PFS - 57.1 cPR 7.94 Nivolumab Ipilimumab + Nivolumab 2 Mucosal Melanoma A - DL5 - 29 Diwakar Davar M.D., Abstract #9508
PRESENTED BY: Melanoma Efficacy Population (n=33) Reason for Progression Comment BOR (Max % change of target lesions) BOR Total infused dose TCR - T cells 1 [x10 9 ] Prior local liver - directed treatments Prior treatments No of prior systemic treatment lines Indication Patient ID Non - target lesion progression Response until 8.5 months PFS - 50.9 cPR 5.42 Clinical trial intrahepatic PV10 Pembrolizumab Clinical trial intrahepatic PV10 Ipilimumab + Nivolumab Anti - CTLA - 4 NF AB + XRT Clinical trial camibirstat (previously FHD - 286) Pembrolizumab 6 Uveal Melanoma A - DL5 - 19 Non - target lesion progression and new lesions Response until 6.2 months PFS - 48.1 cPR 2.89 Idronoxil + XRT Darovasertib (previously IDE196) + Crizotinib LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide 3 Uveal Melanoma A - DL5 - 24 Response until 6.0 months PFS, patient off study at data - cut due to investigator decision (radiation of one target lesion) - 44.8 cPR 6.94 Ipilimumab + Nivolumab Encorafenib + Binimetinib Relatlimab + Nivolumab 3 Cut. Melanoma A - DL5 - 23 Target lesion progression and new lesion Response until 6.0 months PFS - 41.7 cPR 1.62 Tebentafusp 1 Uveal Melanoma A - DL4 - 10 Target lesion progression Response until 5.8 months PFS - 40.8 cPR 2.68 SEA - CD40 + Pembrolizumab 1 Uveal Melanoma A - DL5 - 10 Patient discontinued tumor assessments; censored at last assessment with ongoing response and 6 months PFS - 39.5 cPR 3.18 1.Local radiopharmaceuti cal therapy with Y - 90 2.Melaphlan Ipilimumab + Nivolumab Tebentafusp Melphalan Ipilimumab + Nivolumab DYP - 688 Ipilimumab + Nivolumab 6 Uveal Melanoma A - DL5 - 32 New lesion Disease stabilization until 2.7 months post infusion, unconfirmed response from 2.7 until 5.5 months PFS - 59.3 PR 6.31 Ipilimumab + Nivolumab Dabrafenib + Mekinist 2 Cut. Melanoma A - DL5 - 22 Patient withdrew consent with unconfirmed PR, last evaluable scan prior to termination at 6.0 months PFS - 43.8 PR 1.62 Embolization of right hepatic artery Ipilimumab + Nivolumab Darovasertib Tebentafusp 3 Uveal Melanoma A - DL4 - 09 Target lesion progression Unconfirmed response until 2.8 months PFS - 36.9 PR 3.33 Ipilimumab + Nivolumab Avapritinib Nivolumab + relatlimab 3 Mucosal Melanoma A - DL5 - 28 1 Transduced viable CD8 T cells ; BOR, Best overall response ; DL, Dose level ; PD, Progressive Disease; SD, Stable Disease; PR, Partial Response; cPR , Confirmed Partial Response; PFS, Progression - free survival ( censored at data - cut ) Diwakar Davar M.D., Abstract #9508
PRESENTED BY: Melanoma Efficacy Population (n=33) 1 Transduced viable CD8 T cells ; BOR, Best overall response ; DL, Dose level ; PD, Progressive Disease; SD, Stable Disease; PR, Partial Response; cPR , Confirmed Partial Response; PFS, Progression - free survival ( censored at data - cut ) Reason for Progression Comment BOR (Max % change of target lesions) BOR Total infused dose TCR - T cells 1 [x10 9 ] Prior local liver - directed treatments Prior treatments No of prior systemic treatment lines Indication Patient ID Ongoing disease stabilization at 17.3 months PFS - 20.6 SD 3.68 Ipilimumab + Nivolumab Zimberelimab + Domvanalimab Encorafenib + Binimetinib 3 Cut. Melanoma A - DL5 - 31 Non - target lesion progression Stable disease until 8.6 months PFS - 17.6 SD 8.43 Ipilimumab + Pembrolizumab Tebentafusp Ipilimumab + Nivolumab Darovasertib (previously IDE196) + Binimetinib Camibirstat (previously FHD - 286) 5 Uveal Melanoma A - DL5 - 20 New lesion Disease stabilization until 5.7 months PFS 0.0 SD 1.73 Ipilimumab + Nivolumab 1 Melanoma (Unk. Primary) A - DL4 - 04 New lesion Disease stabilization until 5.5 months PFS - 25.4 SD 5.71 Tebentafusp Ipilimumab + Nivolumab 2 Uveal Melanoma A - DL5 - 18 Target and non - target lesion progression, new lesions Disease stabilization until 3.5 months PFS - 22.6 SD 4.50 Tyrosinase peptides Nivolumab + Ipilimumab Tebentafusp 3 Uveal Melanoma A - DL5 - 12 New lesions, target lesion progression Disease stabilization until 5.9 months PFS 11.4 SD 1.63 Nivolumab Ipilimumab+Nivolumab Dabrafenib + Trametinib Nivolumab 4 Cut. Melanoma A - DL4 - 05 New lesion Disease stabilization until 6.1 months PFS - 18.6 SD 4.04 Ipilimumab + Nivolumab+Tociliziumab Nivolumab + Relatlimab + Tocilizumab + Ipilimumab 2 Cut. Melanoma A - DL5 - 17 Non - target lesion progression, new lesions Disease stabilization until 2.7 months PFS 4.6 SD 5.14 Ipilimumab + Nivolumab Axitinib + Nivolumab 2 Cut. Melanoma A - DL5 - 25 New lesion Disease stabilization until 2.1 months PFS - 11.5 SD 9.76 Pembrolizumab Pembrolizumab TransCon TLR7/8 agonist + Pembrolizumab Brenetafusp 4 Cut. Melanoma A - DL5 - 33 New lesions Progressive disease at 1.4 months PFS - 41.5 PD 2.34 Nivolumab Encorafenib + Binimetinib 2 Cut. Melanoma A - DL5 - 14 Non - target lesion progression Progressive disease at 1.4 months PFS - 37.5 PD 3.71 Tebentafusp Ipilimumab + Nivolumab 2 Uveal Melanoma A - DL5 - 35 New lesion Progressive disease at 1.4 months PFS - 6.3 PD 2.56 NA 0 Uveal Melanoma A - DL4 - 06 Diwakar Davar M.D., Abstract #9508
Exhibit 99.8
© Immatics. Not for further reproduction or distribution. © Immatics. Not for further reproduction or distribution. Immatics Corporate Presentation June 01, 2026
Forward - Looking Statement This presentation (“Presentation”) is provided by Immatics N . V . (“Immatics” or the “Company”) for informational purposes only . The information contained herein does not purport to be all - inclusive and none of Immatics, any of its affiliates, any of its or their respective control persons, officers, directors, employees or representatives makes any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation . Forward - Looking Statements . Certain statements in this presentation may be considered forward - looking statements . Forward - looking statements generally relate to future events or the Company’s future financial or operating performance . For example, statements concerning timing of data read - outs for product candidates, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration - enabling), the timing of IND or CTA filing for pre - clinical stage product candidates, the timing of BLA filings for clinical stage product candidates, estimated market opportunities of product candidates, manufacturing timetables, capacity and success rates, the Company’s focus on partnerships to advance its strategy, and other metrics are forward - looking statements . In some cases, you can identify forward - looking statements by terminology such as “may”, “should”, “expect”, “plan”, “target”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology . Such forward - looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements . These forward - looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain . New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties . Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company’s Annual Report on Form 20 - F and other filings with the Securities and Exchange Commission (SEC) . Nothing in this presentation should be regarded as a representation by any person that the forward - looking statements set forth herein will be achieved or that any of the contemplated results of such forward - looking statements will be achieved . You should not place undue reliance on forward - looking statements, which speak only as of the date they are made . The Company undertakes no duty to update these forward - looking statements . No Offer or Solicitation . This communication is for informational purposes only and does not constitute, or form a part of, an offer to sell or the solicitation of an offer to sell or an offer to buy or the solicitation of an offer to buy any securities, and there shall be no sale of securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction . No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933 , as amended, or in an offering exempt from registration . Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company’s own internal estimates and research . In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions . Finally, while the Company believes its internal research is reliable, such research has not been verified by any independent source . All the scientific and clinical data presented within this presentation are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification . 2
PRAME Is Expressed in More Than 50 Cancers Anzutresgene autoleucel ( anzu - cel, formerly IMA203), 1 Data on file: PRAME target prevalence is based on a proprietary initial mass spec - guided expression threshold applied to RNAseq and/or IHC data (approximate values, values between 95 - 100% shown as 95%); anzu - cel (IMA203), IM203CD8, IMA402 are being evaluated in separate clinical trials ; NSCLC: Non - small cell lung cancer ≥95 % ≥10 % Cancer Cell Death IMA402 PRAME Bispecific a nzu - cel (IMA203) PRAME Cell Therapy IMA203CD8 PRAME Cell Therapy Immatics Is the Global Leader in Precision Targeting of PRAME with 3 clinical product candidates PRAME prevalence in selected indications % PRAME+ patients 1 Indication 95% Cutaneous Melanoma 95% Uterine Carcinoma 95% Uterine Carcinosarcoma 95% Synovial Sarcoma 90% Uveal Melanoma 90% Mucosal Melanoma 85% Ovarian Carcinoma Subtypes 70% Squamous Cell NSCLC 65% Triple - negative Breast Carcinoma 45% Small Cell Lung Cancer 45% Esophageal Carcinoma Subtype 40% Kidney Carcinoma Subtype 35% Cholangiocarcinoma 30% HER2 - Enriched Breast Carcinoma 25% Adenocarcinoma NSCLC 25% Head & Neck Squamous Cell Carcinoma 20% Hepatocellular Carcinoma 20% Bladder Carcinoma 3 PRAME Indication Cutaneous Melanoma Endometrioid Endometrial Carcinoma Uterine Carcinosarcoma Synovial Sarcoma Acral Melanoma Uveal Melanoma Mucosal Melanoma Endometrial Clear Cell Carcinoma Endometrial Serous Carcinoma Ovarian Serous Cystadenocarcinoma Ovarian Clear Cell Carcinoma Ovarian Endometrioid Carcinoma Head and Neck Salivary Duct Carcinoma Adenoid Cystic Carcinoma Neuroblastoma Malignant Rhabdoid Tumor Wilms Tumor (Nephroblastoma) Squamous Cell NSCLC Triple Negative Breast Carcinoma (TNBC) Cervical Adenosquamous Cell Carcinoma Large Cell Neuroendocrine Lung Carcinoma (LCNEC) Basal Cell Carcinoma Mucoepidermoid Carcinoma Large Cell Lung Carcinoma (LCLC) Spindle Cell Melanoma Testicular Germ Cell Tumor (Seminoma and Non - Seminoma) Myxoid Liposarcoma Angiosarcoma Small Cell Lung Cancer (SCLC) Esophageal Small Cell Carcinoma Cutaneous Squamous Cell Carcinoma Thymoma Merkel Cell Carcinoma Endometrial Sarcoma Esophageal Squamous Carcinoma Esophageal Adenosquamous Carcinoma Kidney Renal Papillary Cell Carcinoma Malignant Peripheral Nerve Sheath Tumor (MPNST) Cholangiocarcinoma Cervical Adenocarcinoma Head and Neck Salivary Gland Carcinoma Osteosarcoma HER2 - Enriched Breast Carcinoma Embryonal Rhabdomyosarcoma Adenosquamous NSCLC Diffuse Large B - cell Lymphoma (DLBCL) Sarcomatoid Carcinoma of the Lung Adenocarcinoma NSCLC Head and Neck Squamous Cell Carcinoma (HNSCC) Alveolar Rhabdomyosarcoma Ovarian Mucinous Carcinoma Adrenocortical Carcinoma Kidney Renal Clear Cell Carcinoma Hepatocellular Carcinoma Bladder Urothelial Carcinoma Cervical Squamous Cell Carcinoma Non - Squamous Anal Carcinoma Pancreatic Neuroendocrine Adenocarcinoma Prostate Neuroendocrine Adenocarcinoma Liposarcoma Undifferentiated Pleomorphic Sarcoma Acute Myeloid Leukemia (AML) Ewing Sarcoma Ovarian Leiomyosarcoma Breast Carcinoma, Luminal A Breast Carcinoma, Luminal B Squamous Anal Carcinoma Stomach Adenocarcinoma Esophageal Adenocarcinoma Fibrosarcoma Anaplastic Thyroid Carcinoma (…)
Immatics Is the Global Leader in Precision Targeting of PRAME • P RAME is an intracellular protein pre sented as a peptide on the surface of tumor cells by HLA molecules 1 • The PRAME peptide can be targeted by T - cell receptors (TCRs) engineered by Immatics, thus overcoming limitations of classical antibodies and CAR T - cell therapies not able to access intracellular targets 1,2 • PRAME has multiple functions in tumor biology enhancing tumor cell survival, tumor proliferation and resistance to apoptosis #, 3,4 • PRAME expression has been associated with poor prognosis incl. shorter survival 5,6,7,8 • PRAME is homogenously expressed in tumor tissue 9 4 s qNSCLC Ovarian Cancer PRAME RNA detection in tumor samples (ISH) Anzutresgene autoleucel ( anzu - cel, formerly IMA203), # Activation of proliferative and survival pathways, including PI3K/AKT/mTOR 3 , and i nhibition of retinoic acid signaling preventing retinoic acid - induced differentiation and apoptosis 4 1 Wermke et al., 2025; 2 Chandran et al., 2019, 3 Yu et al., 2023; 4 Epping et al., 2005; 5 Al - Khadairi & Decock . 2019; 6 Naik et al., 2021 ; 7 Gezgin et al., 2017; 8 Field et al., 2016; 9 Hukelmann et al., SITC 2022. PRAME anzu - cel (IMA203)
Target Indication Modality Product candidate 2L melanoma 2 Cell therapy Anzu - cel (IMA203) Uveal melanoma Cell therapy Anzu - cel (IMA203) Solid cancers Cell therapy Anzu - cel (IMA203) + mRNA - 4203 Gynecologic cancers Cell therapy IMA203CD8 Other so lid cancers Melanoma, gynecologic cancers, others Bispecific IMA402 Melanoma, gynecologic cancers, others Bispecific IMA402 + ICI 3 sqNSCLC Bispecific IMA402 + IMA401 MAGEA4/8 HNSCC, sqNSCLC, others Bispecific IMA401 ± ICI other Undisclosed Bispecific Undisclosed 4 Preclinical 1a 1 1b 1 2 3 SUPRAME P hase 5 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), 1 Phase 1a: Dose escalation, Phase 1b: Dose expansion ; 2 2L melanoma: patients with unresectable or metastatic melanoma who have received at least 1 prior PD - 1 inhibitor; 3 In combination with immune checkpoint inhibitor (pembrolizumab or nivolumab/ re latlimab ; 4 mRNA - enabled in vivo expressed TCER® molecules ; HNSCC: head and neck squamous cell carcinoma; ICI: immune checkpoint inhibitor; sqNSCLC : squamous non - small - cell lung cancer PRAME Franchise PRAME Product Candidates Therapeutic Modalities 3 2 3 Combinations PRAME PRAME PRAME PRAME PRAME PRAME PRAME PRAME / MAGEA4/8 Immatics has the Broadest PRAME Franchise with the Most PRAME Indications and Modalities
6 PRAME Wave #2 PRAME Wave #3 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), All patient numbers refer to PRAME+/HLA - A*02:01+ patients in the US and EU5 in 2025; Source: Clarivate D isease Landscape and Forecast; EU5: France, Germany, Italy, Spain, United Kingdom; a 2L: patients with unresectable or metastatic cutaneous melanoma who have received at least 1 prior PD - 1 inhibitor ; ICI: Immune checkpoint inhibitor; SOC: standard of care; sqNSCLC : squamous non - small - cell lung cancer >230K addressable PRAME + /HLA - A*02:01 + patients in the US & EU5 p.a. IMA203CD8 PRAME C ell T herapy IMA402 PRAME Bispecific Market entry in advanced melanoma ~9K addressable patients p.a. Expansion to all advanced PRAME cancers > 75K addressable patients p.a. Expansion to earlier - line PRAME cancers > 145K addressable patients p.a. IMA402 • Anzu - cel will be Immatics’ first PRAME therapy to enter the market – launch targeted in 2027 • First target indications: 2L cutaneous melanoma a ; uveal melanoma Anzu - cel (IMA203) PRAME Wave #1 Anzu - cel (IMA203) PRAME Cell Therapy PRAME • Next - gen half - life extended bispecific as monotherapy or ICI/SOC combo in earlier and later treatment lines • First target indications: melanoma, gynecologic cancers, sqNSCLC (IMA402/ IMA401 combination ) • Enhanced pharmacology provides potential to expand to tumor - agnostic label in 2L PRAME solid cancers beyond melanoma • First target indications: ovarian cancer, endometrial cancer IMA203CD8 Immatics has the Broadest PRAME Franchise with the Most PRAME Indications and Modalities
Immatics has the Broadest PRAME Franchise with the Most PRAME Indications and Modalities PRAME Wave #1 PRAME Wave #2 PRAME Wave #3 > 230K addressable PRAME + /HLA - A*02:01 + patients in the US & EU5 p.a. Anzu - cel (IMA203) PRAME Cell Therapy IMA203CD8 PRAME C ell T herapy IMA402 PRAME Bispecific □ Ph1a data update with focus on ovarian cancer at relevant doses at a major medical conference: 1H 2026 □ Determination of RP2D: 2026 □ Updated data, incl. durability follow - up at RP2D: 2H 2026 EXPECTED MILESTONES STATUS STATUS STATUS • GEN2 PRAME cell therapy leveraging CD8 and CD4 T cells • Enhanced pharmacology • Phase 1 study ongoing • Off - the - shelf Bispecific • Next - gen, half - life extended format • Phase 1b dose expansion ongoing • Orphan Drug and RMAT designation 1 by FDA • Phase 3 SUPRAME trial in patients with advanced melanoma post PD - 1 inhibitor ongoing; Primary endpoint: PFS • Phase 2 cohort in patients with metastatic uveal melanoma ongoing 7 PRAME Anzutresgene autoleucel ( anzu - cel, formerly IMA203), 1 Includes all benefits of Breakthrough Therapy Designation; 2 Pre - specified interim and final analyses expected to be triggered in 2026 as planned upon the occurrence of a defined number of events for PFS (progressive disease or death) ; ICI: immune checkpoint inhibitor; sqNSCLC : squamous non - small - cell lung cancer □ Data update from Ph1/2 trial in cutaneous and uveal melanoma: 2026 □ Ph3 SUPRAME interim & final analyses triggered 2 : 2026 □ BLA submission: 1H 2027 □ Launch: 2H 2027 EXPECTED MILESTONES □ Completion of Ph1b dose expansion with focus on melanoma and gyn - onc to determine the final RP2D: 2026 □ Ph1 data update on IMA402 monotherapy and ICI combination: 2H 2026 □ Initiation of addtl . Ph1b/Ph2 expansion cohorts in melanoma and gyn - onc : 2026 □ Initiation of IMA402/IMA401 combo in sqNSCLC : 2026 EXPECTED MILESTONES x x x x
8 PRAME 1 Target product profile (TPP) in monotherapy in 2L or later settings post SOC at recommended phase 2 dose (“RP2D”) for develop me nt beyond Ph1b. Other factors such as mPFS (median progression free survival) and mOS (median overall survival) may also be considered. SOC: standard of care LYMPHODEPLETION & INFUSION Tumor cell HLA PRAME peptide ADMINISTRATION TO PATIENT LEUKAPHERESIS GENETIC ENGINEERING & EXPANSION TCER® PRODUCTION “OFF - THE - SHELF” PRODUCT PRAME Bispecific Half - life extended (HLE) bispecific T cell engager (TCER®) Modality: Repeat dose Application : Primarily in earlier lines incl. frontline or (neo)adjuvant setting (in combination with SOC) Positioning: Outpatient administration, hospitals and community centers Deployment : ≥20% cORR , ≥6 months mDOR (monotherapy, 2L or later) TPP at RP2D 1 : PRAME Cell Therapy Autologous TCR T - cell Therapy Modality: Single dose (“one and done”) (no tumor surgery, no high - dose IL - 2) Application: Primarily second line and later monotherapy setting Positioning: Administered in specialized hospitals and medical centers; potential for outpatient administration Deployment : ≥40% cORR , ≥6 months mDOR (monotherapy, 2L or later) TPP at RP2D 1 : Cell Therapy TCER® Immatics has the Broadest PRAME Franchise with the Most PRAME Indications and Modalities
Anzu - cel (IMA203) PRAME Cell Therapy Market Entry in Advanced Melanoma PRAME Wave #1 9 Anzutresgene autoleucel ( anzu - cel, formerly IMA203)
Anzu - cel (IMA203) PRAME Cell Therapy: Market Entry in Advanced Melanoma 10 Anzu - cel (IMA203) Opportunity 2L Unresectable or Metastatic Cutaneous Melanoma * ~7.3K addressable PRAME + /HLA - A*02:01 + patients in the US & EU5 ~1.3K addressable PRAME + /HLA - A*02:01 + patients in the US & EU5 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), all patient numbers refer to PRAME+/HLA - A*02:01+ patients in the US and EU5 in 2025; Source: Clarivate D isease Landscape and Forecast; * 2L: patients with unresectable or metastatic melanoma who have received at least 1 prior immune checkpoint inhibitor ; EU5: France, Germany, Italy, Spain, United Kingdom PRAME Wave #1: anzu - cel EU5 US ~3.6K ~3.7K Metastatic Uveal Melanoma EU5 US ~0.7K ~0.6K ANZU - CEL (IMA203)
Positive Data and High Unmet Need 11 SUPRAME: Phase 3 randomized trial of anzu - cel vs. investigator choice in 2L cutaneous melanoma d ongoing (#NCT06743126) Phase 2 single arm cohort of anzu - cel in metastatic uveal melanoma ongoing (#NCT03686124) Anzutresgene autoleucel ( anzu - cel, formerly IMA203), a Manufacturing success rate for Phase 1; b Includes all benefits of Breakthrough Therapy Designation, RMAT designation received in multiple PRAME expressing cancers, including cutaneous and uveal melanoma; c PRAME + /HLA - A*02:01 + addressable patient population, source: Clarivate Disease Landscape and Forecast 2025; d 2L: patients with unresectable or metastatic melanoma who have received at least 1 prior PD - 1 inhibitor ; CRS: cytokine release syndrome; ICANS: immune effector cell associated neurotoxicity syndrome; cORR : confirmed objective response rate; mDOR : median duration of response; mPFS : median progression - free survival; OS: overall survival ; mFU : median follow - up; EU5: France, Germany, Italy, Spain, United Kingdom; Summary: Anzu - cel (IMA203) PRAME Cell Therapy in Advanced Melanoma Predictable and Manageable Tolerability Anticipated & manageable cytopenias associated with lymphodepletion Mostly mild to moderate CRS Infrequent ICANS Potential for outpatient administration Compelling Response Rate cORR : 56% (18/32) 42% (14/33) of patients had deep responses (≥50% tumor size reduction) Encouraging activity in both cutaneous melanoma ( cORR 50%) and uveal melanoma ( cORR 67%) Durable Responses 12.1 months mDOR and ongoing responses for up to >3 years mPFS of 6.1 months mPFS 15.9 months in patients with deep responses m OS : 16.2 months Rapid & Robust Manufacturing Fast turnaround time: 7 - 8 days + 7 days QC release testing 95% manufacturing success rate to reach target dose a Optimized process to achieve desirable cellular functionality Commercial Opportunity ∼ 9K b addressable patients in US/EU5 in cutaneous and uveal melanoma, ~4.3K in the US alone Orphan Drug Designation and RMAT designation c received for the treatment of both, cutaneous and uveal melanoma Data cut - off Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave #1: anzu - cel
Ph 1b Study of Anzu - cel (IMA203) PRAME Cell Therapy in Advanced Melanoma Patient Journey 12 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), 1 Gragert et al. 2013 and census numbers; HLA - A*02:01 prevalence in Immatics’ clinical trials: US 65% and Germany 55% as of March 2025; 2 30 mg/m 2 Flu darabine and 500 mg/m 2 Cy clophosphamide for 4 days; 3 1m IU SC daily days 1 - 5 and twice daily SC days 6 - 10, total dose is approx. only 5% of the overall dose for high - dose IL - 2 given typically with TIL therapy (Sarnaik et al. 2021 Journal of Clinical Oncology); 4 Manufacturing success rate for Phase 1 HLA - A*02:01 Testing Blood sample Treatment & Observation Phase Long Term Follow - up Screening & Manufacturing Phase Manufacturing by Immatics Anzu - cel (IMA203) One - time infusion Lymphodepletion 2 Low dose IL - 2 3 Safety and efficacy monitoring for 12 months Leukapheresis as source for cell product Process time of ~ 2 weeks 7 - 8 - day manufacturing process applying CD8/CD4 T cell selection 7 - day QC release testing PRAME testing in Phase 1 Due to high prevalence, PRAME testing no longer required in SUPRAME trial for cut. melanoma and Phase 2 cohort in uveal melanoma Inclusion by HLA testing o nly – no PRAME testing required Fast turn - around - time (~2 weeks) and manufacturing success rate of 95% 4 Predictable and manageable tolerability profile with potential outpatient administration – no high - dose IL - 2 Standard leukapheresis for product manufacturing – no need for tumor biopsy or surgery Prevalence 1 : US: 41%, EU: 48% PRAME Wave #1: anzu - cel
Patients with Metastatic Melanoma in High Unmet Need Settings: PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma 13 a Mucosal melanoma n=2; melanoma of unknown primary n=1. ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhib ito r; LDH, lactate dehydrogenase; TCR, T - cell receptor; ULN, upper limit of normal. Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave #1: anzu - cel Other Melanoma a n=3 Uveal Melanoma n=16 Cutaneous Melanoma n=14 All Melanoma n=33 Baseline Characteristics 51 (40, 58) 62 (32, 74) 55 (31, 79) 57 (31, 79) Age, median (range) 100 63 21 48 Female, % 33 44 36 39 Baseline ECOG status 1, % 2 (1, 3) 2 (0, 6) 2.5 (1, 5) 2 (0, 6) Prior lines of systemic treatment, median ( range) 2 (1, 2) 1 (0, 4) 2 (1, 3) 1 (0, 4) Prior ICI treatment, median (range) 100 (3/3) 63 (10/16) 100 (14/14) 82 (27/33) ≥1 line of ICI treatment, % (n/N) — 63 (10/16) — — Prior tebentafusp , % (n/N) 8.7 (2.1, 17) 10.3 (3.1, 21) 12.1 (1.5, 31) 10.4 (1.5, 31) Tumor burden Target lesion SLD, cm, median (range) 17 (5, 20) 7 (3, 13) 6 (1, 10) 6 (1, 20) Target + non - target lesions, n, median (range) 67 94 64 79 Liver metastasis, % 33 0 0 3 Brain metastasis, % 100 50 71 64 Lung metastasis, % 13 (81) Uveal melanoma: Liver + extrahepatic, n (%) 2 (13) / 1 (6) Liver only / extrahepatic only, n (%) 33 0.9 (0.8, 1.6) 56 1.1 (0.7, 9.1) 64 1.1 (0.7, 9) 58 1 (0.7, 9.1) Elevated LDH at baseline, % LDH ULN, median, (range) Other Melanoma Uveal Melanoma Cutaneous Melanoma All Melanoma Treatment Experience 3.33 (1.73, 7.94) 3.94 (1.62, 8.43) 4.58 (1.30, 10.20) 4.04 (1.30, 10.20) Infused TCR T cell dose ( 10 9 ), median (range)
Anzu - cel (IMA203) PRAME Cell Therapy Demonstrated a Predictable and Manageable Tolerability Profile All Melanoma ( n =33) TEAEs in ≥30% Grade ≥3 Any grade Preferred term, n (%) 0 22 (67) Nausea 6 (18) 17 (52) ALT/AST increased 3 (9) 14 (42) Rash a 0 13 (39) Fatigue 0 12 (36) Constipation 3 (9) 10 (30) Hyponatremia 0 10 (30) Pyrexia All Melanoma (n=33) AESI Grade ≥3 Any grade Preferred term, n (%) 6 (18) 33 (100) CRS 2 (6) 4 (12) ICANS 1 (3) 2 (6) HLH All Melanoma (n=33) Key Lab Abnormalities Grade ≥3 Any grade Preferred term, n (%) 33 (100) 33 (100) Any cytopenia 33 (100) 33 (100) Neutropenia 17 (52) 33 (100) Anemia 13 (39) 31 (94) Thrombocytopenia 3 3 (100) 33 (100) Leukopenia 33 (100) 33 (100) Lymphopenia a Includes rash and rash maculopapular . Grades were determined according to NCI - CTCAE v 5 . 0 . Grades for CRS and ICANS were determined according to CARTOX criteria ( Neelapu et al, 2018 , for patients enrolled under protocol v 11 . 0 and higher according to Neelapu et al . 2019 ) . All TEAEs regardless of relatedness to study treatment are presented . System Organ Class Blood and lymphatic system disorders excluded from analysis ; Adverse events are coded to Preferred Term (PT) according to the MedDRA v 24 . 0 . Patients are only counted once per preferred time by the highest severity grade reported in the EDC . AESI, adverse event of special interest ; ALT, alanine aminotransferase ; AST, aspartate aminotransferase ; CRS, cytokine release syndrome ; d, day ; HLH, haemophagocytic lymphohistiocytosis ; ICANS, immune effector cell - associated neurotoxicity syndrome ; mo , month ; TEAE, treatment - emergent adverse event . 14 Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave #1: anzu - cel Most frequent TEAEs were anticipated cytopenias associated with lymphodepletion • Most grade ≥3 cytopenias (any lineage) resolved to grade 2 or better within 30 days of lymphodepletion Immune - mediated AESIs occurred by Day 30 of TCR T - cell infusion • Expected and manageable CRS, mostly grade 1/2, consistent with mechanism of action • Infrequent, manageable, and mostly mild ICANS
Anzu - cel (IMA203) PRAME Cell Therapy Induced Rapid and Deep Responses in Metastatic PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma 15 Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave #1: anzu - cel n=33 n=3 n=16 n=14 6 4 % (21/33) 2/3 6 9 % (11/16) 57% (8/14) ORR 5 6 % (18/3 2 ) 1/3 6 7 % (10/15) 5 0 % (7/1 4 ) cORR b 91% (30/33) 3/3 8 8 % (14/16) 9 3 % (13/14) DCR Cutaneous Melanoma Uveal Melanoma Melanoma (other) a All Melanoma • Median time to BOR was 1.4 months (1.2 - 2.8) • Most responders exhibit shrinkage of ≥1 lesion by first scan • Responses observed in target and non - target lesions BOR (RECIST 1.1) PD SD PR cPR cCR Ongoing a Includes melanoma (other) n=3: MM n=2, MUP n=1; b Exploratory analysis of confirmed ORR for patients with ≥2 post - BL scans per RECIST 1.1, PD or death at any prior timepoint, tho se with ongoing unconfirmed PR/CR were excluded. c Patient left study (withdrew consent) with ongoing unconfirmed PR.* Maximum change of target lesions and RECIST1.1 response a t different timepoints. Anzu - cel, a nzutresgene autoleucel ; BOR, best overall response; cCR , confirmed complete response; cORR , confirmed objective response rate; cPR , confirmed partial response; DCR, disease control rate at week 6; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.
Change in Sum of Longest Diameter of Target Lesions from Baseline [%] Months Post T - cell Infusion Ongoing response at 39.6 mo Response until 32.9 mo BL PR cCR cPR PR SD PD Ongoing Anzu - cel (IMA203) PRAME Cell Therapy Induced Durable Responses in Metastatic PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave #1: anzu - cel a Includes melanoma (other) n=3: mucosal melanoma n=2, melanoma of unknown primary n=1. Anzu - cel, a nzutresgene autoleucel ; BL, baseline; cCR , confirmed complete response; cPR , confirmed partial response; mDOR , median duration of response; mFU , median follow - up; mo , month; ND, not defined; PD, progressive disease; PR partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease. 16 All Melanoma a n=33 Uveal Melanoma n=16 Cutaneous Melanoma n=14 14.6 (4.2, 38.2+) 11 (4.4, 31.6) 17.9 (4.2, 38.2+) mDOR [ mo ] (range) 18.7 ND 18.7 mFU [ mo ]
Anzu - cel (IMA203) PRAME Cell Therapy Induced Durable Responses in Metastatic PD - 1 - Relapsed Melanoma and Metastatic Uveal Melanoma Data cutoff Sep 24, 2025 Davar et al., ASCO 2026 PRAME Wave #1: anzu - cel Median Progression Free Survival Median Overall Survival All Melanoma a n=33 Uveal Melanoma n=16 Cutaneous Melanoma n=14 6.1 (1.4, 39.6+) 20.0 8.5 (1.4, 32.9) 10.4 6.0 (1.4 , 39.6+) 20.0 mPFS [ mo ] (range) mFU [ mo ] All Melanoma a n=33 Uveal Melanoma n=16 Cutaneous Melanoma n=14 16.2 (2.4, 39.6+) 17.3 NR (4.5, 34.2) 14.3 1 3 .9 (2.4, 39.6+) 20.0 mOS [ mo ] (range) mFU [ mo ] 6 - month PFS rate: 55% 100 PFS [%] 0 75 50 25 0 6 12 18 24 30 36 42 Time from Infusion [months] 33 16 8 4 2 2 1 0 0 15 20 23 24 24 25 25 At Risk Events PFS for All Melanoma Indications (n=33) 12 - month PFS rate: 37% 24 - month OS: 46% 100 OS [%] 0 75 50 25 0 6 12 18 24 30 36 42 Time from Infusion [months] 33 29 17 7 3 3 1 0 0 2 9 14 14 14 14 14 At Risk Events OS for All Melanoma Indications (n=33) 12 - month OS: 70% a Includes melanoma (other) n=3: mucosal melanoma n=2, melanoma of unknown primary n=1; PFS and OS of ongoing patients censored a t data - cut; PFS and OS rates were calculated using Kaplan - Meier method. Anzu - cel, a nzutresgene autoleucel ; mFU , median follow - up; mOS , median overall survival; mPFS , median progression - free survival; OS, overall survival; PFS, progression - free survival. 17
Anzu - cel (IMA203) PRAME Cell Therapy in Melanoma: Overview of Studies PFS and OS Data in Melanoma Cohorts mOS (months) mPFS (months) Prior lines of therapies M elanoma patient population N Phase Drug Product 16.2 6.1 3% n=0, 24% n=1, 30% n=2, 24% n=3:, 6% n=4, 6% n=5, 6% n=6 82% received prior ICI (median of 1 prior line of ICI in overall population, median of 2 prior lines of ICI in cut. melanoma) Median of 2 prior lines, median of 2.5 prior lines in cut. melanoma 42% cutaneous 48% uveal 9% other 33 1b (Dose Expansion) Anzu - cel in Melanoma 6.3 2.6 0% n=1, 27% n=2, 73% n>2 prior lines 100% received prior ICI (median of 2 prior lines of ICI, median of 2.5 prior lines of ICI in cut. melanoma) Median of 4 prior lines, median of 4.5 prior lines in cut. melanoma 73% cutaneous 18% uveal 9% other 11 1a (Dose Escalation) Anzu - cel in Melanoma 5.3 2.5 0% n=1, 16% n=2, 84% n>2 prior lines 100% received prior ICI (median 3 prior lines of ICI) Median of 4 prior lines, median of 4.5 prior lines in cut. melanoma 63% cutaneous 11% uveal 26% other 19 1a (Dose Escalation) IMA201/202/anzu - cel combined in Melanoma 13.9 4.1 median of 3 prior lines (min/max: 1/9) 100% received prior ICI 54% cutaneous 0% uveal 45% other 153 2 Lifileucel (C - 144 - 01, Cohort 2+4) 1 11.6 2.9 57% n=1, 27% n=2, 12% n>2 prior lines 99% received prior ICI 85% cutaneous 0% uveal 15% other 238 3 Tilsotolimod + Ipilimumab (ILLUMINATE - 301) 2 14.7 2.1 46% n=1, 35% n=2, 19% n≥3 prior lines 99% received prior ICI 68% cutaneous 0% uveal 32% other 354 1/2 Nivolumab + Relatlimab (RELATIVITY - 020, D1 Cohort) 3 18 Data cut - off Sep 30, 2025 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), 1 Chesney et al., 2022; 2 Diab et al., 2024; 3 Ascierto et al., 2023 PFS: progression - free survival; OS: overall survival; ICI: immune checkpoint inhibitor These data are derived from different clinical trials at different points in time with differences in trial design and patien t p opulations. As a result, cross - trial comparisons cannot be made, and no head - to - head clinical trials have been conducted. PRAME Wave #1: anzu - cel
Anzu - cel (IMA203) PRAME Cell Therapy Enhanced mPFS of >1 Year in Melanoma Patients with Deep Responses 19 Data cut - off Sep 24, 2025 • 42% (14/33) patients in dose expansion have a deep response ( ≥ 50% tumor reduction) • This subgroup of patients has highly medically meaningful mPFS of more than 1 year • Patients with <50% tumor reduction (including tumor size increase) still observe a more than 2x longer mPFS as compared to patients treated in dose escalation with suboptimal doses mFU mPFS n ND 2.6 11 Dose Escalation anzu - cel 17.3 5.8 19 Dose Expansion anzu - cel <50% tumor size reduction (including tumor size increase) 39.6 15.9 14 Dose Expansion anzu - cel ≥50% tumor size reduction Log - rank: 0.006 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), b, billion; ND, not defined; mFU , median follow - up; mPFS , median progression - free survival. PRAME Wave #1: anzu - cel Median dose 0.59b Median dose 3.33b Median dose 5.87b
SUPRAME: A Randomized Ph3 Trial of Anzu - cel (IMA203) PRAME - directed TCR T - cell Therapy vs Investigator’s Choice in Unresectable or Metastatic Melanoma post ICI Actively Enrolling, >65 Sites Planned across North America and Europe 20 Anzu - cel (IMA203) n=180 Investigator’s choice n=180 Primary Endpoint • PFS Key Secondary Endpoint • Overall survival Randomization 1:1 Patient Population: Unresectable or metastatic melanoma post ICI N=360 nivolumab/ relatlimab , nivolumab, ipilimumab, pembrolizumab, lifileucel, chemotherapy Anzutresgene autoleucel ( anzu - cel, formerly IMA203), 1 Pre - specified interim and final analyses expected to be triggered in 2026 as planned upon the occurrence of a defined number of events for PFS (progressive disease or death); ICI: immune checkpoint inhibitor; PFS: progression - free survival; ORR: objective response rate; TESAEs: treatment - emergent serious adverse events; AE: adverse eve nt; EORTC: European Organization for Research and Treatment of Cancer ; QLQ - C30: Core Quality of Life questionnaire; EQ - 5D - 5L: European Quality of Life 5 Dimensions 5 Level Version Secondary Endpoints • Efficacy: ORR • Safety: TESAEs, AEs of special • interest • Quality of life: EORTC QLQ - C30 and EQ - 5D - 5L Expected timelines SUPRAME trial • Interim and final analyses triggered 1 : 2026 2026 • BLA submission: 1H 2027 • Launch: 2H 2027 2027 PRAME Wave #1: anzu - cel
Cell Therapy Manufacturing Facility To Support Anzu - cel BLA and Commercialization 21 • ~100,000 sq ft s tate - of - the - art research & GMP manufacturing facility • Modular design for efficient and cost - effective scalability - total of 8 manufacturing suites, plus further expansion space • Capacity sufficient to serve early - stage and registration - directed clinical trial as well as planned initial commercial supply • In - house manufacturing and QC allows full control of process, product and costs • Located in the Houston Metropolitan Area, Texas, offering economic labor and operating costs and talent pool highly qualified in cell therapy manufacturing & QC Anzutresgene autoleucel ( anzu - cel, formerly IMA203); BLA: Biologics License Application PRAME Wave #1: anzu - cel
IMA203CD8 PRAME Cell Therapy Expansion to all Advanced PRAME Cancers PRAME Wave #2 22
IMA203CD8 PRAME Cell Therapy: Expansion of Commercial Opportunity to all Advanced PRAME Cancers 23 IMA203CD8 Opportunity 2L Solid Tumors All patient numbers refer to PRAME + /HLA - A*02:01 + patients in the US and EU5 in 2025; Source: Clarivate Disease Landscape and Forecast; EU5: France, Germany, Italy, Spain, Un it ed Kingdom 1 Bajwa et al. 2021 Journal for Immunotherapy of Cancer; 2 Melenhorst et al. 2022 Nature, Bai et al. 2022 Science Advances; 2L: patients with unresectable or metastatic solid tumors who have received at least 1 prior therapy; sqNSCLC : squamous cell non - small - cell lung cancer, HNSCC: head and neck squamous cell carcinoma The PRAME + /HLA - A*02:01 + addressable patient opportunity across a broad range of PRAME expression is > 75K per year • Co - transduction of CD8αβ alongside PRAME TCR adds functional CD4 + T cells designed to boost cytotoxicity • Proof of concept from preclinical experiments 1 and CD19 CAR T cell studies in leukemia 2 • Based on its enhanced pharmacology, IMA203CD8 provides the potential to expand to tumor - agnostic label in 2L PRAME cancers across broad spectrum of PRAME expression level (see appendix for PRAME expression levels) • Ovarian carcinoma chosen as initial proof - of - concept EU5 US 2K 2K Ovarian 4K 4K Uterine 10K 7K sqNSCLC 2K 2K HNSCC 8K 5K Breast 18K 16K Others TUMOR CELL DEATH CD8 - engineered CD4 T CELL Cytotoxic Activity CD8 T CELL T cell Help Cytotoxic Activity CD8 PRAME TCR PRAME Wave #2: IMA203CD8
Towards Proof - of - concept for Tumor - agnostic Targeting of PRAME Cancers with IMA203CD8 24 Updated data, including durability follow - up at RP2D, planned to be presented in 2H 2026 AE: adverse event; cPR : confirmed partial response; RP2D: recommended phase 2 dose. Summary: IMA203CD8 Cell Therapy in PRAME+ Solid Tumors Manageable Tolerability Activity Across PRAME+ Tumors One - time infusion of IMA203CD8 showed clinical anti - tumor activity across multiple PRAME - positive tumor indications with distinct biology and differing levels of PRAME expression Deep & Durable Responses Development Opportunity IMA203CD8 to be positioned in tumor - agnostic setting of advanced PRAME+ cancers beyond melanoma, starting with gynecologic cancers The Phase 1 trial could also support the positioning of IMA203CD8 without the requirement of post - infusion low - dose IL - 2 in the future Data cutoff Mar 30, 2026 PRAME Wave #2: IMA203CD8 Anticipated cytopenias associated with lymphodepletion Mostly low - grade CRS Infrequent ICANS Potential for outpatient administration • Platinum - resistant ovarian cancer and in uterine cancer at clinically relevant doses (DL4c+) : 63% ORR, 50% cORR , incl. 4 complete responses, and longest ongoing response at 12 months • Synovial sarcoma at low doses: 67% ORR and 64% cORR , including one complete response, and ongoing responses up to ~3 years across all doses at low median dose • Responses were observed ± low - dose IL - 2
Phase 1 Multicenter Trial of IMA203CD8 in PRAME+ Solid Tumors PRAME Testing Biopsy or archived tissue No longer required for indications with high PRAME prevalence, including ovarian and uterine cancer IMA203CD8 Manufacturing (~2 weeks) Lymphodepletion Fludarabine 30mg/m 2 Cyclophosphamide 500mg/m 2 Days - 6 to - 3 ц Low Dose IL - 2 a 1M IU SUBQ QD x 3d, then 1M IU SUBQ BID x 5d Leukapheresis HLA - A*02:01 Testing (blood) Patient Journey SCREENING / MANUFACTURING TREATMENT / OBSERVATION FU IMA203CD8 one - time infusion Enrichment at relevant DLs: ~1.4 – 10 billion total TCR T cells DL3 (n=1) ~0.36 - 0.86 x 10 9 total TCR T cells DL4a (n=6) ~0.87 - 1.44 x 10 9 total TCR T cells DL4c (n=2) ~1.45 - 2.16 x 10 9 total TCR T cells DL5 (n=5) ~2.17 - 3.6 x 10 9 total TCR T cells DL6 (n=8) ~3.6 - 7.2 x 10 9 total TCR T cells DL7 (n=5) ~7.2 - 10 x 10 9 total TCR T cells Dose Escalation Scheme Key Objectives Primary: • Tolerability • Determination of RP2D Secondary: • Efficacy • Pharmacokinetics Key Eligibility Criteria • Advanced or metastatic solid tumors • Age ≥ 18 years • ECOG PS 0 - 1 • HLA - A*02:01 positive • PRAME positive • No available SOC treatment options • Measurable disease (RECIST 1.1) • Adequate organ function IMA203 - 101: NCT03686124; Based on initial safety data observed with anzu - cel (IMA203), IMA203CD8 dose escalation was initiated at DL3. Total TCR T cells calculated from defined number of TCR T cells /m 2 BSA per dose level x 1.8 m 2 BSA; a Dose level ≥ DL4c is evaluated ± IL - 2 , starting without IL - 2. If tolerable, add IL - 2 at the same dose or escalate to next dose without IL - 2; outpt IL - 2 admin . at investigator’s discretion. BID, twice daily; BSA, body surface area; DL, dose level; ECOG PS, Eastern Cooperative Oncology Group Performance St atus; FU, follow - up; IL, interleukin; IU, international unit; PRAME, preferentially expressed antigen in melanoma; QD, daily; SOC, standard of care; SUBQ, subcutaneous; TCR, T - cell receptor. 25 Data cutoff Mar 30, 2026 Busse et al., ASCO 2026 PRAME Wave #2: IMA203CD8
Patients Were Heavily Pretreated with Limited Treatment Options n=27, includes all patients who started lymphodepletion; a Includes 1 patient with endometrial carcinoma; ADC, antibody - drug - conjugate; ECOG PS, Eastern Cooperative Oncology Group Perform ance Status; LDH, lactate dehydrogenase; na , not applicable; PARPi , PARP inhibitor; SLD, sum of longest diameter(s); TCR, T - cell receptor; ULN, upper limit of normal. 26 Data cutoff Mar 30, 2026 Busse et al., ASCO 2026 PRAME Wave #2: IMA203CD8 Uterine Cancer a Ovarian Carcinoma n=3 n=24 52 (49, 55) 60 (35, 75) Age, median (range) 0 10 (42) ECOG PS 1 , n (%) 2 (67) 8 (33) LDH ≥1 x ULN, n (%) 8.1 (1.1, 12.4) 6.2 (1.5, 21.6) Tumor burden Target lesion SLD [cm], median (range) 4 (1, 4) 2 (1, 5) Number of target tumor lesions, median (range) 1 (33) 21 (88) Cancer subtype, high - grade serous , n (%) 2 (67) 10 (42) Liver metastasis, n (%) 3 (100) 17 (71) Peritoneal disease , n (%) na 19 (79) Platinum - resistant, n (%) Baseline Characteristics Uterine Cancer a Ovarian Carcinoma n=3 n=24 1 (33) 3 (100) 4 (17) 24 (100) Prior treatment, n (%) Radiation Systemic treatment 2 (1, 3) 1 (33) 4 (1, 7) 22 (92) Prior lines of systemic treatment Median, (range) ≥3, n (%) na 3 (100) 1 (1, 1) 3 (100) 1 (1, 1) - - 3 (100) 1 (0, 2) 24 (100) 3 (1, 5) 24 (100) 3 (1, 4) 18 (75) 17 (71) 2 (8) Lines post - platinum resistance, med (range) Chemotherapy, n (%) Lines of chemotherapy, median (range) Platinum - based regimen, n (%) Lines of platinum - based regimen, median (range) Targeted therapies, n (%) Bevacizumab PARPi Checkpoint inhibitors Treatment Experience n=3 n=24 Dose 3.2 (1.3, 10.1) 3.3 (0.5, 12.5) Total infused dose TCR T cells [x10 9 ], median (range)
IMA203CD8: Safety in Patients with Gynecologic Indications (n=27 a ) Tolerability across all indications: Busse et al ESMO - IO, 2025. a Includes all patients who started lymphodepletion; b One grade 5 event at DL4a (~1.4 billion total TCR T cells) was deemed to be unlikely related to IMA203CD8 by investigator. Pa ti ent died from sepsis in the setting of IEC - HS. This event led to further modifications of eligibility criteria to exclude patien ts at higher risk for infectious complications or severe immune - related toxicities, together with IL - 2 de - intensification; no further treatment - em ergent fatal events were observed with escalating doses up to ~10 billion total TCR T cells. AE, adverse event; CRS, cytokine re lease syndrome; d, day; DL, dose level; DLT, dose - limiting toxicity; HLH, hemophagocytic lymphohistiocytosis; ICANS, immune effector cell - associated neurotoxicity syndrome; TCR, T - cell receptor; TE AE, treatment - emergent adverse event. 27 Data cutoff Mar 30, 2026 Busse et al., ASCO 2026 PRAME Wave #2: IMA203CD8 Adverse events of special interest TEAEs in ≥25% of patients Any Time Grade ≥ 3 Any grade Preferred term, n (%) 0 22 (81) Nausea 20 (74) 20 (74) Neutropenia 17 (63) 18 (67) Anaemia 3 (11) 16 (59) Rash 11 (41) 16 (59) Thrombocytopenia 2 (7) 13 (48) Abdominal pain 0 12 (44) Vomiting 0 11 (41) Fatigue 1 (4) 10 (37) Hypokalaemia 0 9 (33) Constipation 9 (33) 9 (33) Lymphopenia 2 (7) 8 (30) Hypophosphataemia 0 8 (30) Pyrexia 1 (4) 7 (26) Hypomagnesaemia 0 7 (26) Hyponatraemia Any Time 26 (96) CRS, any grade, n (%) 12 (44) Grade 1 12 (44) Grade 2 2 (7) Grade 3 2 (7) HLH, any grade, n (%) 0 Grade 1 1 (4) Grade 2 0 Grade 3 1 (4) Grade 4 2 (7) ICANS, any grade, n (%) 1 (4) Grade 1 0 Grade 2 1 (4) Grade 3 Overall manageable tolerability profile • Most frequent TEAEs were anticipated cytopenias associated with lymphodepletion • Expected and manageable CRS, mostly grade 1 - 2, consistent with mechanism of action • 2 DLTs: – DL5: Grade 3 ICANS – DL7: G rade 4 skin infection • MTD not reached • No IMA203CD8 - related grade 5 events b
IMA203CD8: BOR in Patients with Gynecologic Indications at All DL (n=26 a ) 28 Data cutoff Mar 30, 2026 Busse et al., ASCO 2026 PRAME Wave #2: IMA203CD8 ,QGLFDWLRQ 7DUJHW/HVLRQVIURP%DVHOLQH 5(&,67 %HVW &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI %DVHOLQH :DWHUIDOO3ORW 6RUWHGE\'/*( &)/ 1ILUVW WKHQ< 3RSXODWLRQ $OOSDWLHQWV 'DWDFXW RII * * + ≥DL4c <DL4c Baseline Tumor reduction: 78% (14/18) Evaluable patients ≥DL4c 63% (12/19) ORR b 50% (9/18) cORR c 68% (13/19) DCR (at week 6) PD Best overall response (RECIST 1.1) SD PR cPR CR cCR Ongoing a Two patients with ovarian cancer at DL4a and DL5 deceased prior to first post - BL scan non - evaluable for assessment of tumor redu ction, not depicted in plot but assessed for ORR calculation; b ORR: according to RECIST 1.1 at any post - BL scan, PD or death at any prior timepoint; c Confirmed ORR for patients with ≥2 post - BL scans per RECIST 1.1, PD or death at any prior timepoint, those with ongoing unconfi rmed PR/CR were excluded. * For those patients who achieved a (c)CR with <100% changes from baseline, target lesions were lymph nodes that resolved to <10 mm per RECIST 1.1; + Patient had a PR prior to CR. BL, baseline; BOR, best overall response; (c)CR, (confirmed) complete response; DCR, disease co nt rol rate; DL, dose level; (c)ORR, (confirmed) objective response rate; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable dis ease.
IMA203CD8: Changes in Tumor Size Over Time in Patients with Gynecologic Indications ≥DL4c (n=19 a ) 29 Data cutoff Mar 30, 2026 Busse et al., ASCO 2026 PRAME Wave #2: IMA203CD8 a One patient with ovarian cancer at DL5 deceased prior to first post - BL scan non - evaluable for assessment of tumor reduction, no t depicted in plot but assessed for ORR calculation. For those patients who achieved a (c)CR with <100% changes from baseline, target lesions were lymph nodes that resolved to <10 mm per RECIST 1.1; # Ong oing confirmed PR (RECIST 1.1) as of last scan at month 7.5, suspected clinical progression by clinical site at month 6 in discrepancy to RECIST response due to tumor marker increase; patient off study at mon th 8 and receiving further anti - tumor treatment. BOR, best overall response; (c)CR, (confirmed) complete response; DCR, disease control rate; (c)ORR, (confirmed) objective response rate; PD, progressive diseas e; (c)PR, (confirmed) partial response; SD, stable disease. # 'DWDFXW RII 3RSXODWLRQ *\Q2QF%XQGOH ,0$ &' LQ'/ FRUKLJKHU 6SLGHU3ORW 8WHULQH&DQFHU 2YDULDQ&DQFHU ,QGLFDWLRQ 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH 5(&,67 0RQWKVSRVW7FHOOLQIXVLRQ 7DUJHW/HVLRQVIURP%DVHOLQH >@ &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI 3' %DVHOLQH 35 2QJRLQJ Months Post T - cell Infusion # PD Best overall response (RECIST 1.1) SD PR cPR CR cCR Ongoing Ovarian Cancer Indication Uterine Cancer • 89% (8/9) of confirmed responses ongoing • longest ongoing response at 12 months post infusion (metabolic complete response)
IMA203CD8: Safety in Synovial Sarcoma 30 Data cutoff Mar 30, 2026 Araujo et al., ASCO 2026 PRAME Wave #2: IMA203CD8 a Testicular/scrotal disorders includes grouped terms; b Grade 3 CRS with transient Grade 3 hepatotoxicity improved to Grade 2 within 10 days; CRS resolved completely without need fo r v asopressors/ventilator support; c Further modification of the inclusion/exclusion criteria and IL - 2 scheme allowed continuation of dose escalation from DL4c up to present DL7; CRS, cytokine release syndrome; HLH, hemophagocytic lymphohistiocytosis; ICANS, immune effector cell - associated neurotoxicity syndrome; LD, lymphodepletion; MTD, maximum tolerated dose; TEAE, treatment - emergent adverse event. Adverse events of special interest (AESI) Grade ≥ 3 Any Grade Preferred term, n (%) 12 (100) 12 (100) Neutropenia 6 (50) 11 (92) Anemia 4 (33) 11 (92) Thrombocytopenia 1 (8) 11 (92) Transaminase elevation 9 (75) 9 (75) Lymphopenia 0 8 (67) Nausea 0 6 (50) Fatigue 0 5 (42) Rash 1 (8) 4 (33) Creatinine elevation 0 4 (33) Constipation 0 4 (33) Headache 0 4 (33) Hyponatremia 1 (8) 4 (33) Hypophosphatemia 0 4 (33) Pyrexia 0 4 (33) Testicular/scrotal disorders a 0 3 (25) Back pain 0 3 (25) Dyspnoea 2 (17) 3 (25) Hypertension 0 3 (25) Insomnia 0 3 (25) Edema peripheral N=12 12 (100) CRS, any grade, n (%) 5 (42) Grade 1 5 (42) Grade 2 2 (17) Grade 3 0 HLH, any grade, n (%) 0 ICANS, any grade, n (%) TEAEs in ≥25% of patients (N=12) • Most frequent TEAEs were anticipated cytopenias associated with lymphodepletion • Infrequent long - term (Day ≥ 90) grade ≥3 TEAEs included cytopenias (n=6) and/or hypertension (n=2) • AESIs were low - grade (1 - 2), occurred early, and were transient • CRS was mostly low - grade (1 - 2), expected and manageable • No HLH or ICANS • 1 DLT b at DL4b (MTD not reached c )
IMA203CD8: BOR in Patients with Synovial Sarcoma (n=12) 31 Data cutoff Mar 30, 2026 Araujo et al., ASCO 2026 PRAME Wave #2: IMA203CD8 a ORR: according to RECIST 1.1 at any post - BL scan, PD or death at any prior timepoint; cORR : according to RECIST 1.1 for patients with ≥2 post - BL scans, PD or death at any prior timepoint; b Confirmed ORR for patients with ≥2 post - BL scans per RECIST 1.1, PD or death at any prior timepoint, those with ongoing unconfirmed PR/CR were exc luded. BL, baseline; BOR, best overall response; (c)CR, (confirmed) complete response; (c)ORR, (confirmed) objective response rate; (c)PR, (confirmed) partial response; DCR, disease control rate; mDOR , median duration of response; mFU , median follow - up; NR, not reached; PD, progressive disease; SD, stable disease; TCR, T - cell receptor. 'DWDFXW RII 3RSXODWLRQ 6\QRYLDO6DUFRPD ,0$ &' 6SLGHU3ORW 6DUFRPD ,QGLFDWLRQ 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH 5(&,67 3' 3' %DVHOLQH %DVHOLQH 35 35 0RQWKVSRVW7FHOOLQIXVLRQ 7DUJHW/HVLRQVIURP%DVHOLQH >@ &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI 2QJRLQJ Clinical activity including durable responses observed at all dose levels Median dose: 1.59 x10 9 total TCR T cells Best overall response (RECIST 1.1) PD SD PR cPR CR cCR Ongoing ,QGLFDWLRQ %HVW &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI7DUJHW/HVLRQVIURP%DVHOLQH 5(&,67 %DVHOLQH 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH 5(&,67 2QJRLQJ :DWHUIDOO3ORW 3RSXODWLRQ 6\QRYLDO6DUFRPD ,0$ &' 'DWDFXW RII 25 0 - 25 - 50 - 75 - 100 Change in Sum of Longest Diameter of Target Lesions from Baseline (%) 15 - 1 - 18 - 26 - 41 - 42 - 50 - 61 - 66 - 73 - 77 - 100 BL Tumor reduction: 92% (11/12) DL4a DL3 DL4a DL4b DL7 DL3 DL4a DL4a DL4a DL4a DL4a DL4b 67% (8/12) ORR a 64% (7/11) cORR b 100% (12/12) DCR (at week 6) 14.8 (3.7, 31.8+) 31.0 mDOR (range), months mFU
IMA402 PRAME Bispecific Expansion to Earlier - Line PRAME Cancers PRAME Wave #3
IMA402 PRAME Bispecific: Expansion of the Commercial Opportunity to Earlier - Line PRAME Cancers 33 IMA402 Opportunity 1 median half - life IMA402: ~7 days; All patient numbers refer to PRAME + /HLA - A*02:01 + patients in the US and EU5 in 2025 based on initial threshold for all indications except for sqNSCLC (optimized threshold considered for further development due to IMA401 combination potential); Source: Clarivate Disease Landscape and Fo rec ast; EU5: France, Germany, Italy, Spain, United Kingdom; q2w: once every two weeks; sqNSCLC : squamous cell non - small - cell lung cancer 1L Solid Tumors >145K addressable PRAME + /HLA - A*02:01 + patients in the US & EU5 TCR Bispecifics (TCER®) PRAME Wave #3: IMA402 EU5 US 6K 6K Cut. Melanoma 9K 7K Ovarian 6K 6K Uterine 23K 16K sqNSCLC 10K 7K Breast 32K 25K Others x Anti - tumor Activity High - affinity and specificity TCR domain targeting tumor pHLA molecules x Antibody - like format with half - life extension (HLE) Long half life of 1 - 2 weeks 1 allows for q2w or longer dosing intervals x Optimized tolerability Low - affinity T cell recruiter against CD3/TCR allows higher dosing
Cancer Cell IMA402 PRAME Bispecific Summary: Phase 1 Dose Escalation Study 34 Tolerability Favorable tolerability profile Most common treatment - related AEs are low - grade CRS and expected & transient lymphopenia Promising clinical activity and deep and durable responses observed at RP2D range during dose escalation 30% (6/20) cORR across all indications, incl. melanoma & ovarian carcinoma Promising early PFS/ iPFS , OS Pharmacokinetics Median half - life of ~7 days Potential for bi - weekly dosing or longer dosing intervals offering a more convenient dosing schedule , including combination treatment approaches Activity & Duration of Response 1 Development Potential Possible future use in later - lines as monotherapy or combination setting with the potential to expand to earlier lines incl. frontline or (neo)adjuvant setting (in combination with ICI/SOC) Initial focus on cut. melanoma, gyn - onc as well as sqNSCLC (IMA402/IMA401 combo) 1 at doses 10 - 30 mg; AE: adverse event; CRS: Cytokine release syndrome; ICI: immune checkpoint inhibitor; RP2D: recommended phase 2 dose; SOC: standard of care Data cut - off Sep 26, 2025 PRAME TCER® IMA402 PRAME Wave #3: IMA402 • Clinical data update as monotherapy and initial data at RP2D range in combination with an immune checkpoint inhibitor expecte d i n 2H 2026 • IMA402/IMA401 combination cohort in soNSCLC is now enrolling at multiple clinical trial sites, with first data expected in 2027
• Ph1a dose escalation completed, MTD not reached at 30 mg • Provisional RP2D range identified at 10 to 30 mg • Ph1b dose expansion ongoing at two distinct doses within RP2D range • Combination with immune checkpoint inhibitor started 35 Phase 1/2 Clinical Trial to Evaluate IMA402 PRAME Bispecific EudraCT No. 2022 - 503133 - 54 - 00; NCT05958121; 1 Cutaneous melanoma, melanoma of unknown primary, uveal melanoma, synovial sarcoma, endometrial carcinoma, ovarian carcinoma, sq uamous non - small cell lung cancer; 2 Based on preclinical in vitro and in vivo data; 3 Step dosing introduced at 0.36 mg, optimized step dosing currently being applied: 0.03 mg/0.3 mg/6 mg/target dose, low - dose dexa methasone used as preventive measure for initial doses as applied for other bispecific T cell engagers; Ability to increase dose to previously cleared dos e l evels; BLRM: bayesian logistic regression model; MABEL: minimum anticipated biological effect level ; MTD: maximum tolerated dose; q1w: every week; q2w: every 2 weeks; RP2D: recommended phase 2 dose. Key Eligibility Criteria Objectives Primary: • Determine MTD and/or RP2D • Assess safety and tolerability Secondary: • Evaluate initial anti - tumor activity (RECIST 1.1 and iRECIST ) • Assess pharmacokinetics • Recurrent and/or refractory solid tumors expressing PRAME 1 • No prospective PRAME testing required • HLA - A*02:01 positive • ECOG performance status 0 - 1 • Received or not eligible for all available indicated standard of care treatments Total safety population (N=80) • MABEL - based starting dose • Dose escalation based on cohorts of 1 - 6 patients using adaptive design (BLRM model) • q1w step dosing (3 doses) up to target dose 3 • q2w dosing planned based on favorable PK and already applied for individual patients 0.36 mg 0.8 mg 3 mg 5 mg 0.12 mg 1.6 mg 0.06 mg 0.02 mg 8 mg 4 mg 12 mg 20 mg 30 mg 10 mg RP2D range Sub - therapeutic dose 2 Data cutoff Sep 26, 2025 PRAME Wave #3: IMA402
Demographics and Baseline Characteristics IMA402 PRAME Bispecific 36 1 Efficacy - evaluable population: All patients treated as of Jun 26, 2025 (who had the opportunity for at least 3 months follow - up or who discontinued early due to disease progression or death), tested positive or not tested/not evaluable for PRAME and received ≥4 infusions as defined per protocol (thereof 3 step doses, currently at 0.03 mg/ 0.3 mg/6 mg, and 1 target dose); Baseline characteristics for melanoma and ovarian carcinoma are listed in the appendix; ECOG: e astern cooperative oncology group ; LDH: Lactate dehydrogenase; RP2D: recommended phase 2 dose; ULN: upper limit of normal. Efficacy population (N=57) 1 Safety population (N=80) RP2D range, ≥10 mg ( n=20) 3 – 8 mg ( n=22) ≤1.6 mg ( n=15) 0.02 - 30 mg 56 (37, 74) 55 (34, 74) 61 (28, 82) 59 (21, 82) Age Median (min, max) 11 (55) 9 (45) 11 (50) 11 (50) 6 (40) 9 (60) 47 (59) 33 (41) ECOG performance status 0, n (%) 1, n (%) 3 (1, 6) 3 (1, 5) 3 (2, 7) 3 (1, 7) Prior lines of systemic treatment Median (min, max) 14 (70) 6 (30) 0 (0) 11 (50) 11 (50) 0 (0) 5 (33) 9 (60) 1 (7) 39 (49) 40 (50) 1 (1) LDH at baseline ≤ 1xULN, n ( %) 1 - 2xULN, n ( %) > 2xULN, n ( %) 76 (21, 255) 68 (25, 258) 80 (46, 398) 80 (16, 398) Baseline tumor burden Median target lesion sum of diameter (mm) (min, max) 4 (2, 11) 6 (30) 3 (15) 6 (1, 15) 8 (36) 1 (5) 4 (2, 10) 8 (53) 1 (7) 4 (1, 15) 33 (41) 6 (8) Tumor lesions Number of lesions, median (min, max) Liver metastases, n (%) Brain metastases, n (%) Heavily pre - treated patient population with comparable baseline characteristics across dose groups Data cutoff Sep 26, 2025 PRAME Wave #3: IMA402
IMA402 PRAME Bispecific Shows a Favorable Tolerability Profile 37 Safety Population (N=80) ≥ Grade 3 All Grades TEAEs, n (%) 48 (60) 78 (98) Any 42 (53) 76 ( 95) Treatment - related • Favorable tolerability across wide dose range and consistent with tolerability at RP2D range (see appendix) • Most frequent/relevant related AEs were • Expected and transient lymphopenia, consistent with the mechanism of action • Low - grade CRS (33% G1, 5% G2, 0% G3, 1% G4) mostly at first step dose • One CRS G4 event in patient at 0.08 mg starting dose only; no further CRS G4 events after step dose optimization • No ICANS observed • No IMA402 - related Grade 5 events • MTD not reached 2 at 30 mg ≥ Grade 3 All Grades Treatment - related AEs 1 , n (%) 30 (38) 40 (50) Lymphopenia 1 (1) 31 (39) Cytokine release syndrome 1 (1) 21 (26) Arthralgia 19 (24) Fatigue 7 (9) 16 (20) Alanine aminotransferase increased 5 (6) 14 (18) Aspartate aminotransferase increased 13 (16) Rash 11 (14) Pruritus 11 (14) Pyrexia 2 (3) 10 (13) Anaemia 1 (1) 10 (13) Myalgia 9 (11) Nausea 3 (4) 8 (10) Gamma - glutamyltransferase increased 7 (9) Lipase increased 7 (9) Abdominal pain 2 (3) 3 (4) Hypertension 2 (3) 2 (3) Neutropenia 1 (1) 2 (3) Blood creatinine increased 1 (1) 2 (3) Stomatitis 1 (1) 2 (3) Tumour pain 1 (1) 1 (1) Acute kidney injury 1 (1) 1 (1) Electrocardiogram abnormal 1 (1) 1 (1) Herpes zoster 1 (1) 1 (1) Immune - mediated arthritis 1 (1) 1 (1) Liver function test increased 1 (1) 1 (1) Tumour lysis syndrome 1 All treatment - emergent adverse events (TEAEs) for IMA402 monotherapy at least possibly related to IMA402 infusion with Grade 1 - 2 occurring in at least 7% of patients and all events with ≥ Grade 3, one additional patient treated with IMA402 at first step dose + pembrolizumab is not included in the safety population/table and had the fol low ing AEs: lymphopenia G3, erythema G1 , TSH decrease G1; 2 Two dose - limiting toxicities (DLTs) at 0.08 mg and 0.3 mg; AE: adverse event; CRS: cytokine release syndrome; G: grade; ICANS: immune effector cell - associated neurotoxicity syndrome; MTD: maximum tolerated dose; RP2D: recommended phase 2 dose . Data cutoff Sep 26, 2025 PRAME Wave #3: IMA402
Clinical Proof - of - Concept of IMA402 PRAME Bispecific across Various Indications Dose - Response Relationship in Monotherapy Setting 1 Melanoma includes cutaneous melanoma, melanoma of unknown primary, uveal melanoma; 2 Other indications include endometrioid carcinoma, synovial sarcoma and one patient with sqNSCLC at 1.6 mg; BL: baseline; BOR: best overall response; cORR : confirmed objective response rate; cPR : confirmed partial response; ICI: immune checkpoint inhibitor; PD: progressive disease; SD: stable disease; PR: partial response; RECIST: response evaluation criteria in solid tumors ; RP2D: recommended phase 2 dose . Melanoma 1 Other Indications 2 Ovarian Carcinoma Indications • All responders with ovarian carcinoma were platinum resistant • All responders with melanoma were ICI - resistant cORR 30% RP2D ≥10 mg 3 - 8 mg ≤ 1.6 mg 38 Data cutoff Sep 26, 2025 N=57 PRAME Wave #3: IMA402
Deep and Durable Responses at RP2D Range 39 6/6 Confirmed Objective Responses Ongoing, incl. Two Complete Metabolic Responses at 12 mg IMA402 Complete metabolic response at 12 mg PD SD cPR Ongoing response/ disease control Ongoing treatment BOR (RECIST 1.1) All indications Melanoma Ovarian carcinoma 2/3 29% (4/14) 30% (6/20) cORR not reached 2.2 not reached 7.3 not reached 4.2 mDOR (mo) mFU (mo) 2/3 57% (8/14) 55% (11/20) Tumor shrinkage 2/3 71% (10/14) 65% (13/20) DCR (at week 6) RECIST 1.1 BL: baseline; BOR: best overall response; cPR : confirmed partial response; cORR: confirmed objective response rate; DCR: disease control rate ; mDOR : median duration of response; mFU : median follow - up; PD: progressive disease; PR: partial response; RP2D: recommended phase 2 dose; SD: stable disease. Complete metabolic response at 12 mg Data cutoff Sep 26, 2025 N=20 PRAME Wave #3: IMA402
Early Promising PFS and OS Snapshot for IMA402 at RP2D Range Survival Outcomes Across All Indications at All Dose Levels Median PFS Median OS ≥10 mg 3 – 8 mg ≤ 1.6 mg Not reached 5.4 13.9 12.1 10.3 NA mOS (mo) mFU (mo) 94% 63% 33% 1y - OS rate ≥10 mg 3 – 8 mg ≤ 1.6 mg 4.8 6.8 1.5 NA 1.4 NA mPFS (mo) mFU (mo) 45% 5% 0% 6m PFS rate Median iPFS 1 ≥10 mg 3 – 8 mg ≤ 1.6 mg Not reached 6.3 2.1 NA 1.4 NA miPFS (mo) mFU (mo) 58% 14% 0% 6m iPFS rate 40 Efficacy population n=15 ≤1.6 mg n=22 3 - 8 mg n=20 ≥10 mg 1 iRECIST , developed by the RECIST Working Group, adapts RECIST 1.1 definition for progression for immunotherapies by introducing unco nfi rmed ( iUPD ) and confirmed ( iCPD ) progression to account for atypical response patterns. Patients with iUPD not confirmed at a subsequent scan but turning into SD or response are not considered progressive according to iRECIST . PFS (according to RECIST 1.1) and iPFS (according to iRECIST ), are prospectively defined co - secondary endpoints in the IMA402 trial protocol to provide a balanced view of efficacy; mFU : median follow - up; (m)PFS: (median) progression - free survival; (m)OS: (median) overall survival; RP2D: recommended phase 2 dose ; 6m: 6 months; 1y: 1 year. Data cutoff Sep 26, 2025 PRAME Wave #3: IMA402
Patient Case: Ongoing PET - based Complete Metabolic Response in Cutaneous Melanoma Patient Characteristics & Outcomes 68 - year - old female with ICI - resistant cutaneous melanoma; i nitial diagnosis in 2004 Patient & Diagnosis • Target lesions: 2 peritoneal, 1 abdominal • Non - target lesions: brain and lung (left and right) • I ntensive i mmune - related previous medical history Disease at Baseline 3 prior lines of therapy: • Adjuvant: nivolumab • Ipilimumab + nivolumab, discontinued due to toxicity • Lenvatinib + pembrolizumab, BOR: PD Prior systemic therapy Initial dose: 5 mg, escalated to 20 mg Bi - weekly treatment 9 months post treatment start Study Treatment • First assessment (6 weeks): PR • Complete response in brain lesion • Ongoing cPR with - 68% tumor reduction and PET scan with c omplete metabolic response at 8 months after switch to 12 mg Response Assessment Scans courtesy of Dr. Dirk Schadendorf , University Hospital Essen BOR: best overall response; (c)PR: (confirmed) partial response; ICI: immune checkpoint inhibitor; PD: progressive disease; P ET: p ositron emission tomography. 41 Baseline 6 weeks 3 months 5 months Peritoneum incl. ovaries Peritoneum Data cutoff Sep 26, 2025 PRAME Wave #3: IMA402
IMA402 PRAME Bispecific Ph1a Dose Escalation Summary and Next Steps Expansion to Earlier - Line PRAME Cancers Promising Monotherapy & High Potential in Combination x Favorable tolerability profile x Deep & durable responses x Promising early PFS/ iPFS and OS Development Opportunities Initial Focus Indications IMA402 1L advanced: ICI combo IMA402 2L ICI - resistant 1 : monotherapy or ICI combo Cut. melanoma IMA402 PSOC: SOC combo IMA402 PROC 1 : monotherapy or non - platinum SOC combo IMA402 2L EC: ICI combo Gyn - Onc IMA402 + IMA401 with or without ICI sqNSCLC Development Opportunities in 2026 » Ph1b dose expansion completion (RP2D with & w/o ICI) » Initiation of additional Ph1b/Ph2 expansion cohorts in focus indications 1 Potential to become registration - directed subject to Ph1b data; 1L: first line or later, 2L: second line or later; cut. melanoma: cutaneous melanoma; EC: endometrial carcinoma; Gyn - Onc : gynecologic cancers; ICI: immune checkpoint inhibitor; OS: overall survival; PFS: progression - free survival; PROC: platinum - resistant ovarian cancer; PSOC: platinum - sensitive ovarian cancer; RP2D: recommended phase 2 dose; SOC: standard of care; sqNSCLC : squamous cell non - small cell lung cancer. 42 Data cutoff Sep 26, 2025 PRAME Wave #3: IMA402
Expands addressable market as first step in sqNSCLC , potential for many other indications like HNSCC, e sophageal s quamous carcinoma, TNBC, endometrial carcinoma, ovarian carcinoma, melanoma, sarcoma and other s as next steps Bispecifics Combination with Increased Commercial Potential PRAME+ or MAGEA4/8+ i ncluding 60% double positive > 90% Potential to Unlock >90% of sqNSCLC Patients with IMA401 + IMA402 Dual Targeting 43 Data on file - dot plot: PRAME and MAGEA4/8 mRNA expression in stage III/IV sqNSCLC TCGA samples (TPM, log - scale), PRAME and MAGEA4/8 target prevalences are based on an optimized proprietary target expression th reshold applied to TCGA data; Bar graph: In vitro LDH - killing assay, A375 tumor cell line with low target density of PRAME (~50 copies per cell) and medium target density of MAGE A4/8 (~250 copies per cell), TCER® concentration: 1nM IMA401 and 10 nM IMA402; 3 Refers to addressable 1L advanced HLA - A*02:01/target+ patients in the US & EU5 in 2025, Source: Clarivate Disease Landscape and Forecast; HNSCC: head and neck squamous cell carcinoma; sqNSCLC : squamous non - small cell lung cancer. >90% of patients with sqNSCLC are targetable, potentially unlocking broad treatment coverage for ~40K patients with sqNSCLC in the US and EU per year 3 Expanded Patient Reach Dual targeting has the potential to improve depth and durability of tumor response by counteracting tumor heterogeneity and escape ~ 6 0% of patients with sqNSCLC express both targets Synergistic Anti - Tumor Activity In vitro model of PRAME and MAGEA4/8 double positive tumor PRAME MAGEA4/8 w / o T C E R I M A 4 0 2 I M A 4 0 1 I M A 4 0 1 + I M A 4 0 2 0.0 0.2 0.4 0.6 0.8 Tumor cell killing [OD 490 nm - 650 nm ] IMA402 + IMA401 Combo
IMA401 MAGEA4/8 Bispecific Maximizing the Potential of Bispecifics Combination Entering the PRAME Franchise
Cancer Cell MAGEA4/8 IMA401 MAGEA4/8 Bispecific Summary: Phase 1 Dose Escalation Study 45 1 at RP2D of 1 - 2 mg; AE: Adverse Event; CRS: Cytokine Release Syndrome; (c)ORR: (confirmed) objective response rate; DCR: disease control rate; ICI : immune checkpoint inhibitor; HNSCC: Head and neck squamous cell carcinoma; sqNSCLC : squamous cell non - small - cell lung cancer • 29% cORR (4/14) in head and neck cancer • 33% cORR (2/6) in melanoma • Promising early clinical activity in sqNSCLC Tolerability Activity & Duration of Response 1 Opportunity to develop IMA401 in combination with IMA402 in sqNSCLC and other indications Combined target prevalence supports broad patient coverage and potential synergistic activity >90% of patients with sqNSCLC are targetable Development Potential Favorable tolerability at RP2D ± pembrolizumab, suggesting the potential of IMA401 for broad combinability Most frequent clinically relevant TRAE were low - grade cytokine release syndrome (CRS), expected and transient lymphopenia, consistent with the mechanism of action, and manageable neutropenia. Pharmacokinetics Median terminal half - life of >2 weeks P otential for: • Flexibility in dosing schedules • Combination with IMA402 with or without ICI • Phase 1a dose escalation completed • IMA401/IMA402 combination cohort in sqNSCLC is now enrolling at multiple clinical trial sites, with first data expected in 2027 TCER® IMA401 MAGEA4/8 Bispecific IMA401 Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026
Phase 1 Basket Trial of IMA401 in MAGEA4/8 Solid Tumors 46 EudraCT No 2021 - 004326 - 30; NCT05359445; a Step dosing introduced at dose levels ≥1 mg, low - dose dexamethasone partially used as preventive measure for initial doses as ap plied for other bispecific T - cell engagers; ability to increase dose to previously cleared dose levels; b q2w: once every two weeks, weekly (q1w) IMA401 dosing was applied up to 0.54 mg; c MTD was not reached at 2.5 mg as defined by the adaptive BLRM model specifying probabilities of DLTs at tested doses. BLRM, Bayesian logistic regression model; ICI, immune checkpoint in hibitor; IV, intravenous; MABEL, minimum anticipated biological effect level; MTD, maximum tolerated dose, RP2D, recommended phase 2 dose; q6w, every 6 weeks. MAGEA4/8 Bispecific IMA401 Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 0.18 mg 0.54 mg 1.8 mg 0.06 mg 1.2 mg 0.02 mg 0.0066 mg 2.0 mg 1.0 mg 1.5 mg 2.5 mg Phase 1a dose escalation completed 1.8 mg 1.2 mg 2.0 mg 1.0 mg 1.5 mg Dose selection : MTD not reached per adaptive BLRM model c , RP2D defined at 1 - 2 mg based on optimal risk - benefit - profile 1.0 mg 1.5 mg + Pembrolizumab + Pembrolizumab ICI combination : Pembrolizumab started 1 week before IMA401 (400 mg IV q6w) • MABEL - based starting dose • Dose escalation based on cohorts of 1 - 6 patients using adaptive design (BLRM model) • Initial q1w step dosing a (2 - 4 doses) up to target dose, q2w after reaching target dose b Phase 1a Dose Escalation 0.0066 mg - 2.5 mg IMA401 ( n=61 ) RP2D Selection 1.0 - 2.0 mg IMA401 ( n=32 ) ICI Combination at RP2D 1.0 or 1.5 mg IMA401 with Pembrolizumab ( n=12 ) RP2D selection completed IMA401 + ICI completed
Phase 1 Basket Trial of IMA401 in MAGEA4/8 Solid Tumors 47 a Includes small molecule drugs and antibodies . b IMA401 dose in pembrolizumab expansion cohorts were 1 mg (n=8) or 1.5 mg (n=4); adNSCLC , adenocarcinoma non - small cell lung cancer ; ECOG, Eastern Cooperative Oncology Group; GCT, germ cell tumor; H&N, head and neck ; HNSCC, head and neck squamous cell carcinoma; ICI, immune checkpoint inhibitor ; LCNEC, large cell neuroendocrine carcinoma; LDH, lactate dehydrogenase ; NET CUP, neuroendocrine tumor of cancer of unknown primary ; RP2D, recommended phase 2 dose; SCLC, small cell lung cancer ; SLD, sum of longest diameter(s); sqNSCLC , squamous cell non - small cell lung cancer ; TNBC, triple - negative breast cancer ; ULN, upper limit of normal. MAGEA4/8 Bispecific IMA401 Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 RP2D (1 - 2 mg) All Dose Levels Baseline Characteristics IMA401 + Pembrolizumab b n=12 IMA401 (Monotherapy) n=32 IMA401 ± Pembrolizumab n=61 63 (33, 77) 62 (19, 82) 62 (19, 82) Age (years) , median (min, max) 12 (100)/ 0 (0) 19 (59)/ 13 (41) 39 (64)/ 22 (36) Sex , m ale/female n (%) 6 (42) 6 (50) 0 11 (34) 20 (63) 1 (3) 21 (34) 38 (62) 2 (3) ECOG performance status 0, n (%) 1, n (%) 2, n (%) 8 (67) 4 (33) 0 17 (53) 14 (44) 1 (3) 36 (59) 21 (34) 4 (7) LDH at baseline < 1xULN, n (%) 1 - 2xULN, n (%) > 2xULN, n (%) 63.1 (15.5, 121.0) 60 (11.3, 202.8) 67 (11.3, 202.8) Baseline tumor burden Target lesion SLD [cm], median (range) 4.5 (2, 10) 4 (33) 0 4 (1, 10) 10 (31) 2 (6) 4 (1, 10) 18 (30) 4 (7) Tumor lesions Number of lesions, median (min, max) Liver metastases, n (%) Brain metastases, n (%) Treatment Experience 3 (1, 4) 4 (1, 8) 3 (1, 8) No. of prior lines of systemic treatment median (min, max) 11 (92) 11 (92) 9 (75) 0 0 25 (78) 18 (56) 22 (69) 2 (6) 4 (13) 52 (85) 40 (66) 41 (67) 4 (7) 7 (11) Prior treatments, n (%) Chemotherapy ICI Targeted Therapy a Hormone Therapy Others Highly heterogenous patient population with >15 different indications # of Patients Different Indications (all dose levels) 16 H&N (squamous, adenocarcinoma, others) 8 Melanoma (Cutaneous & Mucosal) 8 Synovial Sarcoma 4 sqNSCLC 4 TNBC 3 adNSCLC 3 Ovarian Carcinoma 2 Gastric Cancer 2 SCLC 2 Urothelial Carcinoma 1 Bladder Carcinoma 1 Esophageal Carcinoma 1 Gallbladder Adenocarcinoma 1 LCNEC Esophageal 1 LCNEC Lung 1 NET CUP 1 Non - melanoma Skin Cancer (Squamous) 1 Penile Cancer 1 Testicular GCT
Tolerability of IMA401 Monotherapy 48 a All TRAEs at least possibly related to IMA401 infusion and / or pembrolizumab infusion with grade 1 - 2 occurring in at least 10% of all patients , all events with ≥ grade 3; b in patients with and without dexamethasone pre - medication , one possibly related death (pneumonia in the context of lung tumor progression and concurrent neutropenia) as previously reported , patient did not receive dexamethasone pre - medication ; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CSF, colony - stimulating factor , CRS, cytokine release syndrome , DLT, dose - limiting toxicity ; ICANS, immune effector cell - associated neurotoxicity syndrome ; GGT, gamma - glutamyltransferase ; MoA , mechanism of action ; RP2D, recommended phase 2 dose; TRAE, treatment - related adverse event . MAGEA4/8 Bispecific IMA401 Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 IMA401 (Monotherapy) A ll treated patients > 2 mg n=7 1 - 2 mg (RP2D) n=32 All Dose Levels N=61 Treatment - related Adverse Events (safety analysis set) ≥ Grade 3 All Grades ≥ Grade 3 All Grades ≥ Grade 3 All Grades TRAEs a , n (%) 7 (100) 7 (100) 16 (50) 28 (88) 31 (51) 54 (89) Any TRAE 0 3 (43) 0 12 (38) 0 23 (38) Cytokine release syndrome 5 (71) 5 (71) 7 (22) 9 (28) 16 (26) 20 (33) Lymphopenia 5 (71) 5 (71) 5 (16) 11 (34) 11 (18) 19 (31) Neutropenia 2 (29) 3 (43) 0 5 (16) 2 (3) 10 (16) Thrombocytopenia 1 (14) 1 (14) 4 (13) 7 (22) 5 (8) 9 (15) Leukopenia 1 (14) 2 (29) 1 (3) 7 (22) 2 (3) 9 (15) Headache 3 (43) 4 (57) 2 (6) 2 (6) 7 (11) 8 (13) Anaemia 1 (14) 4 (57) 0 0 2 (3) 7 (11) Facial pain 0 1 (14) 1 (3) 3 (9) 1 (2) 7 (11) ALT increased 0 1 (14) 0 2 (6) 0 7 (11) Pyrexia 0 0 2 (6) 3 (9) 3 (5) 5 (8) AST increased 0 0 2 (6) 3 (9) 2 (3) 4 (7) Hypertension 0 0 0 0 1 (2) 2 (3) GGT increased 0 0 0 0 1 (2) 2 (3) Hypoxia 0 0 1 (3) 1 (3) 1 (2) 1 (2) C - reactive protein increased 0 0 0 0 1 (2) 1 (2) Chest pain 1 (14) 1 (14) 0 0 1 (2) 1 (2) Febrile neutropenia 1 (14) 1 (14) 0 0 1 (2) 1 (2) Pneumonia 0 0 1 (3) 1 (3) 1 (2) 1 (2) Sinus tachycardia • Most common AEs: • Low - grade CRS (38% G1 - G2, no ≥G3 ), mainly at first step dose, resolving within 1 - 3 days • Transient, mechanism - related lymphopenia • Mostly transient neutropenia, manageable with dexamethasone and G - CSF; not recurring after resolution with continued IMA401 treatment • No ICANS observed • MTD not reached • Neutropenia - related DLTs in 5 patients (incl. 3 at >RP2D b ) • No DLTs at RP2D with dexamethasone premedication Manageable tolerability profile with mostly transient AEs, consistent with MoA
Tolerability of IMA401 at RP2D ± Pembrolizumab 49 a All TRAEs at least possibly related to IMA401 infusion and / or pembrolizumab infusion with grade 1 - 2 occurring in at least 10% of all patients , all events with ≥ grade 3 and typical ICI - associated toxicities ; b IMA401 dose in pembrolizumab expansion cohorts were 1 mg (n=8) or 1.5 mg (n=4); ICI, immune checkpoint inhibitor ; RP2D, recommended phase 2 dose; TRAE, treatment - related adverse event . MAGEA4/8 Bispecific IMA401 Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 IMA401 + Pembrolizumab IMA401 (Monotherapy) 1 - 2 mg (RP2D) b n=12 1 - 2 mg (RP2D) n=32 Treatment - related Adverse Events (safety analysis set) ≥ Grade 3 All Grades ≥ Grade 3 All Grades TRAEs a , n (%) 3 (25) 11 (92) 16 (50) 28 (88) Any TRAE 0 5 (42) 0 12 (38) Cytokine release syndrome 2 (17) 4 (33) 7 (22) 9 (28) Lymphopenia 0 1 (8) 5 (16) 11 (34) Neutropenia 0 1 (8) 0 5 (16) Thrombocytopenia 0 1 (8) 4 (13) 7 (22) Leukopenia 0 0 1 (3) 7 (22) Headache 0 0 2 (6) 2 (6) Anaemia 0 0 0 0 Facial pain 0 2 (17) 1 (3) 3 (9) Alanine aminotransferase increased 0 3 (25) 0 2 (6) Pyrexia 0 1 (8) 2 (6) 3 (9) Aspartate aminotransferase increased 0 0 2 (6) 3 (9) Hypertension 1 (8) 1 (8) 0 0 Gamma - glutamyltransferase increased 0 0 0 0 Hypoxia 0 0 1 (3) 1 (3) C - reactive protein increased 0 0 0 0 Chest pain 0 0 0 0 Febrile neutropenia 0 0 0 0 Pneumonia 0 0 1 (3) 1 (3) Sinus tachycardia Any group analyzed ICI - associated toxicities 0 Immune - mediated colitis 0 Immune - mediated pneumonitis 0 Immune - mediated hepatitis 0 Nephritis 0 Adrenal insufficiency 0 Immune - mediated hypophysitis No overlapping and/or additive toxicity observed in the combination cohort, supporting IMA401 combinability with ICIs.
Tolerability of IMA401 at RP2D ± Pembrolizumab 50 Efficacy population: all patients in the safety set who received 4 IMA401 infusions in monotherapy and in addition at least 1 pe mbrolizumab infusion in combination therapy and had a post - baseline efficacy assessment, including patients with clinical progression; a Two patients not shown in plot due to clinical progression before post - infusion scan. b One patient not shown in plot due to clinical progression before post - infusion scan. BOR, best overall response; (c)ORR, (confirmed) objective response rate; (c)PR, (confirmed) partial response ; DCR, disease control rate; H&N, head and neck cancer; PD, progressive disease; PFS, progression - free survival; RECIST, response evaluation criteria in solid tumors; RP2D, recommended phase 2 dose; SD, stable disease; OS, overall survival; mDOR , median duration of response. MAGEA4/8 Bispecific IMA401 Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 H&N b ( n= 14) BOR (RECIST 1.1) PD SD PR cPR Ongoing response /disease control Other a (n=27, 14 different indications) IMA401 monotherapy IMA401 + Pembrolizumab 29 % ( 4/14 ) cORR 64% (9/14) DCR H&N (n=14) sqNSCLC Cut. Melanoma Cut. Melanoma Muc . Melanoma NET CUP Penile Cancer All H&N responders achieved deep responses with 60% - 100% tumor reduction
Durable Responses to IMA401 ± Pembrolizumab in Patients with H&N Cancer 51 Efficacy population: all patients in the safety set who received 4 IMA401 infusions in monotherapy and in addition at least 1 pe mbrolizumab infusion in combination therapy and had a post - baseline efficacy assessment, including patients with clinical progression; a One patient not shown in plot due to clinical progression before post - infusion scan. BOR, best overall response; cPR , confirmed partial response; DOR, duration of response; H&N, head and neck cancer; PD, progressive disease; PR, partial response; RECIST, response evaluation c rit eria in solid tumors; RP2D, recommended phase 2 dose; SD, stable disease. MAGEA4/8 Bispecific IMA401 Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 0 6 12 18 24 -100 -50 0 50 100 Months post First IMA401 Infusion C h a n g e i n S u m o f L o n g e s t D i a m e t e r o f T a r g e t L e s i o n s f r o m B a s e l i n e [ % ] BL PR ⯈ Palliative Radiotherapy + ⯈ ⯈ ⯈ ⯈ n=14 a IMA401 + Pembrolizumab 8.8 mo mDOR 63% 43% 12m OS rate 6m PFS rate 3 of 4 responses ongoing at data cut - off
Patient Case: Partial Response after IMA401 + Pembrolizumab in sqNSCLC 52 a Treatment start 5 weeks after last prior systemic therapy; scans courtesy of treating physician Prof. Dr. Martin Wermke, TU D re sden; BOR, best overall response; ICI, immune checkpoint inhibitor; PR, partial response; Pt, patient; Q6W, once every 6 weeks; SD, stable disease; sqNSCLC , squamous cell non - small cell lung cancer. MAGEA4/8 Bispecific IMA401 Wermke et al., ASCO 2026 Data cutoff Mar 02, 2026 Lung Baseline 7 weeks Jaw Head Head PR with IMA401 in 5 th line ICI - resistant sqNSCLC patient with shrinkage of all target lesions Patient Characteristics & Outcome 63 - year - old male with ICI - resistant sqNSCLC ; initial diagnosis in July 2018 Patient & Diagnosis Multiple metastases i n lymph nodes, skin, lung and bone Disease at Baseline 4 prior lines of systemic therapy with BOR SD • Adjuvant: cisplatin, vinorelbine • Carboplatin, ipilimumab, nivolumab, paclitaxel, BOR: SD • Docetaxel, ramucirumab, BOR: SD • Progressed after all prior treatments • Carboplatin, gemcitabine, BOR: SD, discontinued early due to toxicity Prior systemic therapy 1 mg IMA401 + 400 mg pembrolizumab Q6W; Pt died during a biopsy due to pulmonary haemorrhage Study Treatment a PR at first scan post IMA401 treatment start with - 39% tumor reduction Response Assessment
© Immatics. Not for further reproduction or distribution. v Appendix
Anzu - cel (IMA203): Significant Shift in PFS and OS Between Dose Escalation & Dose Expansion PFS of 6 Months and OS of 16 Months in Melanoma Efficacy Population 54 Progression Free Survival Data cut - off Sep 24, 2025 Overall Survival mPFS N 2.6 months 11 Dose Escalation 6.1 months 33 Dose Expansion mOS N 6.3 months 11 Dose Escalation 16.2 months 33 Dose Expansion • Significant shift in mPFS and mOS between melanoma patients treated during the dose escalation and dose expansion • mPFS in dose escalation is comparable to reported data in 2L+ cut. melanoma population * • mOS in dose escalation is shorter than reported mOS for 2L+ cut. melanoma population * • All patients in the dose escalation group deceased and 9 /23 evaluable patients are alive in dose expansion # Log - rank test: p <0.0001 Log - rank test: p <0.0001 Anzutresgene autoleucel ( anzu - cel, formerly IMA203), Overall survival (OS) and progression - free survival (PFS) censored at data - cut; * These data are derived from different clinical trials at different points in time with differences in trial design and patient populations. As a result, cross - trial comparisons cannot b e made, and no head - to - head clinical trials have been conducted # 10 patients out of study at data - cut (withdrew consent) PRAME Wave #1: anzu - cel
0 10 20 30 1×10 1 1×10 2 1×10 3 1×10 4 1×10 5 1×10 6 1×10 7 40 60 80 1002004006008001000 Days post-infusion V e c t o r c o p i e s / µ g D N A IMA203CD8 T - cell Persistence in Peripheral Blood in Multiple Indications 55 • Sustained persistence of IMA 203 CD 8 T cells beyond 1 - year post - infusion represent an important prerequisite for durable clinical benefit in all main indications evaluated • Similar kinetics between indications with n o significant differences seen in terms of peak expansion, time point of peak expansion and persistence at day 30 , 60 and 90 post - infusion between indications ( data on file ) Melanoma Data cutoff March 30, 2026 S ynovial Sarcoma Gyn ecologic Indications Shorter follow - up for gynecologic indications due to later study treatment 0 10 20 30 1×10 1 1×10 2 1×10 3 1×10 4 1×10 5 1×10 6 1×10 7 40 60 80 1002004006008001000 Days post-infusion V e c t o r c o p i e s / µ g D N A PRAME Wave #2: IMA203CD8
Opportunity of IMA203CD8 across Broad Range of PRAME+ Indications 56 Data on file; PRAME expression: evaluated biopsies (FFPE tissue) prior to treatment with anzutresgene autoleucel ( anzu - cel, formerly IMA203) or IMA203CD8, melanoma: cutaneous melanoma, uveal melanoma, acral melanoma, melanoma of unknown primary, Gyn (gynecologic cancers): ovarian carcinoma and endometrial cancer; O the r: head and neck cancer, lung cancer, synovial sarcoma, triple - negative breast cancer and others . IMA203CD8 shows higher number of deep responses at - 100% tumor reduction at lower infused dose compared to anzu - cel. IMA203CD8 may offer an enhanced opportunity to treat cancers across a broad spectrum of PRAME expression including ovarian carcinoma, uterine cancer, sqNSCLC , triple - negative breast cancer and others Potential of IMA203CD8 in PRAME - positive tumors with varying expression levels Data cutoff March 30, 2026 PRAME expression relative to threshold p<0.001 ns p<0.001 Deep responses with IMA203CD8 at low doses Anzu-cel IMA203CD8 -100 -50 0 50 100 B e s t % C h a n g e i n S u m o f L o n g e s t D i a m e t e r o f T a r g e t L e s i o n s f r o m B a s e l i n e a n d B O R ( R E C I S T 1 . 1 ) -30 -85 Number of patients Total infused dose TCR-T cells [x10 9 ] Tumor burden at baseline (mm) 90 1.71 (0.44-12.50) 72.55 (11.00-434.40) 51 4.50 (1.00-10.20) 100.60 (11.00-309.80) PRAME Wave #2: IMA203CD8
IMA203CD8 Shows Broad Clinical Activity across Diverse PRAME+ Solid Tumors Clinical Activity in PRAME+ T umors with D istinct P athology / Biology Clinical Activity Immunological phenotype a Relative PRAME Expression Hot High Melanoma Mixed High Uterine cancer Cold High Synovial sarcoma / Uveal melanoma Cold Low Ovarian carcinoma 57 Clinical activity to date spans different PRAME levels, tumor biologies and tumor immune phenotypes, supporting broad applicability of IMA203CD8 for PRAME+ solid tumors, beyond the ones investigated x x x x a Hot = T cell infiltrated/inflamed; Cold = non - T - cell infiltrated /non - inflamed according to Galon and Bruni, Nat Rev Drug Discov , 2019 . Dominant phenotype for a tumor indication shown, intermediate “altered” immunological phenotypes not assessed for simplicity. Mixed: larger fractions of molecular subtypes ex ist with both, hot and cold immunological phenotype PRAME Wave #2: IMA203CD8 Araujo et al, ASCO 2026 Busse et al, ESMO - IO 2025 Busse et al, ESMO - IO 2025 Busse et al, ASCO 2026 Busse et al, ASCO 2026
Potential of PRAME - Directed Therapies in Solid Cancers PRAME Target Expression and Prevalences in Selected Solid Cancer Types Hukelmann et al., SITC 2022, updated prevalences as of May 2025; 1 Data on file: PRAME target prevalence is based on a proprietary mass spec - guided initial expression threshold applied to TCGA or in - house (SCL C) RNAseq data (approximate values, values between 95 - 100% shown as 95%); 2 PRAME target prevalence in uveal melanoma based on IMADetect® qPCR testing of screening biopsies from clinical trial patients d emonstrates substantial higher prevalence of ~90% compared to prevalence based on TCGA data of 50%, TCGA: early & late - stage pri mary tumor samples, Immatics clinical trials: late - stage/metastatic tumor samples, Role of PRAME in metastasis of uveal melanoma: Field et al. 2016 Clinical Cancer Research; MS: mass spectrometry; NSCLC: non - small cell lung cancer Selected indications Clinical activity shown No clinical activity expected Potential for clinical activity 95% 90% (50% 2 ) 95% 85% 95% 95% 70% 65% 45% 40% 35% 25% 25% 25% 25% 20% 20% Cutaneous Melanoma Uveal Melanoma 2 Uterine Carcinoma Ovarian Carcinoma (serous) Uterine Carcinosarcoma Synovial Sarcoma Squamous Cell NSCLC Triple - negative Breast Carcinoma Small Cell Lung Cancer Kidney Carcinoma (papillary) Cholangiocarcinoma Adenocarcinoma NSCLC Breast Carcinoma (all subtypes) Head & Neck Squamous Cell Carcinoma Esophageal Carcinoma (all subtypes) Hepatocellular Carcinoma Bladder Carcinoma Initial threshold to determine PRAME positive patients in current clinical trials 1 Presumed optimized threshold 58 PRAME
© Immatics. Not for further reproduction or distribution. v Thank you Making a Meaningful Impact on the Lives of Patients with Cancer www.immatics.com
FAQ
What are the key results for anzu-cel in advanced melanoma from Immatics (IMTX)?
Anzu-cel showed strong activity in advanced melanoma, with 56% confirmed objective response and 64% overall response in 33 patients. Disease control reached 91%, median duration of response was 14.6 months, progression-free survival 6.1 months and overall survival 16.2 months, with some responses beyond three years.
How did IMA203CD8 perform in gynecologic cancers for Immatics (IMTX)?
IMA203CD8, given as a one-time infusion, produced anti-tumor activity in heavily pretreated ovarian and uterine cancers at clinically relevant doses. Among patients treated at higher dose levels, objective responses and disease control were observed, while safety was dominated by predictable cytopenias and manageable cytokine release syndrome.
What safety profile was reported for Immatics’ PRAME-targeted cell therapies?
Across IMA203CD8 and anzu-cel, the most frequent events were cytopenias from lymphodepletion and mainly Grade 1–2 cytokine release syndrome. Immune neurotoxicity and hemophagocytic lymphohistiocytosis occurred infrequently, and no treatment-related Grade 5 events were reported in the presented datasets.
What are the main findings for the IMA401 MAGEA4/8 bispecific in the Immatics (IMTX) 6-K?
IMA401 showed a manageable tolerability profile and encouraging anti-tumor activity at the 1–2 mg recommended Phase 2 dose, as monotherapy and with pembrolizumab. The data span multiple solid tumors, including head and neck cancer and lung cancer, and support moving into combination with the PRAME-directed bispecific IMA402.
How is Immatics expanding development of its PRAME franchise after these data?
Immatics is advancing the SUPRAME Phase 3 trial of anzu-cel in cutaneous melanoma and a Phase 2 cohort in uveal melanoma. It is also expanding IMA203CD8 into additional PRAME-positive solid tumors and launching an IMA401/IMA402 combination cohort in squamous non-small cell lung cancer.
Are the Immatics (IMTX) clinical results in this 6-K considered final?
No. The company states all scientific and clinical data are preliminary, from ongoing early-phase trials, and subject to further quality checks and source-data verification. Larger, later-phase studies and complete clinical study reports will be needed to confirm efficacy and safety.
Filing Exhibits & Attachments
144 documentsPress Releases
- EX-99.1 EXHIBIT 99.1 40.3 KB
- EX-99.2 EXHIBIT 99.2 36.2 KB
- EX-99.3 EXHIBIT 99.3 34.2 KB
- EX-99.4 EXHIBIT 99.4 29.3 KB
- EX-99.5 EXHIBIT 99.5 33.3 KB
- EX-99.6 EXHIBIT 99.6 48.6 KB
- EX-99.7 EXHIBIT 99.7 36.9 KB
- EX-99.8 EXHIBIT 99.8 115.0 KB
- EX-9904 GRAPHIC 494.5 KB
- EX-9904 GRAPHIC 434.9 KB
- EX-9904 GRAPHIC 394.9 KB
- EX-9904 GRAPHIC 427.2 KB
- EX-9904 GRAPHIC 258.9 KB
- EX-9904 GRAPHIC 336.0 KB
- EX-9904 GRAPHIC 354.2 KB
- EX-9904 GRAPHIC 335.5 KB
- EX-9904 GRAPHIC 347.8 KB
- EX-9904 GRAPHIC 432.4 KB
- EX-9904 GRAPHIC 174.7 KB
- EX-9904 GRAPHIC 73.1 KB
- EX-9904 GRAPHIC 197.6 KB
- EX-9904 GRAPHIC 440.3 KB
- EX-9904 GRAPHIC 445.4 KB
- EX-9905 GRAPHIC 335.0 KB
- EX-9905 GRAPHIC 424.6 KB
- EX-9905 GRAPHIC 414.4 KB
- EX-9905 GRAPHIC 406.7 KB
- EX-9905 GRAPHIC 317.7 KB
- EX-9905 GRAPHIC 328.7 KB
- EX-9905 GRAPHIC 340.2 KB
- EX-9905 GRAPHIC 344.4 KB
- EX-9905 GRAPHIC 364.6 KB
- EX-9905 GRAPHIC 395.1 KB
- EX-9905 GRAPHIC 429.0 KB
- EX-9905 GRAPHIC 203.7 KB
- EX-9905 GRAPHIC 75.1 KB
- EX-9905 GRAPHIC 184.9 KB
- EX-9905 GRAPHIC 343.6 KB
- EX-9905 GRAPHIC 250.3 KB
- EX-9905 GRAPHIC 381.8 KB
- EX-9906 GRAPHIC 555.4 KB
- EX-9906 GRAPHIC 475.3 KB
- EX-9906 GRAPHIC 387.6 KB
- EX-9906 GRAPHIC 314.9 KB
- EX-9906 GRAPHIC 263.6 KB
- EX-9906 GRAPHIC 395.8 KB
- EX-9906 GRAPHIC 496.6 KB
- EX-9906 GRAPHIC 510.8 KB
- EX-9906 GRAPHIC 419.2 KB
- EX-9906 GRAPHIC 325.1 KB
- EX-9906 GRAPHIC 294.7 KB
- EX-9906 GRAPHIC 384.7 KB
- EX-9906 GRAPHIC 411.1 KB
- EX-9906 GRAPHIC 383.9 KB
- EX-9906 GRAPHIC 474.5 KB
- EX-9906 GRAPHIC 149.2 KB
- EX-9906 GRAPHIC 72.0 KB
- EX-9906 GRAPHIC 167.9 KB
- EX-9906 GRAPHIC 311.5 KB
- EX-9906 GRAPHIC 380.8 KB
- EX-9906 GRAPHIC 364.7 KB
- EX-9906 GRAPHIC 408.7 KB
- EX-9906 GRAPHIC 264.4 KB
- EX-9906 GRAPHIC 382.2 KB
- EX-9906 GRAPHIC 72.0 KB
- EX-9907 GRAPHIC 356.3 KB
- EX-9907 GRAPHIC 538.8 KB
- EX-9907 GRAPHIC 365.5 KB
- EX-9907 GRAPHIC 430.6 KB
- EX-9907 GRAPHIC 307.0 KB
- EX-9907 GRAPHIC 418.5 KB
- EX-9907 GRAPHIC 472.5 KB
- EX-9907 GRAPHIC 412.7 KB
- EX-9907 GRAPHIC 358.7 KB
- EX-9907 GRAPHIC 375.5 KB
- EX-9907 GRAPHIC 271.1 KB
- EX-9907 GRAPHIC 403.4 KB
- EX-9907 GRAPHIC 411.8 KB
- EX-9907 GRAPHIC 325.4 KB
- EX-9907 GRAPHIC 538.8 KB
- EX-9907 GRAPHIC 182.9 KB
- EX-9907 GRAPHIC 71.3 KB
- EX-9907 GRAPHIC 367.3 KB
- EX-9907 GRAPHIC 389.5 KB
- EX-9907 GRAPHIC 397.5 KB
- EX-9908 GRAPHIC 571.5 KB
- EX-9908 GRAPHIC 419.4 KB
- EX-9908 GRAPHIC 278.5 KB
- EX-9908 GRAPHIC 341.5 KB
- EX-9908 GRAPHIC 344.3 KB
- EX-9908 GRAPHIC 382.9 KB
- EX-9908 GRAPHIC 365.8 KB
- EX-9908 GRAPHIC 314.6 KB
- EX-9908 GRAPHIC 184.4 KB
- EX-9908 GRAPHIC 243.4 KB
- EX-9908 GRAPHIC 358.8 KB
- EX-9908 GRAPHIC 299.6 KB
- EX-9908 GRAPHIC 310.3 KB
- EX-9908 GRAPHIC 296.9 KB
- EX-9908 GRAPHIC 317.0 KB
- EX-9908 GRAPHIC 282.2 KB
- EX-9908 GRAPHIC 295.1 KB
- EX-9908 GRAPHIC 396.8 KB
- EX-9908 GRAPHIC 264.2 KB
- EX-9908 GRAPHIC 334.2 KB
- EX-9908 GRAPHIC 331.2 KB
- EX-9908 GRAPHIC 174.7 KB
- EX-9908 GRAPHIC 315.2 KB
- EX-9908 GRAPHIC 295.0 KB
- EX-9908 GRAPHIC 361.6 KB
- EX-9908 GRAPHIC 248.9 KB
- EX-9908 GRAPHIC 244.5 KB
- EX-9908 GRAPHIC 258.0 KB
- EX-9908 GRAPHIC 262.9 KB
- EX-9908 GRAPHIC 271.3 KB
- EX-9908 GRAPHIC 285.8 KB
- EX-9908 GRAPHIC 168.0 KB
- EX-9908 GRAPHIC 286.3 KB
- EX-9908 GRAPHIC 295.2 KB
- EX-9908 GRAPHIC 289.0 KB
- EX-9908 GRAPHIC 277.4 KB
- EX-9908 GRAPHIC 380.8 KB
- EX-9908 GRAPHIC 267.4 KB
- EX-9908 GRAPHIC 289.0 KB
- EX-9908 GRAPHIC 254.9 KB
- EX-9908 GRAPHIC 342.8 KB
- EX-9908 GRAPHIC 368.3 KB
- EX-9908 GRAPHIC 335.9 KB
- EX-9908 GRAPHIC 168.4 KB
- EX-9908 GRAPHIC 398.7 KB
- EX-9908 GRAPHIC 332.8 KB
- EX-9908 GRAPHIC 433.1 KB
- EX-9908 GRAPHIC 438.8 KB
- EX-9908 GRAPHIC 377.6 KB
- EX-9908 GRAPHIC 272.1 KB
- EX-9908 GRAPHIC 226.6 KB
- EX-9908 GRAPHIC 343.0 KB
- EX-9908 GRAPHIC 127.7 KB
- EX-9908 GRAPHIC 300.1 KB
- EX-9908 GRAPHIC 262.8 KB
- EX-9908 GRAPHIC 244.4 KB
- EX-9908 GRAPHIC 268.1 KB
- EX-9908 GRAPHIC 269.5 KB
- EX-9908 GRAPHIC 185.1 KB